Original Article
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
N Engl J Med 2011; 365:2255-2267December 15, 2011DOI: 10.1056/NEJMoa1107579
Comments
open through December 21, 2011
- Abstract
Background
In patients with established cardiovascular disease, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein (LDL) cholesterol levels with statin therapy. It is unclear whether extended-release niacin added to simvastatin to raise low levels of high-density lipoprotein (HDL) cholesterol is superior to simvastatin alone in reducing such residual risk.
Methods
We randomly assigned eligible patients to receive extended-release niacin, 1500 to 2000 mg per day, or matching placebo. All patients received simvastatin, 40 to 80 mg per day, plus ezetimibe, 10 mg per day, if needed, to maintain an LDL cholesterol level of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). The primary end point was the first event of the composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization.
Results
A total of 3414 patients were randomly assigned to receive niacin (1718) or placebo (1696). The trial was stopped after a mean follow-up period of 3 years owing to a lack of efficacy. At 2 years, niacin therapy had significantly increased the median HDL cholesterol level from 35 mg per deciliter (0.91 mmol per liter) to 42 mg per deciliter (1.08 mmol per liter), lowered the triglyceride level from 164 mg per deciliter (1.85 mmol per liter) to 122 mg per deciliter (1.38 mmol per liter), and lowered the LDL cholesterol level from 74 mg per deciliter (1.91 mmol per liter) to 62 mg per deciliter (1.60 mmol per liter). The primary end point occurred in 282 patients in the niacin group (16.4%) and in 274 patients in the placebo group (16.2%) (hazard ratio, 1.02; 95% confidence interval, 0.87 to 1.21; P=0.79 by the log-rank test).
Conclusions
Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.)
Media in This Article
Figure 1
Kaplan–Meier Curve for the Primary End Point.Table 1
Baseline Demographic and Clinical Characteristics of the Study Patients.Article Activity
- Article
More than 18 million North Americans have coronary heart disease, and despite profound advances in both pharmacologic and interventional management, both morbidity and mortality remain appreciable.1,2 Elevated low-density lipoprotein (LDL) cholesterol levels are an established predictor of the risk of coronary heart disease. Multiple primary and secondary prevention trials have shown a significant reduction of 25 to 35% in the risk of cardiovascular events with statin therapy3; however, residual risk persists despite the achievement of target LDL cholesterol levels.
Epidemiologic studies have shown that, in addition to elevated LDL cholesterol levels, low levels of high-density lipoprotein (HDL) cholesterol are an independent predictor of the risk of coronary heart disease,4,5 with a strong inverse association between HDL cholesterol levels and the rates of incident coronary heart disease events. Previously, studies from the Coronary Drug Project showed that the rate of cardiovascular events was decreased among patients with established coronary heart disease who had been randomly assigned to receive immediate-release niacin as compared with those assigned to receive placebo,6,7 and the Veterans Affairs HDL Intervention Trial (VA-HIT; ClinicalTrials.gov number, NCT00283335)8 suggested that raising low levels of HDL cholesterol with gemfibrozil in men with coronary heart disease and normal LDL cholesterol levels was associated with reductions in the rate of cardiovascular events. Subsequently, the HDL-Atherosclerosis Treatment Study (HATS, NCT00000553)9 showed that treatment with simvastatin plus niacin resulted in significant regression of angiographic coronary atherosclerosis and reductions in the rate of clinical events.
At least two studies10,11 focusing on aggressive lowering of lipid levels with high doses of statins to achieve a target LDL cholesterol level of less than 70 mg per deciliter (1.81 mmol per liter) in very-high-risk patients have shown major reductions in clinical end points. A post hoc analysis of the Treating to New Targets trial (TNT, NCT00327691)11 showed that, among patients who had achieved LDL cholesterol values of less than 70 mg per deciliter, the 5-year rate of cardiovascular events was 25% lower among those in the highest quintile of HDL cholesterol levels than among those in the lowest quintile. This suggests that HDL cholesterol levels have a prognostic value for patients receiving statin therapy that is independent of LDL cholesterol levels.
The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial tested whether extended-release niacin added to intensive statin therapy, as compared with statin therapy alone, would reduce the risk of cardiovascular events in patients with established atherosclerotic cardiovascular disease and atherogenic dyslipidemia (low levels of HDL cholesterol, elevated triglyceride levels, and small, dense particles of LDL cholesterol). Patients with this profile represent an expanding reservoir of patients at increased risk for cardiovascular events,12,13 for whom more effective treatment is needed.
Methods
Trial Oversight
The AIM-HIGH Study was an investigator-initiated trial that was approved and sponsored by the National Heart, Lung, and Blood Institute (NHLBI). The design and organization of the trial and the baseline data have been described previously.14,15 Abbott Laboratories provided additional support from an unrestricted research grant. The extended-release niacin (Niaspan), the matching placebo, and the ezetimibe were provided by Abbott Laboratories; Merck donated the simvastatin. The companies that provided financial support or products had no role in the oversight or design of the study or in the analysis or interpretation of the data. The study protocol, available with the full text of this article at NEJM.org, was reviewed and approved by an independent protocol review committee and by the institutional review board at each participating clinical site. An independent data and safety monitoring board oversaw the conduct of the trial and reviewed the safety and efficacy data. Data management and statistical analyses were performed at the data coordinating center (Axio Research, Seattle) with oversight by the executive committee for the trial (see the Supplementary Appendix, available at NEJM.org). After termination of the blinded study treatment on May 25, 2011, the members of the executive committee had full access to trial information and vouch for the accuracy and completeness of the data and analyses.
Study Design
Patients were recruited at 92 clinical centers in the United States and Canada. After providing written informed consent, eligible patients entered a 4-to-8-week open-label phase during which they received simvastatin at a dose of 40 mg per day, plus niacin at doses that were increased weekly from 500 mg per day to 2000 mg per day. Patients in whom a dose of at least 1500 mg of niacin per day was associated with an acceptable side-effect profile were randomly assigned, in a 1:1 ratio, to niacin or matching placebo. Randomization was performed with the use of a secure Internet application. Patients attended clinic visits at 6-month intervals and were contacted by telephone in alternate quarterly intervals.
Study Population
Eligible patients were 45 years of age or older and had established cardiovascular disease, which was defined as documented stable coronary heart disease, cerebrovascular or carotid disease, or peripheral arterial disease (Table 1 in the Supplementary Appendix). All eligible patients had low baseline levels of HDL cholesterol (<40 mg per deciliter [1.03 mmol per liter] for men; <50 mg per deciliter [1.29 mmol per liter] for women), elevated triglyceride levels (150 to 400 mg per deciliter [1.69 to 4.52 mmol per liter]), and LDL cholesterol levels lower than 180 mg per deciliter (4.65 mmol per liter) if they were not taking a statin at entry. Patients who were screened were required to discontinue lipid-modifying drugs, except for statins or ezetimibe, at least 4 weeks before enrollment. A fasting lipid profile was obtained in eligible patients to establish baseline levels; analyses were performed by the core laboratory. Potential participants were excluded if, within 4 weeks before enrollment, they had been hospitalized for an acute coronary syndrome or had undergone a planned revascularization procedure or if they had had a stroke within the preceding 8 weeks. Details of the inclusion and exclusion criteria are provided in the Supplementary Appendix.
Study Intervention and Adherence
Patients in the niacin group received niacin at a dose of 1500 to 2000 mg per day plus simvastatin. Patients in the placebo group received simvastatin plus a matching placebo that contained a small dose (50 mg) of immediate-release niacin in each 500-mg or 1000-mg tablet to mask the identity of the blinded treatment to patients and study personnel. In both groups, the dose of simvastatin was adjusted according to an algorithm specified in the protocol to achieve and maintain the LDL cholesterol level during treatment in the range of 40 to 80 mg per deciliter (1.03 to 2.07 mmol per liter). Subjects in both groups could receive ezetimibe, at a dose of 10 mg per day, to achieve the target LDL cholesterol level. To maintain the masking of the therapy, only LDL cholesterol levels were reported to the clinical sites. Adherence to niacin or placebo was measured by means of manual pill counts at clinic visits.
End Points
The primary end point was the composite of the first event of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, hospitalization (for >23 hours) for an acute coronary syndrome, or symptom-driven coronary or cerebral revascularization. Secondary composite end points included death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, or hospitalization for a “high-risk” acute coronary syndrome (with high risk characterized by accelerating ischemic symptoms or prolonged chest pain with electrocardiographic evidence of ischemia or increases in biomarker values to greater than the upper limit of the normal range but less than 2 times that upper limit); death from coronary heart disease, nonfatal myocardial infarction, or ischemic stroke; and death from cardiovascular causes. Tertiary end points included death from any cause, individual components of the primary end point, and prespecified subgroups defined according to sex, history or no history of diabetes, and presence or absence of the metabolic syndrome.
Ascertainment of End Points
A clinical events committee reviewed suspected primary end points (including silent myocardial infarction) with supporting documentation that did not reveal the treatment assignments. Electrocardiograms were read at a central reading facility at Saint Louis University; all lipid and serum chemical analyses were performed at the Northwest Lipid Metabolism and Diabetes Research Laboratory.
After the database was locked, the clinical events committee was asked to review all nonstroke events of the central nervous system again, with treatment assignments masked, to classify potential transient ischemic attacks, since these were not categorized at the initial review; stroke events were not re-reviewed. The results of this post hoc review are noted separately but are not included in the analyses.
Statistical Analysis
The original composite primary end point consisted of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, or high-risk acute coronary syndrome.14 Because the rate of the primary end point was lower than projected, the protocol was amended to change the end point of “high-risk acute coronary syndrome” to include hospitalization for an acute coronary syndrome and symptom-driven coronary or cerebral revascularization, on the basis of a blinded examination of data by the executive committee; an independent review committee appointed by the NHLBI, whose members did not have access to data on treatment-specific results, reviewed and recommended approval of this amendment in March 2010. In this event-driven trial, we expected to observe 800 adjudicated primary events during a mean follow-up period of 4.6 years. With this number of events, we estimated that the study would have 85% power to detect a 25% reduction in the revised five-component primary end point, at a one-sided alpha level of 0.025. A formal interim analysis plan specified asymmetric boundaries for stopping the trial early on the basis of a demonstration of efficacy or lack of efficacy. The boundary for lack of efficacy required an observed hazard ratio of 1.02 or greater with a P value for futility of less than 0.001 when 50% of events were reported. The follow-up period was scheduled to end in December 2012. At a meeting on April 25, 2011, the data and safety monitoring board recommended that the blinded intervention be stopped because the boundary for lack of efficacy had been crossed and an unexpected higher rate of ischemic stroke had been observed among patients who were being treated with niacin; the NHLBI accepted that recommendation.
The baseline characteristics of the patients, the data on adherence to the study drug, and the difference in the percentage change in lipid levels were compared between the study groups with the use of the chi-square test or two-sample t-test, as appropriate. The significance of the changes in lipid values among the participants in the niacin group was tested with the use of a Wilcoxon signed-rank test. Ranked data such as the dose of statins were compared with the use of Spearman rank correlation. All end-point analyses were performed according to the intention-to-treat principle. The analyses of efficacy end points were performed with the use of time-to-event methods. We used an unadjusted log-rank statistic to compare the two treatment groups and a Cox proportional-hazards model to estimate hazard ratios, confidence intervals, and the adjusted Wald statistic for various end points. The models were adjusted for history or no history of diabetes and for sex. The analyses of prespecified subgroups are reported with no adjustment for multiplicity. We used a Cox model to test for the significance of the interaction between treatment and subgroup variable with respect to the primary outcome.
Results
Study Population
Among 8162 patients who gave written informed consent, 4273 (52.4%) began the open-label niacin run-in phase, and 3414 of those patients (79.9%) were randomly assigned to a study group — 1718 to the niacin group and 1696 to the placebo group (Fig. 1 in the Supplementary Appendix). The mean (±SD) age of the patients was 64±9 years; 85.2% were men, 92.2% were white, 33.9% had diabetes (type 1 or type 2), 71.4% had hypertension, and 81.0% had the metabolic syndrome. The population was well-balanced with respect to all recorded characteristics (Table 1Table 1
Baseline Demographic and Clinical Characteristics of the Study Patients.).Lipid Levels
Among the 3196 patients (93.6%) who were taking a statin at entry, the baseline median LDL cholesterol level was 71 mg per deciliter (1.84 mmol per liter), the median HDL cholesterol level was 35 mg per deciliter (0.91 mmol per liter), and the median triglyceride level was 161 mg per deciliter (1.82 mmol per liter). Before entry, 76.2% of patients had been taking statins for at least 1 year, and 39.5% had been taking them for 5 years or longer. Among the 218 patients who were not taking a statin at entry, the baseline LDL cholesterol level was 124 mg per deciliter (3.21 mmol per liter), the HDL cholesterol level was 33 mg per deciliter (0.85 mmol per liter), and the triglyceride level was 215 mg per deciliter (2.43 mmol per liter).
At 2 years, the HDL cholesterol level had increased by 25.0% to 42 mg per deciliter (1.09 mmol per liter) in the niacin group, whereas it had increased by 9.8% to 38 mg per deciliter (0.98 mmol per liter) in the placebo group (P<0.001). Triglyceride levels had decreased by 28.6% in the niacin group and by 8.1% in the placebo group. The LDL cholesterol level had further decreased by 12.0% in the niacin group and by 5.5% in the placebo group. These lipid findings persisted through 3 years of follow-up (Table 2Table 2
Lipid Values at Baseline and during Follow-up., and Fig. 2 in the Supplementary Appendix).Adherence
The end points could be ascertained for all but 52 patients. During the follow-up period, the dose of the study drug was reduced in 6.3% of the patients in the niacin group and 3.4% of the patients in the placebo group (P<0.001). The study drug was discontinued in 25.4% of the patients in the niacin group and in 20.1% of the patients in the placebo group (P<0.001). The annualized rate of discontinuation of niacin was 8.4% per patient-year, but the overall rate of adherence among the patients who continued treatment was at least 75% (Table 3Table 3
Reductions and Discontinuation of Study Drugs and Levels of Statins.). More than 86% of the patients continued to receive simvastatin, and approximately 50% were taking 40 mg per day. More patients in the placebo group than in the niacin group were taking 80 mg per day (24.7% vs. 17.5%, P=0.02), which was the maximum dose of simvastatin. More patients in the placebo group than in the niacin group were taking ezetimibe (21.5% vs. 9.5%, P<0.001). The proportions of patients receiving cardiac preventive therapies (e.g., aspirin and other antiplatelet therapies, beta-blockers, and inhibitors of the renin–angiotensin system) were high and were similar in the two groups during the follow-up period.Primary and Secondary End Points
The primary end point occurred in 282 patients in the niacin group (16.4%) and 274 in the placebo group (16.2%) (hazard ratio with niacin, 1.02; 95% confidence interval [CI], 0.87 to 1.21; P=0.80 for the superiority of niacin therapy with the use of a Cox proportional-hazards model and P=0.79 by the log-rank test) (Table 4Table 4
Primary, Secondary, and Tertiary End Points. and Figure 1Figure 1Kaplan–Meier Curve for the Primary End Point.). Among components of the primary end point, there was an unexpected imbalance with respect to the rate of ischemic stroke as the first event between patients assigned to niacin and those assigned to placebo (27 patients [1.6%] vs. 15 patients [0.9%]). A total of 8 patients, all of whom had been in the niacin group, had an ischemic stroke sometime between 2 months and 4 years after discontinuation of the study drug. When all the patients with ischemic strokes were considered, rather than just those in whom the stroke was the first study event, a nonsignificant trend persisted among patients assigned to niacin as compared with those assigned to placebo (29 patients vs. 18 patients; hazard ratio, 1.61; 95% CI, 0.89 to 2.90; P=0.11). In a blinded, exploratory re-review of all possible neurologic events by the clinical events committee, three cases of transient ischemic attacks in the niacin group were reclassified as ischemic strokes, but these post hoc reclassifications are not included in the analyses.Niacin therapy had a similar lack of effect on the composite secondary end point of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, or hospitalization for a high-risk acute coronary syndrome (hazard ratio, 1.08; 95% CI, 0.87 to 1.34; P=0.49) and on the composite secondary end point of death from coronary heart disease, nonfatal myocardial infarction, or ischemic stroke (hazard ratio, 1.13; 95% CI, 0.90 to 1.42; P=0.30) (Table 4, and Fig. 3A in the Supplementary Appendix). The number of patients who died from cardiovascular causes was low in both the niacin group and the placebo group (45 patients [2.6%] and 38 patients [2.2%], respectively; P=0.47).
There were no significant interactions with respect to the primary end point between the treatment assignment and prespecified subgroups defined according to age (<65 years vs. ≥65 years), sex, presence or absence of diabetes, presence or absence of the metabolic syndrome, prior or no prior myocardial infarction, and use or no use of statins at entry (Fig. 3B in the Supplementary Appendix).
Adverse Effects
Symptoms leading to discontinuation of the study drug are noted in Table 3 . Adverse effects were rare and included liver-function abnormalities (0.5% in the placebo group and 0.8% in the niacin group), muscle symptoms or myopathy (0.3% of the patients overall), and rhabdomyolysis (1 patient in the placebo group and 4 in the niacin group).
Discussion
In this trial involving patients with established, nonacute cardiovascular disease and low levels of baseline HDL cholesterol who achieved and maintained low levels of LDL cholesterol (<70 mg per deciliter) while receiving intensive statin treatment, extended-release niacin plus simvastatin as compared with simvastatin alone was associated with significant increases in HDL cholesterol levels and decreases in triglyceride levels, but there was no significant reduction in the primary composite end point of cardiovascular events over a mean follow-up period of 36 months. A very high percentage of patients (94%) were already taking a statin at trial entry, and many had taken one for long periods; 20% had taken niacin previously. At 2 years of follow-up, among patients assigned to niacin, LDL cholesterol levels had decreased by an additional 12.0% to a median of 62 mg per deciliter and HDL cholesterol levels had increased by 25.0% to 42 mg per deciliter, whereas in the placebo group, LDL cholesterol levels had decreased minimally to a median of 68 mg per deciliter and HDL cholesterol levels had increased by 9.8% to 38 mg per deciliter.
Although previous studies of niacin6,16-18 have shown apparent benefits both in surrogate outcome measures (improvements in carotid intima–media thickness19 and regression of angiographic coronary-artery stenoses18) and in clinical outcomes, we observed no clinical benefit with extended-release niacin in patients with established coronary heart disease and low levels of baseline HDL cholesterol. In the original placebo-controlled Coronary Drug Project trial,6 treatment with immediate-release niacin in high doses (3000 mg per day) was associated with a significant reduction (by 14%) in the rate of death from coronary heart disease or myocardial infarction and a reduction by 26% in the rate of strokes or transient ischemic attacks — event-rate reductions that are similar to those in placebo-controlled trials of statins. In the 5-year placebo-controlled Veterans Affairs HDL Intervention Trial8 involving 2531 men with low HDL cholesterol levels at baseline, treatment with gemfibrozil was associated with a reduction by 22% in the rate of the primary end point (death from coronary heart disease or nonfatal myocardial infarction) and a reduction by 27% in the rate of stroke, despite the fact that HDL cholesterol levels were increased by only 6% (from 32 mg per deciliter [0.83 mmol per liter] to 34 mg per deciliter [0.88 mmol per liter]). However, the baseline LDL cholesterol level in that trial, which predated the widespread use of statins, was 111 mg per deciliter (2.87 mmol per liter), as compared with 71 mg per deciliter in the present study among patients who were taking a statin at trial entry. This between-trial difference of 40 mg per deciliter in the baseline LDL cholesterol level is consistent with the considerable effect statins have had on reducing both elevated LDL cholesterol levels and the rate of cardiovascular events.
Beyond the important role of statins in secondary prevention of cardiovascular events, our findings further underscore the profound, continuing evolutions in medical therapy over the past several decades, with the development of other disease-modifying interventions such as antiplatelet therapy, beta-blockers for patients who have had a myocardial infarction, and inhibitors of the renin–angiotensin system, all of which improve outcomes and were widely used in our study. The aggregate effects of contemporary medical therapy, particularly if such therapy incorporates the intensive use of statins and reduces LDL cholesterol levels to approximately 60 mg per deciliter (1.55 mmol per liter) in both groups, may have further reduced the rates of incident cardiovascular events during the follow-up period. This may make it difficult to show incremental clinical benefit with the administration of additional therapeutic lipid-modifying interventions such as niacin, fibrates, and inhibitors of the cholesterol ester transfer protein. Nevertheless, trials of niacin (Heart Protection Study 2: Treatment of HDL to Reduce the Incidence of Vascular Events [HPS2-THRIVE], NCT00461630) and inhibitors of the cholesterol ester transfer protein (A Study of the Effect of Dalcetrapib on Atherosclerotic Disease in Patients with Coronary Artery Disease [dal-OUTCOMES], NCT01059682; and the Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification trial [REVEAL], NCT01252953) are ongoing in patients with stable cardiovascular disease. A large, international trial of simvastatin plus niacin and laropiprant as compared with simvastatin alone in patients with coronary heart disease (the HPS2-THRIVE) is in the follow-up phase; enrollment has been completed. Unlike in the present study, enrolled patients were not preselected on the basis of a particular lipid profile such as low baseline HDL cholesterol levels.
The unexpected rate of ischemic stroke among patients in the niacin group warrants comment. Although the number of ischemic strokes was higher in the niacin group, the overall rate was low, and we cannot be certain whether this observation reflects a causal association or possibly the statistical “play of chance.” No previous studies or meta-analyses20 have shown an increased incidence of stroke with niacin in any therapeutic formulation, dose, or dosing regimen. Although careful review of the stroke outcomes and potential predisposing factors in the present study have failed to provide evidence that there is a causal link between extended-release niacin and ischemic stroke, this finding will be examined further in additional analyses and in other studies of niacin involving patients with cardiovascular disease.
There are several limitations to our study. First, our findings may not be generalizable to all patients with coronary disease or all patients with low HDL cholesterol levels. Although the results of the study may cast doubt on the clinical importance of therapeutic interventions directed toward modulating low levels of HDL cholesterol and elevated triglyceride levels — at least with respect to niacin therapy in patients with cardiovascular disease and dyslipidemia whose condition is stable — it remains unclear whether other populations may benefit from such treatment. Our trial excluded patients who had had a recent hospitalization for an acute coronary syndrome or acute myocardial infarction; such patients are at much higher risk than were the patients in our study. Only 6% of the patients in our study were not taking statins at entry, and these patients had much higher LDL cholesterol levels and lower HDL cholesterol levels at baseline than did the patients who were taking statins. Thus, it is unclear whether the 94% of patients who were taking statins at entry and had very low levels of LDL cholesterol at baseline had a lower risk of subsequent cardiovascular events than we originally projected or whether, as a recent study suggests,21 the intensive use of statins for 1 year or more may have caused “delipidation” of the lipid-rich necrotic core and potentially converted coronary plaques vulnerable to rupture into stable, quiescent ones. In addition, the generalizability of the findings of our trial is further limited by the low percentage of women enrolled (15%) and the very low rate of ethnic minorities recruited (8%).
Second, the patients in the placebo group received a small dose (50 mg) of immediate-release niacin in each placebo tablet to mask the identity of the blinded treatment to patients and study personnel. It seems highly unlikely that the moderate increase in HDL cholesterol levels observed in the patients receiving placebo could have resulted from the very small dose of immediate-release niacin contained in each 500-mg or 1000-mg placebo tablet (a cumulative dose of 100 to 200 mg per day); data from studies involving persons who were given 100, 200, or even 500 mg per day as a single dose for 5 weeks showed no change in any monitored lipid value beyond 4 hours after each daily dose.22 Multiple doses of short-acting niacin must be given daily to observe an effect on lipid or lipoprotein variables.
Finally, it is possible that the follow-up period of the trial (mean, 36 months) was not long enough to show a clinical treatment effect of niacin. However, the Kaplan–Meier curves for the primary end point were nearly identical at the time of termination of the study.
In summary, the AIM-HIGH trial was designed to determine the superiority of treatment with niacin plus a statin as compared with statin therapy, with or without ezetimibe, in further decreasing the incidence of major cardiac events among patients with coronary heart disease who had residual dyslipidemia and low levels of HDL cholesterol at baseline but who met a treatment goal of an LDL cholesterol level of 40 to 80 mg per deciliter. In such patients who had established, nonacute, atherosclerotic cardiovascular disease and guideline-driven, intensively controlled levels of LDL cholesterol while receiving simvastatin, we found no incremental benefit of niacin in reducing cardiovascular events over a follow-up period of 36 months, despite significant increases in HDL cholesterol levels and decreases in triglyceride levels. Whether such benefits might be observed in higher-risk cardiac patients or in those whose LDL cholesterol levels are not intensively controlled by statins will require further prospective study.
Supported by the National Heart, Lung, and Blood Institute and by an unrestricted grant from Abbott Laboratories. Abbott Laboratories donated the extended-release niacin, the matching placebo, and the ezetimibe; Merck donated the simvastatin. Neither of these companies had any role in the oversight or design of the study or in the analysis or interpretation of the data.
Dr. Boden reports receiving consulting fees from Abbott; Dr. Probstfield, receiving consulting fees from Amylin, Genentech, and Sanofi-Aventis and grant support through his institution from Abbott, Eli Lilly, and Sanofi-Aventis; Dr. Anderson, receiving consulting fees from Merck, lecture fees from Merck and Oryx Pharmaceuticals, and support through his institution from Merck for rounds speakers; Dr. Chaitman, receiving consulting fees from Merck, Pfizer, and Roche; Mr. Koprowicz, being employed by Axio Research; Ms. McBride, being employed by Axio Research; and Dr. Teo, receiving grant support through his institution from Novartis.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
No other potential conflict of interest relevant to this article was reported.
The members of the Writing Group (William E. Boden, M.D., University at Buffalo, Buffalo, NY; Jeffrey L. Probstfield, M.D., University of Washington, Seattle; Todd Anderson, M.D., University of Calgary and Libin Cardiovascular Institute, Calgary, AB, Canada; Bernard R. Chaitman, M.D., Saint Louis University, St. Louis; Patrice Desvignes-Nickens, M.D., National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD; Kent Koprowicz, M.S., Axio Research, Seattle; Ruth McBride, Sc.B., Axio Research, Seattle; Koon Teo, M.B., Ph.D., McMaster University, Hamilton, ON, Canada; and William Weintraub, M.D., Christiana Care Health Services, Wilmington, DE) assume responsibility for the content and integrity of this article.
This article (10.1056/NEJMoa1107579) was published on November 15, 2011, and updated on July 12, 2012, at NEJM.org.
Source Information
Address reprint requests to Ms. McBride at Axio Research, 2601 Fourth Ave., Suite 200, Seattle, WA 98121, or at ruthm@axioresearch.com.
Additional investigators in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial are listed in the Supplementary Appendix, available at NEJM.org.
- References
References
1
Tracking heart disease and stroke in Canada. Heart and Stroke Foundation of Canada, June 2009 (http://www.phac-aspc.gc.ca/publicat/2009/cvd-avc/pdf/cvd-avs-2009-eng.pdf).
2
Heart disease and stroke statistics -- 2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215
CrossRef | Web of Science | Medline3
Cholesterol Treatment Trialists' (CTT) Collaboration
CrossRef | Web of Science | Medline4
Castelli WP
Web of Science | Medline5
Assmann G Schulte H von Eckardstein A Huang Y
CrossRef | Web of Science | Medline6
The Coronary Drug Project Research Group
CrossRef | Web of Science | Medline7
Canner PL Berge KG Wenger NK
CrossRef | Web of Science | Medline8
Rubins HB Robins SJ Collins D
Free Full Text | Web of Science | Medline9
Brown BG Zhao XQ Chait A
Free Full Text | Web of Science | Medline10
Cannon CP Braunwald E McCabe CH
Free Full Text | Web of Science | Medline11
Barter P Gotto AM LaRosa JC
Free Full Text | Web of Science | Medline12
Khot UN Khot MB Bajzer CT
CrossRef | Web of Science | Medline13
Nichols GA Ambegaonkar BM Sazonov V Brown JP
CrossRef | Web of Science | Medline14
The AIM-HIGH Investigators. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. Am Heart J 2011;161(3):471.e2-477.e2.
15
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. Am Heart J 2011;161:538-543
CrossRef | Web of Science | Medline16
Cashin-Hemphill L Mack WJ Pogoda JM Sanmarco ME Azen SP Blankenhorn DH
CrossRef | Web of Science | Medline17
Taylor AJ Sullenberger LE Lee HJ Lee JK Grace KA
CrossRef | Web of Science | Medline18
Villines TC Stanek EJ Devine PJ
CrossRef | Web of Science | Medline19
Taylor AJ Lee HJ Sullenberger LE
CrossRef | Web of Science | Medline20
Bruckert E Labreuche J Amarenco P
CrossRef | Web of Science | Medline21
Zhao X-Q Dong L Hatsukami T
CrossRef | Web of Science22
Carlson LA. Nicotinic acid: its metabolism and its effects on plasma free fatty acids. In: Metabolic effects of nicotinic acid and its derivatives — proceedings of a workshop held in Films, Switzerland, 1970. Bern, Switzerland: Hans Huber, 1971:157-65.
- Citing Articles (863)
Citing Articles
1
Hayato Tada, Junji Kobayashi, Masa-aki Kawashiri, Kazuya Miyashita, Atsushi Nohara, Akihiro Inazu, Katsuyuki Nakajima, Hiroshi Mabuchi, Masakazu Yamagishi. (2016) Changes in lipoprotein lipase and endothelial lipase mass in familial hypercholesterolemia during three-drug lipid-lowering combination therapy. Lipids in Health and Disease 15
CrossRef2
Michihiro Hosojima, Ryohei Kaseda, Hazuki Kondo, Mikio Fujii, Masatoshi Kubota, Reiko Watanabe, Naohito Tanabe, Motoni Kadowaki, Yoshiki Suzuki, Akihiko Saito. (2016) Beneficial effects of rice endosperm protein intake in Japanese men with risk factors for metabolic syndrome: a randomized, crossover clinical trial. BMC Nutrition 2:1
CrossRef3
Nicholas J. Woudberg, Julia H. Goedecke, Dee Blackhurst, Miguel Frias, Richard James, Lionel H. Opie, Sandrine Lecour. (2016) Association between ethnicity and obesity with high-density lipoprotein (HDL) function and subclass distribution. Lipids in Health and Disease 15:1
CrossRef4
Eliot A. Brinton, Joseph Triscari, Philippe Brudi, Erluo Chen, Amy O. Johnson-Levonas, Christine McCrary Sisk, Rae Ann Ruck, Alexandra A. MacLean, Darbie Maccubbin, Yale B. Mitchel. (2016) Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Lipids in Health and Disease 15:1
CrossRef5
Annelise Genoux, Laeticia Lichtenstein, Jean Ferrières, Thibaut Duparc, Vanina Bongard, Paul-Louis Vervueren, Guillaume Combes, Dorota Taraszkiewicz, Meyer Elbaz, Michel Galinier, Bertrand Nassar, Jean-Bernard Ruidavets, Bertrand Perret, Laurent O. Martinez. (2016) Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study. BMC Medicine 14:1
CrossRef6
Tania Tsatralis, Anisyah Ridiandries, Stacy Robertson, Laura Z. Vanags, Yuen Ting Lam, Joanne T. M. Tan, Martin K. C. Ng, Christina A. Bursill. (2016) Reconstituted high-density lipoproteins promote wound repair and blood flow recovery in response to ischemia in aged mice. Lipids in Health and Disease 15:1
CrossRef7
Michael B. Boffa. (2016) Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease. Current Atherosclerosis Reports 18:12
CrossRef8
Maciej Banach, Tomas Stulc, Ricardo Dent, Peter P. Toth. (2016) Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology 225, 184-196
CrossRef9
Jonathan E. Feig, Jessica L. Feig, George D. Dangas. (2016) The role of HDL in plaque stabilization and regression. Coronary Artery Disease 27:7, 592-603
CrossRef10
Marsha E. Samson, Swann A. Adams, Anwar T. Merchant, Whitney D. Maxwell, Jiajia Zhang, Charles L. Bennett, James R. Hebert. (2016) Cardiovascular disease incidence among females in South Carolina by type of oral contraceptives, 2000–2013: a retrospective cohort study. Archives of Gynecology and Obstetrics 294:5, 991-997
CrossRef11
Alexander Kulik. (2016) Secondary prevention after coronary artery bypass graft surgery. Current Opinion in Cardiology 31:6, 635-643
CrossRef12
Seth G. Thacker, Abdalrahman Zarzour, Ye Chen, Mustafa S. Alcicek, Lita A. Freeman, Dennis O. Sviridov, Stephen J. Demosky, Alan T. Remaley. (2016) High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation. Immunology 149:3, 306-319
CrossRef13
Amirhosssein Sahebkar, Željko Reiner, Luis E. Simental-Mendía, Gianna Ferretti, Arrigo F.G. Cicero. (2016) Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. Metabolism 65:11, 1664-1678
CrossRef14
Om P Ganda, Joanna Mitri. (2016) Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes. Current Cardiology Reports 18:11
CrossRef15
Maria Drakopoulou, Konstantinos Toutouzas, Konstantinos Stathogiannis, Andreas Synetos, George Trantalis, Dimitrios Tousoulis. (2016) Managing the lipid profile of coronary heart disease patients. Expert Review of Cardiovascular Therapy 14:11, 1263-1271
CrossRef16
Diana Golden, Antonina Kolmakova, Sunitha Sura, Anthony T. Vella, Ani Manichaikul, Xin-Qun Wang, Suzette J. Bielinski, Kent D. Taylor, Yii-Der Ida Chen, Stephen S. Rich, Annabelle Rodriguez. (2016) Lymphocyte activation gene 3 and coronary artery disease. JCI Insight 1:17
CrossRef17
Pamela A. Kushner, Michael E. Cobble. (2016) Hypertriglyceridemia: the importance of identifying patients at risk. Postgraduate Medicine, 1-11
CrossRef18
, Takumi Hirata, Daisuke Sugiyama, Shin-ya Nagasawa, Yoshitaka Murakami, Shigeyuki Saitoh, Akira Okayama, Hiroyasu Iso, Fujiko Irie, Toshimi Sairenchi, Yoshihiro Miyamoto, Michiko Yamada, Shizukiyo Ishikawa, Katsuyuki Miura, Hirotsugu Ueshima, Tomonori Okamura. (2016) A pooled analysis of the association of isolated low levels of high-density lipoprotein cholesterol with cardiovascular mortality in Japan. European Journal of Epidemiology
CrossRef19
Winfried März, Hubert Scharnagl, Ioanna Gouni-Berthold, Günther Silbernagel, Alexander Dressel, Tanja B. Grammer, Ulf Landmesser, Hans Dieplinger, Eberhard Windler, Ulrich Laufs. (2016) LDL-Cholesterol: Standards of Treatment 2016: A German Perspective. American Journal of Cardiovascular Drugs 16:5, 323-336
CrossRef20
David C. Tong, Andrew M. Wilson, Jamie Layland. (2016) Novel risk factors for acute coronary syndromes and emerging therapies. International Journal of Cardiology 220, 815-824
CrossRef21
Setor K. Kunutsor, Hassan Khan, Kristiina Nyyssönen, Jari A. Laukkanen. (2016) Lipoprotein(a) and risk of sudden cardiac death in middle-aged Finnish men: A new prospective cohort study. International Journal of Cardiology 220, 718-725
CrossRef22
Malcolm Anastasius, Maaike Kockx, Wendy Jessup, David Sullivan, Kerry-Anne Rye, Leonard Kritharides. (2016) Cholesterol efflux capacity: An introduction for clinicians. American Heart Journal 180, 54-63
CrossRef23
C. Michael Gibson, Serge Korjian, Pierluigi Tricoci, Yazan Daaboul, John H. Alexander, Philippe G. Steg, A. Michael Lincoff, John J.P. Kastelein, Roxana Mehran, Denise D'Andrea, Bela Merkely, Maciej Zarebinski, Ton Oude Ophius, Robert A. Harrington. (2016) Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. American Heart Journal 180, 22-28
CrossRef24
J.D. García Díaz, J.M. Mesa Latorre, A.R. Valbuena Parra, D. Corps Fernández. (2016) Trastornos del metabolismo lipídico. Medicine - Programa de Formación Médica Continuada Acreditado 12:19, 1059-1071
CrossRef25
Sundararajan Srikanth, Prakash Deedwania. (2016) Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome. Current Hypertension Reports 18:10
CrossRef26
Alberico L. Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M. John Chapman, Heinz Drexel, Arno W. Hoes, Catriona S. Jennings, Ulf Landmesser, Terje R. Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W.M. Monique Verschuren, Charalambos Vlachopoulos, David A. Wood, Jose Luis Zamorano. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Atherosclerosis 253, 281-344
CrossRef27
Hong Y. Choi, Anouar Hafiane, Adel Schwertani, Jacques Genest. (2016) High-density Lipoproteins – Biology, Epidemiology and Clinical Management. Canadian Journal of Cardiology
CrossRef28
Dario Rahelić, Eugen Javor, Tomo Lucijanić, Marko Skelin. (2016) Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium–glucose co-transporter 2 inhibitors. Annals of Medicine, 1-12
CrossRef29
S. J. Park, K. J. Yeum, B. Choi, Y. S. Kim, N. S. Joo. (2016) Positive correlation of serum HDL cholesterol with blood mercury concentration in metabolic syndrome Korean men (analysis of KNANES 2008–2010, 2013). Journal of Endocrinological Investigation 39:9, 1031-1038
CrossRef30
Sumeet A. Khetarpal, Arman Qamar, John S. Millar, Daniel J. Rader. (2016) Targeting ApoC-III to Reduce Coronary Disease Risk. Current Atherosclerosis Reports 18:9
CrossRef31
Peter P. Toth. (2016) Novel Therapies for Low-Density Lipoprotein Cholesterol Reduction. The American Journal of Cardiology 118:6, 19A-32A
CrossRef32
Massimo F. Piepoli, Arno W. Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, Alberico L. Catapano, Marie-Therese Cooney, Ugo Corrà, Bernard Cosyns, Christi Deaton, Ian Graham, Michael Stephen Hall, F.D. Richard Hobbs, Maja-Lisa Løchen, Herbert Löllgen, Pedro Marques-Vidal, Joep Perk, Eva Prescott, Josep Redon, Dimitrios J. Richter, Naveed Sattar, Yvo Smulders, Monica Tiberi, H. Bart van der Worp, Ineke van Dis, W.M. Monique Verschuren. (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis 252, 207-274
CrossRef33
Peter Bramlage, Stefanie Lanzinger, Wolfgang Rathmann, Anton Gillessen, Nikolaus Scheper, Sebastian M. Schmid, Matthias Kaltheuner, Jochen Seufert, Thomas Danne, Reinhard W. Holl. (2016) Dyslipidaemia and its treatment in patients with type 2 diabetes: A joint analysis of the German DIVE and DPV registries. Diabetes, Obesity and Metabolism
CrossRef34
Dave L. Dixon, Cory Trankle, Leo Buckley, Eric Parod, Salvatore Carbone, Benjamin W. Van Tassell, Antonio Abbate. (2016) A review of PCSK9 inhibition and its effects beyond LDL receptors. Journal of Clinical Lipidology 10:5, 1073-1080
CrossRef35
Tisha R. Joy, Emily T. Brennan. (2016) Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?. Journal of Clinical Lipidology 10:5, 1067-1072
CrossRef36
Meyer Elbaz, Julien Faccini, Vanina Bongard, Cécile Ingueneau, Dorotea Taraszkiewicz, Bertrand Perret, Jean Ferrières, Jean-Bernard Ruidavets, Cécile Vindis. (2016) High-density lipoprotein subclass profile and mortality in patients with coronary artery disease: Results from the GENES study. Archives of Cardiovascular Diseases
CrossRef37
David R. Saxon, Robert H. Eckel. (2016) Statin Intolerance: A Literature Review and Management Strategies. Progress in Cardiovascular Diseases 59:2, 153-164
CrossRef38
Jennifer G. Robinson. (2016) Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non‐Familial Hypercholesterolemia. Progress in Cardiovascular Diseases 59:2, 165-171
CrossRef39
Jacqueline L. Cartier, Anne Carol Goldberg. (2016) Familial Hypercholesterolemia: Advances in Recognition and Therapy. Progress in Cardiovascular Diseases 59:2, 125-134
CrossRef40
Alberico L. Catapano, Ian Graham, Guy De Backer, Olov Wiklund, M. John Chapman, Heinz Drexel, Arno W. Hoes, Catriona S. Jennings, Ulf Landmesser, Terje R. Pedersen, Željko Reiner, Gabriele Riccardi, Marja-Riita Taskinen, Lale Tokgozoglu, W. M. Monique Verschuren, Charalambos Vlachopoulos, David A. Wood, Jose Luis Zamorano. (2016) 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, ehw272
CrossRef41
Nikolaos Papageorgiou, Effimia Zacharia, Emmanuel Androulakis, Alexandros Briasoulis, Marietta Charakida, Dimitris Tousoulis. (2016) HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation. Expert Opinion on Therapeutic Targets 20:8, 907-921
CrossRef42
T. D. Filippatos, E. Klouras, F. Barkas, M. Elisaf. (2016) Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Review of Cardiovascular Therapy 14:8, 953-962
CrossRef43
Shigemasa Tani, Ken Nagao, Atsushi Hirayama. (2016) Association of systemic inflammation with the serum apolipoprotein A-1 level: A cross-sectional pilot study. Journal of Cardiology 68:2, 168-177
CrossRef44
Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros. (2016) Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 65:8, 1109-1123
CrossRef45
Nicholas Brownell, Anand Rohatgi. (2016) Modulating cholesterol efflux capacity to improve cardiovascular disease. Current Opinion in Lipidology 27:4, 398-407
CrossRef46
Josephine N. Tran, Tzu Chun Kao, Toros Caglar, Karen M. Stockl, John A. Spertus, Heidi C. Lew, Brian K. Solow, Paul S. Chan. (2016) Impact of the 2013 Cholesterol Guideline on Patterns of Lipid-Lowering Treatment in Patients with Atherosclerotic Cardiovascular Disease or Diabetes After 1 Year. Journal of Managed Care & Specialty Pharmacy 22:8, 901-908
CrossRef47
Massimo F. Piepoli, Arno W. Hoes, Stefan Agewall, Christian Albus, Carlos Brotons, Alberico L. Catapano, Marie-Therese Cooney, Ugo Corrà, Bernard Cosyns, Christi Deaton, Ian Graham, Michael Stephen Hall, F. D. Richard Hobbs, Maja-Lisa Løchen, Herbert Löllgen, Pedro Marques-Vidal, Joep Perk, Eva Prescott, Josep Redon, Dimitrios J. Richter, Naveed Sattar, Yvo Smulders, Monica Tiberi, H. Bart van der Worp, Ineke van Dis, W. M. Monique Verschuren. (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 37:29, 2315-2381
CrossRef48
Stephan Krähenbühl, Ivana Pavik-Mezzour, Arnold von Eckardstein. (2016) Unmet Needs in LDL-C Lowering: When Statins Won’t Do!. Drugs 76:12, 1175-1190
CrossRef49
Robert W. McGarrah. (2016) Refocusing the AIM on HDL in the metabolic syndrome. Atherosclerosis 251, 531-533
CrossRef50
Andrei C. Sposito. (2016) HDL metrics, let’s call the number thing off?. Atherosclerosis 251, 525-527
CrossRef51
Kang He Zheng, Fleur M. van der Valk, Loek P. Smits, Mara Sandberg, Jean-Louis Dasseux, Rudi Baron, Ronald Barbaras, Constance Keyserling, Bram F. Coolen, Aart J. Nederveen, Hein J. Verberne, Thijs E. Nell, Danielle J. Vugts, Raphaël Duivenvoorden, Zahi A. Fayad, Willem J.M. Mulder, Guus A.M.S. van Dongen, Erik S.G. Stroes. (2016) HDL mimetic CER-001 targets atherosclerotic plaques in patients. Atherosclerosis 251, 381-388
CrossRef52
Osman Najam, Kausik K. Ray. (2016) Where to now in cardiovascular disease prevention. Atherosclerosis 251, 483-489
CrossRef53
John J. Albers, April Slee, Jerome L. Fleg, Kevin D. O’Brien, Santica M. Marcovina. (2016) Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial. Atherosclerosis 251, 454-459
CrossRef54
Nathan O. Stitziel, Sekar Kathiresan. (2016) Leveraging human genetics to guide drug target discovery. Trends in Cardiovascular Medicine
CrossRef55
Marco Masetti, Luciano Potena. (2016) Cholesterol efflux capacity: A weak player in the complex plot of cardiac allograft vasculopathy. The Journal of Heart and Lung Transplantation
CrossRef56
Philip C. Robinson, Hyon K. Choi, Ron Do, Tony R. Merriman. (2016) Insight into rheumatological cause and effect through the use of Mendelian randomization. Nature Reviews Rheumatology 12:8, 486-496
CrossRef57
Teemu J. Niiranen, Ramachandran S. Vasan. (2016) Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches. Expert Review of Cardiovascular Therapy 14:7, 855-869
CrossRef58
Wijtske Annema, Arnold von Eckardstein. (2016) Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. Translational Research 173, 30-57
CrossRef59
Byambaa Enkhmaa, Erdembileg Anuurad, Lars Berglund. (2016) The unresolved mystery of high-density lipoprotein: time for a paradigm shift?. Translational Research 173, 1-6
CrossRef60
Matthew J. Feinstein, Donald M. Lloyd-Jones. (2016) Monoclonal Antibodies for Lipid Management. Current Atherosclerosis Reports 18:7
CrossRef61
Changting Xiao, Satya Dash, Cecilia Morgantini, Robert A. Hegele, Gary F. Lewis. (2016) Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol. Diabetes 65:7, 1767-1778
CrossRef62
Jorie Versmissen, Ranitha Vongpromek, Reyhana Yahya, Jeroen B. van der Net, Leonie van Vark-van der Zee, Jeannette Blommesteijn-Touw, Darcos Wattimena, Trinet Rietveld, Clive R. Pullinger, Christina Christoffersen, Björn Dahlbäck, John P. Kane, Monique Mulder, Eric J. G. Sijbrands. (2016) Familial hypercholesterolaemia: cholesterol efflux and coronary disease. European Journal of Clinical Investigation 46:7, 643-650
CrossRef63
Ronald B. Goldberg, Vera A. Bittner, Richard L. Dunbar, Jerome L. Fleg, George Grunberger, John R. Guyton, Lawrence A. Leiter, Ruth McBride, Jennifer G. Robinson, Debra L. Simmons, Carol Wysham, Ping Xu, William E. Boden. (2016) Effects of Extended-Release Niacin Added to Simvastatin/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. The American Journal of Medicine 129:7, 753.e13-753.e22
CrossRef64
G.B. John Mancini, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A. Hegele, Dominic Ng, Glen J. Pearson, Janet Pope, A. Yashar Tashakkor. (2016) Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology 32:7, S35-S65
CrossRef65
Tamio Teramoto, Kiyoko Uno, Izuru Miyoshi, Irfan Khan, Katherine Gorcyca, Robert J. Sanchez, Shigeto Yoshida, Kazuhiro Mawatari, Tomoya Masaki, Hidenori Arai, Shizuya Yamashita. (2016) Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan. Atherosclerosis
CrossRef66
R. Preston Mason, Samuel C.R. Sherratt, Robert F. Jacob. (2016) Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents. Journal of Cardiovascular Pharmacology 68:1, 33-40
CrossRef67
Arshag D. Mooradian. (2016) Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm. Drugs 76:11, 1081-1091
CrossRef68
Ali Javaheri, Maria Molina, Payman Zamani, Amrith Rodrigues, Eric Novak, Susan Chambers, Patricia Stutman, Wilhelmina Maslanek, Mary Williams, Scott M. Lilly, Peter Heeger, Mohamed H. Sayegh, Anil Chandraker, David M. Briscoe, Kevin P. Daly, Randall Starling, David Ikle, Jason Christie, J. Eduardo Rame, Lee R. Goldberg, Jeffrey Billheimer, Daniel J. Rader. (2016) Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. The Journal of Heart and Lung Transplantation
CrossRef69
Kevin C. Maki, John R. Guyton, Carl E. Orringer, Ian Hamilton-Craig, Dominik D. Alexander, Michael H. Davidson. (2016) Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. Journal of Clinical Lipidology 10:4, 905-914
CrossRef70
Todd J. Anderson, Jean Grégoire, Glen J. Pearson, Arden R. Barry, Patrick Couture, Martin Dawes, Gordon A. Francis, Jacques Genest, Steven Grover, Milan Gupta, Robert A. Hegele, David C. Lau, Lawrence A. Leiter, Eva Lonn, G.B. John Mancini, Ruth McPherson, Daniel Ngui, Paul Poirier, John L. Sievenpiper, James A. Stone, George Thanassoulis, Richard Ward. (2016) 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology
CrossRef71
R. Spector. (2016) New Insight into the Dietary Cause of Atherosclerosis: Implications for Pharmacology. Journal of Pharmacology and Experimental Therapeutics 358:1, 103-108
CrossRef72
Andreea Milasan, François Dallaire, Gaétan Mayer, Catherine Martel. (2016) Effects of LDL Receptor Modulation on Lymphatic Function. Scientific Reports 6, 27862
CrossRef73
Gerhard W. Naerr, Philipp Rein, Christoph H. Saely, Heinz Drexel. (2016) Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascular Pharmacology 81, 22-30
CrossRef74
Raf H. M. van Hoof, Sylvia Heeneman, Joachim E. Wildberger, M. Eline Kooi. (2016) Dynamic Contrast-Enhanced MRI to Study Atherosclerotic Plaque Microvasculature. Current Atherosclerosis Reports 18:6
CrossRef75
Cheryl L. Wellington, Ruth Frikke-Schmidt. (2016) Relation between plasma and brain lipids. Current Opinion in Lipidology 27:3, 225-232
CrossRef76
Ravi B. Patel, Muthiah Vaduganathan, Ayman Samman-Tahhan, Andreas P. Kalogeropoulos, Vasiliki V. Georgiopoulou, Gregg C. Fonarow, Mihai Gheorghiade, Javed Butler. (2016) Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. The American Journal of Cardiology 117:11, 1845-1850
CrossRef77
Jianmin Chen, Christoph Thiemermann. (2016) Selenium and Niacin for Sepsis Therapy. Critical Care Medicine 44:6, 1256-1257
CrossRef78
Woon Yong Kwon, Gil Joon Suh, Kyung Su Kim, Yoon Sun Jung, Sung Hee Kim, Jae Seong Kim, Kyoung Min You. (2016) Niacin and Selenium Attenuate Sepsis-Induced Lung Injury by Up-Regulating Nuclear Factor Erythroid 2–Related Factor 2 Signaling*. Critical Care Medicine 44:6, e370-e382
CrossRef79
David M. Tehrani, Yanglu Zhao, Michael J. Blaha, Samia Mora, Rachel H. Mackey, Erin D. Michos, Matthew J. Budoff, William Cromwell, James D. Otvos, Paul D. Rosenblit, Nathan D. Wong. (2016) Discordance of Low-Density Lipoprotein and High-Density Lipoprotein Cholesterol Particle Versus Cholesterol Concentration for the Prediction of Cardiovascular Disease in Patients With Metabolic Syndrome and Diabetes Mellitus (from the Multi-Ethnic Study of Atherosclerosis [MESA]). The American Journal of Cardiology 117:12, 1921-1927
CrossRef80
Talar Markossian, Nicholas Burge, Benjamin Ling, Julia Schneider, Ivan Pacold, Vinod Bansal, David Leehey, Kevin Stroupe, Alex Chang, Holly Kramer. (2016) Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD. American Journal of Kidney Diseases 67:6, 965-977
CrossRef81
D. Sinning, D. M. Leistner, U. Landmesser. (2016) Einfluss der Lipidstoffwechselparameter auf die Entstehung und Progression der koronaren Herzerkrankung. Herz 41:4, 273-280
CrossRef82
Dominic K. T. Pang, Zengxuan Nong, Brian G. Sutherland, Cynthia G. Sawyez, Debra L. Robson, Jelena Toma, J. Geoffrey Pickering, Nica M. Borradaile. (2016) Niacin promotes revascularization and recovery of limb function in diet-induced obese mice with peripheral ischemia. Pharmacology Research & Perspectives 4:3, e00233
CrossRef83
Auryan Szalat, Ronen Durst, Eran Leitersdorf. (2016) Managing dyslipidaemia in type 2 diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 30:3, 431-444
CrossRef84
Katrina L. Ellis, Amanda J. Hooper, John R. Burnett, Gerald F. Watts. (2016) Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism. Nature Reviews Endocrinology 12:8, 467-484
CrossRef85
Haitham M. Ahmed, Michael Miller, Khurram Nasir, John W. McEvoy, David Herrington, Roger S. Blumenthal, Michael J. Blaha. (2016) Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis. American Journal of Epidemiology 183:10, 875-883
CrossRef86
Aurélie Lenglet, Sophie Liabeuf, Najeh El Esper, Sandrine Brisset, Janette Mansour, Anne-Sophie Lemaire-Hurtel, Aurelien Mary, Michel Brazier, Said Kamel, Romuald Mentaverri, Gabriel Choukroun, Albert Fournier, Ziad A. Massy. (2016) Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. Nephrology Dialysis Transplantation, gfw042
CrossRef87
Teja Klancic, Lavinia Woodward, Susanna M. Hofmann, Edward A. Fisher. (2016) High density lipoprotein and metabolic disease: Potential benefits of restoring its functional properties. Molecular Metabolism 5:5, 321-327
CrossRef88
L L N Husemoen, T Skaaby, B H Thuesen, N Grarup, C H Sandholt, T Hansen, O Pedersen, A Linneberg. (2016) Mendelian randomisation study of the associations of vitamin B12 and folate genetic risk scores with blood pressure and fasting serum lipid levels in three Danish population-based studies. European Journal of Clinical Nutrition 70:5, 613-619
CrossRef89
Peter P Toth, Michel Farnier, Joanne E Tomassini, JoAnne M Foody, Andrew M Tershakovec. (2016) Statin combination therapy and cardiovascular risk reduction. Future Cardiology 12:3, 289-315
CrossRef90
Stephen J. Nicholls, Giacomo Ruotolo, H. Bryan Brewer, Ming-Dauh Wang, Liping Liu, Mark B. Willey, Mark A. Deeg, Kathryn A. Krueger, Steven E. Nissen. (2016) Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. Journal of Clinical Lipidology 10:3, 519-527.e4
CrossRef91
Calvin Yeang, Ming-Yow Hung, Young-Sup Byun, Paul Clopton, Xiaohong Yang, Joseph L. Witztum, Sotirios Tsimikas. (2016) Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). Journal of Clinical Lipidology 10:3, 594-603
CrossRef92
Rishi K. Wadhera, Dylan L. Steen, Irfan Khan, Robert P. Giugliano, JoAnne M. Foody. (2016) A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality. Journal of Clinical Lipidology 10:3, 472-489
CrossRef93
Naveed Sattar, David Preiss, Jennifer G Robinson, C Stephen Djedjos, Mary Elliott, Ransi Somaratne, Scott M Wasserman, Frederick J Raal. (2016) Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data. The Lancet Diabetes & Endocrinology 4:5, 403-410
CrossRef94
Konstantinos Dean Boudoulas, Filippos Triposkiadis, Paraschos Geleris, Harisios Boudoulas. (2016) Coronary Atherosclerosis: Pathophysiologic Basis for Diagnosis and Management. Progress in Cardiovascular Diseases 58:6, 676-692
CrossRef95
Björn W. Karlson, Michael K. Palmer, Stephen J. Nicholls, Pia Lundman, Philip J. Barter. (2016) A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. The American Journal of Cardiology 117:9, 1444-1448
CrossRef96
Cheol Hyun Lee, Jong Shin Woo, Chang Bum Park, Jin Man Cho, Young Keun Ahn, Chong Jin Kim, Myung Ho Jeong, Weon Kim. (2016) Roles of High-Density Lipoprotein Cholesterol in Patients With Acute Myocardial Infarction. Medicine 95:18, e3319
CrossRef97
Scott M. Grundy. (2016) Metabolic syndrome update. Trends in Cardiovascular Medicine 26:4, 364-373
CrossRef98
Paul D. Thompson, Gregory Panza, Amanda Zaleski, Beth Taylor. (2016) Statin-Associated Side Effects. Journal of the American College of Cardiology 67:20, 2395-2410
CrossRef99
Purav Mody, Parag H. Joshi, Amit Khera, Colby R. Ayers, Anand Rohatgi. (2016) Beyond Coronary Calcification, Family History, and C-Reactive Protein. Journal of the American College of Cardiology 67:21, 2480-2487
CrossRef100
Rabea Asleh, Nina S. Levy, Gheorge Doros, Tina Costacou, Jennifer G. Robinson, Shany Blum, Hagit Goldenstein, William E. Boden, Debra L. Simmons, Megan A. Lacy, George Grunberger, Todd J. Anderson, Andrew P. Levy. (2016) Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes. Journal of the American College of Cardiology 67:21, 2553-2554
CrossRef101
Udho Thadani, Quang Tuan Nguyen, Han Yaling. . Acute Coronary Syndrome. 2016:, 86-112.
CrossRef102
Vien T. Truong, Kim N. Huynh, Tam Ngo, Sara Shah, Hau Van Tran, Chisalu Nchekwube, Nabeel Ali, Faisal Latif. . Hyperlipidemia. 2016:, 1-29.
CrossRef103
Evan A. Stein. (2016) What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?. Current Opinion in Endocrinology & Diabetes and Obesity 23, 97-105
CrossRef104
J. Pang, D. C. Chan, S. J. Hamilton, V. S. Tenneti, G. F. Watts, P. H. R. Barrett. (2016) Effect of niacin on triglyceride-rich lipoprotein apolipoprotein B-48 kinetics in statin-treated patients with type 2 diabetes. Diabetes, Obesity and Metabolism 18:10.1111/dom.2016.18.issue-4, 384-391
CrossRef105
Harsh Goel, Richard L. Dunbar. (2016) Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics. Current Atherosclerosis Reports 18
CrossRef106
Kirstin A. Carswell, Ajay P. Belgaumkar, Stephanie A. Amiel, Ameet G. Patel. (2016) A Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels. Obesity Surgery 26, 843-855
CrossRef107
Hermann Toplak, Bernhard Ludvik, Monika Lechleitner, Hans Dieplinger, Bernhard Föger, Bernhard Paulweber, Thomas Weber, Bruno Watschinger, Sabine Horn, Thomas C. Wascher, Heinz Drexel, Marianne Brodmann, Ernst Pilger, Alexander Rosenkranz, Erich Pohanka, Rainer Oberbauer, Otto Traindl, Franz Xaver Roithinger, Bernhard Metzler, Hans-Peter Haring, Stefan Kiechl. (2016) Austrian Lipid Consensus on the management of metabolic lipid disorders to prevent vascular complications. Wiener klinische Wochenschrift 128, 216-228
CrossRef108
Sarah Bou Malham, Anne Carol Goldberg. (2016) Cardiovascular risk reduction: the future of cholesterol lowering drugs. Current Opinion in Pharmacology 27, 62-69
CrossRef109
P. J. Barter, K.-A. Rye. (2016) New Era of Lipid-Lowering Drugs. Pharmacological Reviews 68, 458-475
CrossRef110
Wendy R. Russell, Athanasia Baka, Inger Björck, Nathalie Delzenne, Dan Gao, Helen R. Griffiths, Ellie Hadjilucas, Kristiina Juvonen, Sampo Lahtinen, Mirian Lansink, Luc Van Loon, Hannu Mykkänen, Elin östman, Gabriele Riccardi, Sophie Vinoy, Martin O. Weickert. (2016) Impact of Diet Composition on Blood Glucose Regulation. Critical Reviews in Food Science and Nutrition 56, 541-590
CrossRef111
Neil J. Stone, Alexander Turin, Jared A. Spitz, Christopher W. Valle, Sakina Kazmi. (2016) Statin therapy across the lifespan: evidence in major age groups. Expert Review of Cardiovascular Therapy 14, 341-366
CrossRef112
Sudeepta Dandapat, Jennifer G. Robinson. (2016) Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. Current Neurology and Neuroscience Reports 16
CrossRef113
Kohei Takata, Satoshi Imaizumi, Emi Kawachi, Eiji Yahiro, Yasunori Suematsu, Tomohiko Shimizu, Satomi Abe, Yoshino Matsuo, Kyoko Nakajima, Tetsuhiko Yasuno, Shiro Jimi, Bo Zhang, Yoshinari Uehara, Shin-ichiro Miura, Keijiro Saku. (2016) The ApoA-I mimetic peptide FAMP promotes recovery from hindlimb ischemia through a nitric oxide (NO)-related pathway. International Journal of Cardiology 207, 317-325
CrossRef114
Jatinder S. Minhas, Prashanth Patel, Pankaj K. Gupta. (2016) Limitations of a Cardiac Risk (QRISK2) Calculator in Patients with High Density Lipoprotein (HDL). High Blood Pressure & Cardiovascular Prevention 23, 47-50
CrossRef115
Juan Pedro-Botet, Teresa Mantilla-Morató, Ángel Díaz-Rodríguez, Ángel Brea-Hernando, Pedro González-Santos, Antonio Hernández-Mijares, Xavier Pintó, Jesús Millán Núñez-Cortés. (2016) El papel de la dislipemia aterogénica en las guías de práctica clínica. Clínica e Investigación en Arteriosclerosis 28, 65-70
CrossRef116
Michael H. Davidson, Joanne E. Tomassini, Erin Jensen, David Neff, Adam B. Polis, Andrew M. Tershakovec. (2016) Changing characteristics of statin-related cIMT trials from 1988 to 2006. Atherosclerosis 246, 121-129
CrossRef117
Robert W. McGarrah, Damian M. Craig, Carol Haynes, Z. Elaine Dowdy, Svati H. Shah, William E. Kraus. (2016) High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis 246, 229-235
CrossRef118
Ada Cuevas M., Rodrigo Alonso K. (2016) DISLIPIDEMIA DIABÉTICA. Revista Médica Clínica Las Condes 27:2, 152-159
CrossRef119
Markolf Hanefeld, Frank Pistrosch, Stefan R. Bornstein, Andreas L. Birkenfeld. (2016) The metabolic vascular syndrome - guide to an individualized treatment. Reviews in Endocrine and Metabolic Disorders 17:1, 5-17
CrossRef120
Kevin D. O’Brien, Daniel S. Hippe, Huijun Chen, Moni B. Neradilek, Jeffrey L. Probstfield, Suzanne Peck, Daniel A. Isquith, Gador Canton, Chun Yuan, Nayak L. Polissar, Xue-Qiao Zhao, William S. Kerwin. (2016) Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial. Data in Brief 6, 476-481
CrossRef121
Lisandro D. Colantonio, Vera Bittner. (2016) Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Endocrinology and Metabolism Clinics of North America 45:1, 171-184
CrossRef122
Bhavin B. Adhyaru, Terry A. Jacobson. (2016) New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk. Endocrinology and Metabolism Clinics of North America 45:1, 17-37
CrossRef123
Merle Myerson. (2016) Lipid Management in Human Immunodeficiency Virus. Endocrinology and Metabolism Clinics of North America 45:1, 141-169
CrossRef124
Eliot A. Brinton. (2016) Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. Endocrinology and Metabolism Clinics of North America 45:1, 185-204
CrossRef125
Fernando Isidro Lago Deibe, Iria Bermejo Gestal, Guillermo Villar Zamora, Laura Otero Gómez. (2016) Viejos y nuevos hipolipemiantes. FMC - Formación Médica Continuada en Atención Primaria 23:3, 172-184
CrossRef126
Akhil Narang, Victor Mor-Avi, Nicole M. Bhave, Giacomo Tarroni, Cristiana Corsi, Michael H. Davidson, Roberto M. Lang, Amit R. Patel. (2016) Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. Journal of Clinical Lipidology 10:2, 314-322
CrossRef127
Harold E. Bays. (2016) A lipidologist perspective of global lipid guidelines and recommendations, part 2: Lipid treatment goals. Journal of Clinical Lipidology 10:2, 240-264
CrossRef128
Daniel J. Rader. (2016) New Therapeutic Approaches to the Treatment of Dyslipidemia. Cell Metabolism 23:3, 405-412
CrossRef129
Sivaram Pillarisetti. (2016) Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes. Trends in Pharmacological Sciences 37:3, 207-219
CrossRef130
Hannele Yki-Järvinen. . Effects of treatment of NAFLD on the metabolic syndrome. 2016:, 189-195.
CrossRef131
Michael J. Lipinski, Umberto Benedetto, Ricardo O. Escarcega, Giuseppe Biondi-Zoccai, Thibault Lhermusier, Nevin C. Baker, Rebecca Torguson, H. Bryan Brewer, Ron Waksman. (2016) The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. European Heart Journal 37, 536-545
CrossRef132
Sabina A. Murphy, Christopher P. Cannon, Michael A. Blazing, Robert P. Giugliano, Jennifer A. White, Yuliya Lokhnygina, Craig Reist, KyungAh Im, Erin A. Bohula, Daniel Isaza, Jose Lopez-Sendon, Mikael Dellborg, Uma Kher, Andrew M. Tershakovec, Eugene Braunwald. (2016) Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome. Journal of the American College of Cardiology 67, 353-361
CrossRef133
Stephen J. Nicholls, Rishi Puri, Kathy Wolski, Christie M. Ballantyne, Philip J. Barter, H. Bryan Brewer, John J. P. Kastelein, Bo Hu, Kiyoko Uno, Yu Kataoka, Jean-Paul R. Herrman, Bela Merkely, Marilyn Borgman, Steven E. Nissen. (2016) Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. American Journal of Cardiovascular Drugs 16, 55-65
CrossRef134
W. Annema, A. Dikkers, J. Freark de Boer, R. P. F. Dullaart, J.-S. F. Sanders, S. J. L. Bakker, U. J. F. Tietge. (2016) HDL Cholesterol Efflux Predicts Graft Failure in Renal Transplant Recipients. Journal of the American Society of Nephrology 27, 595-603
CrossRef135
Richard L. Dunbar, Harsh Goel. (2016) Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part I: Alternative Niacin Regimens. Current Atherosclerosis Reports 18
CrossRef136
Richard Haynes, Kazem Rahimi. (2016) Niacin: old habits die hard. Heart 102, 170-171
CrossRef137
Florian Kronenberg. (2016) Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. Cardiovascular Drugs and Therapy 30, 87-100
CrossRef138
Yuji Takahashi, Yasuki Ito, Norio Wada, Atsushi Nagasaka, Masato Fujikawa, Toshihiro Sakurai, Rojeet Shrestha, Shu-Ping Hui, Hitoshi Chiba. (2016) Development of homogeneous assay for simultaneous measurement of apoE-deficient, apoE-containing, and total HDL-cholesterol. Clinica Chimica Acta 454, 135-142
CrossRef139
Kevin D. O'Brien, Daniel S. Hippe, Huijun Chen, Moni B. Neradilek, Jeffrey L. Probstfield, Suzanne Peck, Daniel A. Isquith, Gador Canton, Chun Yuan, Nayak L. Polissar, Xue-Qiao Zhao, William S. Kerwin. (2016) Longer duration of statin therapy is associated with decreased carotid plaque vascularity by magnetic resonance imaging. Atherosclerosis 245, 74-81
CrossRef140
Christina Reith, Jane Armitage. (2016) Management of residual risk after statin therapy. Atherosclerosis 245, 161-170
CrossRef141
Amirhossein Sahebkar, Guglielmo Beccuti, Luis E. Simental-Mendía, Valerio Nobili, Simona Bo. (2016) Nigella Sativa (Black Seed) Effects on Plasma Lipid Concentrations in Humans: a Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Pharmacological Research
CrossRef142
Michael M. Page, Amanda J. Hooper, John R. Burnett. (2016) Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?. Expert Opinion on Pharmacotherapy 17, 275-281
CrossRef143
Harold E. Lebovitz. . Hyperglycemia Secondary to Nondiabetic Conditions and Therapies. 2016:, 737-751.e6.
CrossRef144
Mason W. Freeman, Geoffrey A. Walford. . Lipoprotein Metabolism and the Treatment of Lipid Disorders. 2016:, 715-736.e7.
CrossRef145
GPS Shantha, JG Robinson. (2016) Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids. Clinical Pharmacology & Therapeutics 99:10.1002/cpt.v99.1, 59-71
CrossRef146
Anish Bhatt, Anand Rohatgi. (2016) HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target. Current Atherosclerosis Reports 18
CrossRef147
Seth S. Martin, Parag H. Joshi, Erin D. Michos. . Lipids in Coronary Heart Disease. 2016:, 67-80.
CrossRef148
Rae-Ellen W. Kavey. (2016) Management of Moderate Hypertriglyceridemia in Childhood and Adolescence. Current Cardiovascular Risk Reports 10
CrossRef149
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Ralph A. DeFronzo, Daniel Einhorn, Vivian A. Fonseca, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Robert R. Henry, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul D. Rosenblit, Guillermo E. Umpierrez. (2016) CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2016 EXECUTIVE SUMMARY. Endocrine Practice 22, 84-113
CrossRef150
D.G. Kallend, J.A.A. Reijers, S.E. Bellibas, A. Bobillier, H. Kempen, J. Burggraaf, M. Moerland, P.L.J. Wijngaard. (2016) A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease. European Heart Journal - Cardiovascular Pharmacotherapy 2, 23-29
CrossRef151
Jane Nelson Worel, Laura L. Hayman. (2016) Preventing Cardiovascular Disease in Patients With Diabetes. The Journal of Cardiovascular Nursing 31, 198-200
CrossRef152
Y. C. Chen, J. Rivera, M. Fitzgerald, C. Hausding, Y.-L. Ying, X. Wang, K. Todorova, S. Hayrabedyan, E. R. Barnea, K. Peter. (2016) PreImplantation factor prevents atherosclerosis via its immunomodulatory effects without affecting serum lipids. Thrombosis and Haemostasis 115:5, 1010-1024
CrossRef153
Gurveen Malhotra, Ankur Sethi, Rohit Arora. (2016) Hypertriglyceridemia and Cardiovascular Outcomes. American Journal of Therapeutics 23:3, e862-e870
CrossRef154
Sergio Montserrat-de la Paz, Maria C. Naranjo, Sergio Lopez, Rocio Abia, Francisco J. G. Muriana, Beatriz Bermudez. (2016) Niacin and olive oil promote skewing to the M2 phenotype in bone marrow-derived macrophages of mice with metabolic syndrome. Food Funct. 7:5, 2233-2238
CrossRef155
Do-Sim Park, Kyeong Ho Yun, Hyun Young Park, Sang Jae Rhee, Nam-Ho Kim, Seok Kyu Oh, Jin-Won Jeong. (2016) Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol. Korean Circulation Journal 46:3, 309
CrossRef156
Kengo Moriyama, Eiko Takahashi. (2016) HDL<sub>2</sub>/HDL<sub>3</sub> Ratio Changes, Metabolic Syndrome Markers, and Other Factors in a Japanese Population. Journal of Atherosclerosis and Thrombosis 23:6, 704-712
CrossRef157
David S. Schade, Brendan Cavanaugh, Barry Ramo, R. Philip Eaton. (2016) The Application of the LDL Principle. World Journal of Cardiovascular Diseases 06:05, 109-125
CrossRef158
Alice Ossoli, Chiara Pavanello, Laura Calabresi. (2016) High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis. Endocrinology and Metabolism 31:2, 223
CrossRef159
Shinji Koba, Makoto Ayaori, Harumi Uto-Kondo, Fumiaki Furuyama, Yuya Yokota, Fumiyoshi Tsunoda, Makoto Shoji, Katsunori Ikewaki, Youichi Kobayashi. (2016) Beneficial Effects of Exercise-Based Cardiac Rehabilitation on High-Density Lipoprotein-Mediated Cholesterol Efflux Capacity in Patients with Acute Coronary Syndrome. Journal of Atherosclerosis and Thrombosis 23:7, 865-877
CrossRef160
Santosh K. Padala, Mandeep S. Sidhu, William E. Boden. . Stable Ischemic Heart Disease Stable Ischemic Heart Disease. 2016:, 1-70.
CrossRef161
Min Kyong Moon. (2016) Management of Dyslipidemia according to the 2015 Treatment Guideline for Diabetes: Controversies and Issues to Resolve. The Journal of Korean Diabetes 17:2, 96
CrossRef162
(2016) 8. Cardiovascular Disease and Risk Management. Diabetes Care 39:Supplement 1, S60-S71
CrossRef163
Henry J. Pownall, Antonio M. Gotto. (2016) New Insights into the High-Density Lipoprotein Dilemma. Trends in Endocrinology & Metabolism 27:1, 44-53
CrossRef164
W. Virgil Brown, JoAnne M. Foody, Franklin J. Zieve, Joanne E. Tomassini, Arvind Shah, Andrew M. Tershakovec. (2016) Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapy. Journal of Clinical Lipidology 10:1, 116-123
CrossRef165
Francine K. Welty, Abdulhamied Alfaddagh, Tarec K. Elajami. (2016) Targeting inflammation in metabolic syndrome. Translational Research 167:1, 257-280
CrossRef166
A. Pirillo, G.D. Norata, A.L. Catapano. . Advances in Hypercholesterolemia. 2016.
CrossRef167
Nan Chen, William H. Frishman. (2016) High-Density Lipoprotein Infusion Therapy and Atherosclerosis. Cardiology in Review 24:6, 298-302
CrossRef168
Gerald Klose, Ulrich Schwabe. . Lipidsenkende Mittel. 2016:, 523-530.
CrossRef169
Francis R. Joshi, Nikil K. Rajani, Markus Abt, Mark Woodward, Jan Bucerius, Venkatesh Mani, Ahmed Tawakol, David Kallend, Zahi A. Fayad, James H.F. Rudd. (2016) Does Vascular Calcification Accelerate Inflammation?. Journal of the American College of Cardiology 67:1, 69-78
CrossRef170
Miroslav Zeman, Marek Vecka, František Perlík, Barbora Staňková, Robert Hromádka, Eva Tvrzická, Jakub Širc, Jakub Hrib, Aleš Žák. (2016) Pleiotropic effects of niacin: Current possibilities for its clinical use. Acta Pharmaceutica 66:4
CrossRef171
Kyu Pill Kim, Jong Sung Kim, Sung Soo Kim, Jin Kyu Jung, Seok Joon Yoon, Chang Jung Wei. (2016) Relationship among Alcohol Consumption, Facial Flushing Response and Dyslipidemia in Male. Korean Journal of Health Promotion 16:3, 153
CrossRef172
Sridevi Krishnan, Jincui Huang, Hyeyoung Lee, Andres Guerrero, Lars Berglund, Erdembileg Anuurad, Carlito B. Lebrilla, Angela M. Zivkovic. (2015) Combined High-Density Lipoprotein Proteomic and Glycomic Profiles in Patients at Risk for Coronary Artery Disease. Journal of Proteome Research 14, 5109-5118
CrossRef173
Robert M. Stoekenbroek, John JP Kastelein, Roeland Huijgen. (2015) PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Medicine 13
CrossRef174
Michel P. Hermans, Evariste Bouenizabila, Daniel K. Amoussou-guenou, Sylvie A. Ahn, Michel F. Rousseau. (2015) Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. Cardiovascular Diabetology 14
CrossRef175
Tomáš Stulc, Richard Ceška, Antonio M. Gotto. (2015) Statin Intolerance: the Clinician’s Perspective. Current Atherosclerosis Reports 17
CrossRef176
Gianluigi Savarese, Gaetano M. De Ferrari, Giuseppe M.C. Rosano, Pasquale Perrone-Filardi. (2015) Safety and efficacy of ezetimibe: A meta-analysis. International Journal of Cardiology 201, 247-252
CrossRef177
Steven E. Gryn, Robert A. Hegele. (2015) Novel therapeutics in hypertriglyceridemia. Current Opinion in Lipidology 26, 484-491
CrossRef178
MyNgan Duong, Belinda A. Di Bartolo, Stephen J. Nicholls. (2015) Acute high-density lipoprotein therapies. Current Opinion in Lipidology 26, 521-525
CrossRef179
Benoit J. Arsenault, Marjorie Boyer, John J.P. Kastelein. (2015) What does the future hold for cholesteryl ester transfer protein inhibition?. Current Opinion in Lipidology 26, 526-535
CrossRef180
Brian A. Ference. (2015) Mendelian randomization studies. Current Opinion in Lipidology 26, 566-571
CrossRef181
Ulrich Julius. (2015) Niacin as antidyslipidemic drug 1. Canadian Journal of Physiology and Pharmacology 93, 1043-1054
CrossRef182
Allison B. Reiss, Iryna Voloshyna, Joshua De Leon, Nobuyuki Miyawaki, Joseph Mattana. (2015) Cholesterol Metabolism in CKD. American Journal of Kidney Diseases 66, 1071-1082
CrossRef183
Michel Krempf, Ross J Simpson, Dena Rosen Ramey, Philippe Brudi, Hilde Giezek, Joanne E Tomassini, Raymond Lee, Michel Farnier. (2015) Patient and physician factors influence decision-making in hypercholesterolemia: a questionnaire-based survey. Lipids in Health and Disease 14
CrossRef184
Elise Vo, Stanley J. Goldberg. (2015) Immediate release niacin effect at stratified lipid levels. IJC Metabolic & Endocrine 9, 48-53
CrossRef185
Alan J. Garber, Martin Julian Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel Dagogo-Jack, Michael B. Davidson, Daniel Einhorn, Jeffrey R. Garber, W. Timothy Garvey, George Grunberger, Yehuda Handelsman, Irl B. Hirsch, Paul S. Jellinger, Janet B. McGill, Jeffrey I. Mechanick, Paul David Rosenblit, Guillermo E. Umpierrez. (2015) CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2015 EXECUTIVE SUMMARY. Endocrine Practice 21, 1403-1414
CrossRef186
Osman Najam, Gilles Lambert, Kausik K Ray. (2015) The past, present and future of lipid-lowering therapy. Clinical Lipidology 10, 481-498
CrossRef187
E Yang. (2015) PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?. Clinical Pharmacology & Therapeutics 98:10.1002/cpt.v98.6, 590-601
CrossRef188
Jamal S. Rana, Jennifer Y. Liu, Howard H. Moffet, Matthew D. Solomon, Alan S. Go, Marc G. Jaffe, Andrew J. Karter. (2015) Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. The American Journal of Cardiology 116:11, 1700-1704
CrossRef189
Rishi Puri, Steven E. Nissen, Venu Menon, Mingyuan Shao, Amy Hsu, George L. Bakris, John J.P. Kastelein, Bryan Williams, Juergen Armbrecht, Patrick Brunel, Yu Kataoka, Stephen J. Nicholls. (2015) Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis 243:2, 553-559
CrossRef190
Philip J. Barter, Kerry-Anne Rye. (2015) Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?. Clinical Therapeutics 37:12, 2716-2731
CrossRef191
Damon A. Bell, Gerald F. Watts. (2015) Contemporary and Novel Therapeutic Options for Hypertriglyceridemia. Clinical Therapeutics 37:12, 2732-2750
CrossRef192
Traci Turner, Evan A. Stein. (2015) Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes. Clinical Therapeutics 37:12, 2751-2769
CrossRef193
Erica Hoe, Robert A. Hegele. (2015) Lipid Management in Diabetes with a Focus on Emerging Therapies. Canadian Journal of Diabetes 39, S183-S190
CrossRef194
Marcio Sommer Bittencourt, Rodrigo Julio Cerci. (2015) Statin effects on atherosclerotic plaques: regression or healing?. BMC Medicine 13:1
CrossRef195
Evan A. Stein, Frederick J. Raal. (2015) Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future. Current Cardiology Reports 17
CrossRef196
William H. Frishman. (2015) Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?. The American Journal of Medicine 128:11, 1160-1161
CrossRef197
Carlos G. Santos-Gallego. (2015) HDL: Quality or quantity?. Atherosclerosis 243:1, 121-123
CrossRef198
Monica Gomaraschi, Alice Ossoli, Maria Pia Adorni, Elisabetta Damonte, Eric Niesor, Fabrizio Veglia, Guido Franceschini, Renee Benghozi, Laura Calabresi. (2015) Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. Vascular Pharmacology 74, 80-86
CrossRef199
Samata Basani, Abhimanyu Garg. (2015) Marked lowering of high-density lipoprotein cholesterol levels due to high dose bexarotene therapy. Journal of Clinical Lipidology 9:6, 832-836
CrossRef200
Terry A. Jacobson, Kevin C. Maki, Carl E. Orringer, Peter H. Jones, Penny Kris-Etherton, Geeta Sikand, Ralph La Forge, Stephen R. Daniels, Don P. Wilson, Pamela B. Morris, Robert A. Wild, Scott M. Grundy, Martha Daviglus, Keith C. Ferdinand, Krishnaswami Vijayaraghavan, Prakash C. Deedwania, Judith A. Aberg, Katherine P. Liao, James M. McKenney, Joyce L. Ross, Lynne T. Braun, Matthew K. Ito, Harold E. Bays, W. Virgil Brown. (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology 9:6, S1-S122.e1
CrossRef201
Camelia S. Stancu, Mihaela G. Carnuta, Gabriela M. Sanda, Laura Toma, Mariana Deleanu, Loredan S. Niculescu, Shlomo Sasson, Maya Simionescu, Anca V. Sima. (2015) Hyperlipidemia-induced hepatic and small intestine ER stress and decreased paraoxonase 1 expression and activity is associated with HDL dysfunction in Syrian hamsters. Molecular Nutrition & Food Research 59:11, 2293-2302
CrossRef202
Taufiq Salahuddin, Balaji Natarajan, Martin P. Playford, Aditya A. Joshi, Heather Teague, Youssef Masmoudi, Mariana Selwaness, Marcus Y. Chen, David A. Bluemke, Nehal N. Mehta. (2015) Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis. European Heart Journal 36, 2662-2665
CrossRef203
Ralph Burkhardt. (2015) Hyperlipidemia and cardiovascular disease. Current Opinion in Lipidology 26, 468-469
CrossRef204
Keun-Sik Hong, Bum Joon Kim, Jun-Young Lee, Sun U. Kwon, . (2015) Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial. International Journal of Stroke 10:10.1111/ijs.2015.10.issue-7, 1153-1158
CrossRef205
John S. Millar, Marina Cuchel. (2015) ApoA-I-Directed Therapies for the Management of Atherosclerosis. Current Atherosclerosis Reports 17
CrossRef206
C. Roger White, Dennis I. Goldberg, G.M. Anantharamaiah. (2015) Recent developments in modulating atherogenic lipoproteins. Current Opinion in Lipidology 26, 369-375
CrossRef207
Maiwand Ahmadsei, Dirk Lievens, Christian Weber, Philipp von Hundelshausen, Norbert Gerdes. (2015) Immune-mediated and lipid-mediated platelet function in atherosclerosis. Current Opinion in Lipidology 26, 438-448
CrossRef208
Ishwarlal Jialal, Nicola Abate. (2015) Ezetimibe–Statin Combination to Reduce Cardiovascular Events: The Evidence Base. Metabolic Syndrome and Related Disorders 13, 327-328
CrossRef209
Joseph V. Danavi, Shermeen B. Memon, Binh An P. Phan. (2015) Statin Alternatives: A Review of Over-the-Counter Lipid-Lowering Supplements. Alternative and Complementary Therapies 21, 198-209
CrossRef210
Patrick M. Hutchins, Jay W. Heinecke. (2015) Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL. Current Opinion in Lipidology 26, 388-393
CrossRef211
Peter P. Toth. (2015) Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease. Journal of the American College of Cardiology 66, 1873-1875
CrossRef212
Vera Bittner, Luqin Deng, Robert S. Rosenson, Ben Taylor, Stephen P. Glasser, Shia T. Kent, Michael E. Farkouh, Paul Muntner. (2015) Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease. Journal of the American College of Cardiology 66, 1864-1872
CrossRef213
Peter P Toth. (2015) Ezetimibe provides incremental reduction in risk for cardiovascular events and need for revascularisation following an acute coronary syndrome. Evidence Based Medicine 20, 176-176
CrossRef214
Masayasu Izuhara, Koh Ono, Hiroki Shiomi, Takeshi Morimoto, Yutaka Furukawa, Yoshihisa Nakagawa, Satoshi Shizuta, Tomohisa Tada, Junichi Tazaki, Takahiro Horie, Yasuhide Kuwabara, Osamu Baba, Tomohiro Nishino, Toru Kita, Takeshi Kimura. (2015) High-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after percutaneous coronary intervention: A report from the CREDO-Kyoto registry cohort-2. Atherosclerosis 242:2, 632-638
CrossRef215
Matthew K. Ito. (2015) Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature. Atherosclerosis 242:2, 647-656
CrossRef216
Karen R. Sando, Michelle Knight. (2015) Nonstatin Therapies for Management of Dyslipidemia: A Review. Clinical Therapeutics 37:10, 2153-2179
CrossRef217
Christina Goldie, Allen J Taylor, Peter Nguyen, Cody McCoy, Xue-Qiao Zhao, David Preiss. (2015) Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart, heartjnl-2015-308055
CrossRef218
Laurence Zhu, Longhou Fang. (2015) AIBP: A Novel Molecule at the Interface of Cholesterol Transport, Angiogenesis, and Atherosclerosis. Methodist DeBakey Cardiovascular Journal 11, 160-165
CrossRef219
Li-Hao Huang, Andrew Elvington, Gwendalyn J. Randolph. (2015) The role of the lymphatic system in cholesterol transport. Frontiers in Pharmacology 6
CrossRef220
Michael P. Dubé, Lauren Komarow, Carl J. Fichtenbaum, Joseph J. Cadden, Edgar T. Overton, Howard N. Hodis, Judith S. Currier, James H. Stein. (2015) Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation. Clinical Infectious Diseases 61, 840-849
CrossRef221
Hasan K. Siddiqi, Daniel Kiss, Daniel Rader. (2015) HDL-cholesterol and cardiovascular disease. Current Opinion in Cardiology 30, 536-542
CrossRef222
Kuang-Yuh Chyu, Prediman K. Shah. (2015) HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis. Frontiers in Pharmacology 6
CrossRef223
Caroline S. Fox, Sherita Hill Golden, Cheryl Anderson, George A. Bray, Lora E. Burke, Ian H. de Boer, Prakash Deedwania, Robert H. Eckel, Abby G. Ershow, Judith Fradkin, Silvio E. Inzucchi, Mikhail Kosiborod, Robert G. Nelson, Mahesh J. Patel, Michael Pignone, Laurie Quinn, Philip R. Schauer, Elizabeth Selvin, Dorothea K. Vafiadis. (2015) Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association. Diabetes Care 38, 1777-1803
CrossRef224
Merle Myerson, Carlos Malvestutto, Judith A. Aberg. (2015) Management of lipid disorders in patients living with HIV. The Journal of Clinical Pharmacology 55, 957-974
CrossRef225
Robert S. Rosenson, H. Bryan Brewer, Benjamin J. Ansell, Philip Barter, M. John Chapman, Jay W. Heinecke, Anatol Kontush, Alan R. Tall, Nancy R. Webb. (2015) Dysfunctional HDL and atherosclerotic cardiovascular disease. Nature Reviews Cardiology 13, 48-60
CrossRef226
Sanjiv Gupta. (2015) LDL Cholesterol, Statins And PCSK 9 Inhibitors. Indian Heart Journal 67, 419-424
CrossRef227
Susan Kühnast, Marta Fiocco, José W.A. van der Hoorn, Hans M.G. Princen, J. Wouter Jukema. (2015) Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials. European Journal of Pharmacology 763, 48-63
CrossRef228
Tetsuya Ishikawa, Makoto Ayaori, Harumi Uto-Kondo, Takatomo Nakajima, Makoto Mutoh, Katsunori Ikewaki. (2015) High-density lipoprotein cholesterol efflux capacity as a relevant predictor of atherosclerotic coronary disease. Atherosclerosis 242:1, 318-322
CrossRef229
Rae-Ellen W. Kavey. (2015) Combined dyslipidemia in childhood. Journal of Clinical Lipidology 9:5, S41-S56
CrossRef230
Marta Farràs, Olga Castañer, Sandra Martín-Peláez, Álvaro Hernáez, Helmut Schröder, Isaac Subirana, Daniel Muñoz-Aguayo, Sònia Gaixas, Rafael de la Torre, Magí Farré, Laura Rubió, Óscar Díaz, Sara Fernández-Castillejo, Rosa Solà, Maria José Motilva, Montserrat Fitó. (2015) Complementary phenol-enriched olive oil improves HDL characteristics in hypercholesterolemic subjects. A randomized, double-blind, crossover, controlled trial. The VOHF study. Molecular Nutrition & Food Research 59:9, 1758-1770
CrossRef231
Juan J. Badimon, Carlos G. Santos-Gallego. (2015) HDL Dysfunction. Journal of the American College of Cardiology 66:13, 1486-1488
CrossRef232
Mimi Guarneri, Ryan Bradley. . Integrative Nutritional Therapy for Cardiovascular Disease. 2015:, 143-188.
CrossRef233
Shiu Lun Au Yeung, Chaoqiang Jiang, Meijing Long, Kar Keung Cheng, Bin Liu, Weisen Zhang, Tai Hing Lam, Gabriel Matthew Leung, C. Mary Schooling. (2015) Evaluation of Moderate Alcohol Use With QT Interval and Heart Rate Using Mendelian Randomization Analysis Among Older Southern Chinese Men in the Guangzhou Biobank Cohort Study. American Journal of Epidemiology 182:4, 320-327
CrossRef234
Jennifer G. Robinson, Neil J. Stone. (2015) The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. European Heart Journal 36, 2110-2118
CrossRef235
Yu Du, Li Wang, Bin Hong. (2015) High-density lipoprotein-based drug discovery for treatment of atherosclerosis. Expert Opinion on Drug Discovery 10, 841-855
CrossRef236
Hong-ping Zhao, Bing-ren Xiang. (2015) Discontinued cardiovascular drugs in 2013 and 2014. Expert Opinion on Investigational Drugs 24, 1083-1092
CrossRef237
Katia Bravo, Gladys P Velarde. (2015) Ethnicity and coronary artery disease: the role of high-density lipoprotein – a change in paradigm. Expert Review of Cardiovascular Therapy 13, 923-931
CrossRef238
Ricardo Ladeiras-Lopes, Stefan Agewall, Ahmed Tawakol, Bart Staels, Evan Stein, Robert J. Mentz, Adelino Leite-Moreira, Faiez Zannad, Wolfgang Koenig. (2015) Atherosclerosis: Recent trials, new targets and future directions. International Journal of Cardiology 192, 72-81
CrossRef239
Miao Hu, Ya-Ling Yang, Paul Chan, Brian Tomlinson. (2015) Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia. Pharmacogenomics 16, 1387-1397
CrossRef240
Preethi Mani, Anand Rohatgi. (2015) Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?. Current Atherosclerosis Reports 17
CrossRef241
Peiqiu Cao, Haitao Pan, Tiancun Xiao, Ting Zhou, Jiao Guo, Zhengquan Su. (2015) Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDL. International Journal of Molecular Sciences 16, 17245-17272
CrossRef242
Joost Besseling, Barbara Sjouke, John J.P. Kastelein. (2015) Screening and treatment of familial hypercholesterolemia – Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). Atherosclerosis 241:2, 597-606
CrossRef243
Amirhossein Sahebkar, Gerald F Watts. (2015) Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?. Expert Review of Clinical Pharmacology 8, 363-366
CrossRef244
Ahmed H Abdelhafiz, Joanne J Russell, Andrew Key, Alan J Sinclair. (2015) Older people with diabetes – avoiding hospitalization. Diabetes Management 5, 311-326
CrossRef245
Renata Cífková, Alena Krajčoviechová. (2015) Dyslipidemia and Cardiovascular Disease in Women. Current Cardiology Reports 17
CrossRef246
Valentina Kon, Haichun Yang, Sergio Fazio. (2015) Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Archives of Medical Research 46, 379-391
CrossRef247
Richard Kones, Umme Rumana. (2015) Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs. Drugs 75, 1201-1228
CrossRef248
Chi-kin Ip, Dong-mei Jin, Jia-jia Gao, Zhe Meng, Jing Meng, Zhi Tan, Jing-feng Wang, Deng-feng Geng. (2015) Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: A meta-analysis of randomized controlled trials. International Journal of Cardiology 191, 138-148
CrossRef249
Jason W. Castle, Kevin P. Kent, Ying Fan, Kirk D. Wallace, Cynthia E.L. Davis, Jeannette C. Roberts, Michael E. Marino, Kai E. Thomenius, Hae W. Lim, Eric Coles, Michael H. Davidson, Steven B. Feinstein, Anthony DeMaria. (2015) Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. Atherosclerosis 241:1, 92-99
CrossRef250
Lee Joseph, Jennifer G. Robinson. (2015) Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Progress in Cardiovascular Diseases 58:1, 19-31
CrossRef251
Anand Rohatgi. (2015) High-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity. Progress in Cardiovascular Diseases 58:1, 32-40
CrossRef252
Peter Alagona, Tariq Ali Ahmad. (2015) Cardiovascular Disease Risk Assessment and Prevention. Medical Clinics of North America 99:4, 711-731
CrossRef253
Renato Quispe, Mohammed Al-Hijji, Kristopher J. Swiger, Seth S. Martin, Mohamed B. Elshazly, Michael J. Blaha, Parag H. Joshi, Roger S. Blumenthal, Allan D. Sniderman, Peter P. Toth, Steven R. Jones. (2015) Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology 9:4, 511-518.e5
CrossRef254
Ryan E. Temel, J. Mark Brown. (2015) A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion. Trends in Pharmacological Sciences 36:7, 440-451
CrossRef255
Danish Saleheen, Robert Scott, Sundas Javad, Wei Zhao, Amrith Rodrigues, Antonino Picataggi, Daniya Lukmanova, Megan L Mucksavage, Robert Luben, Jeffery Billheimer, John J P Kastelein, S Matthijs Boekholdt, Kay-Tee Khaw, Nick Wareham, Daniel J Rader. (2015) Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. The Lancet Diabetes & Endocrinology 3:7, 507-513
CrossRef256
Jarcho, John A., Keaney, John F. Jr., . (2015) Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT. New England Journal of Medicine 372:25, 2448-2450
Free Full Text257
Cannon, Christopher P., Blazing, Michael A., Giugliano, Robert P., McCagg, Amy, White, Jennifer A., Theroux, Pierre, Darius, Harald, Lewis, Basil S., Ophuis, Ton Oude, Jukema, J. Wouter, De Ferrari, Gaetano M., Ruzyllo, Witold, De Lucca, Paul, Im, KyungAh, Bohula, Erin A., Reist, Craig, Wiviott, Stephen D., Tershakovec, Andrew M., Musliner, Thomas A., Braunwald, Eugene, Califf, Robert M., . (2015) Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine 372:25, 2387-2397
Free Full Text258
Osman Najam, Kausik K. Ray. (2015) Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management. Cardiology and Therapy 4, 25-38
CrossRef259
Derbew Fikadu Berhe, Kristina Juhlin, Kristina Star, Kidanemariam G. M. Beyene, Mukesh Dheda, Flora M. Haaijer-Ruskamp, Katja Taxis, Peter G. M. Mol. (2015) Adverse Drug Reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase. Tropical Medicine & International Health 20:10.1111/tmi.2015.20.issue-6, 797-806
CrossRef260
Asma Khaliq, B. Delia Johnson, R. David Anderson, Anthony A. Bavry, Rhonda M. Cooper-DeHoff, Eileen M. Handberg, C. Noel Bairey Merz, Stephen J. Nicholls, Steven Nissen, Carl J. Pepine. (2015) Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. Cardiovascular Endocrinology 4, 45-52
CrossRef261
Olga V. Savinova, Kristi Fillaus, William S. Harris, Gregory C. Shearer. (2015) Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. Atherosclerosis 240, 520-525
CrossRef262
Liying Chen, Wenhua Zhu, Linhe Mai, Lizheng Fang, Kejing Ying. (2015) The association of metabolic syndrome and its components with brachial-ankle pulse wave velocity in south China. Atherosclerosis 240, 345-350
CrossRef263
Dennis Sprecher, Miles Maxwell, Joanne Goodman, Brian White, Chi-Man Tang, Valerie Boullay, Anne-Charlotte de Gouville. (2015) Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist. European Journal of Pharmacology 756, 1-7
CrossRef264
Francis O'Neill, Meliana Riwanto, Marietta Charakida, Sophie Colin, Jasmin Manz, Eve McLoughlin, Tauseef Khan, Nigel Klein, Christopher W.M. Kay, Kalpesh Patel, Giulia Chinetti, Bart Staels, Francesco D'Aiuto, Ulf Landmesser, John Deanfield. (2015) Structural and functional changes in HDL with low grade and chronic inflammation. International Journal of Cardiology 188, 111-116
CrossRef265
Jonathan E. Feig, Jessica L. Feig, Annapoorna S. Kini. (2015) Statins, atherosclerosis regression and HDL: Insights from within the plaque. International Journal of Cardiology 189, 168-171
CrossRef266
Kun Ren, Zhen-Li Tang, Yue Jiang, Yan-Mei Tan, Guang-Hui Yi. (2015) Apolipoprotein M. Clinica Chimica Acta 446, 21-29
CrossRef267
Parag H. Joshi, Seth S. Martin, Roger S. Blumenthal. (2015) The Remnants of Residual Risk∗. Journal of the American College of Cardiology 65:21, 2276-2278
CrossRef268
Robert P. Giugliano, Marc S. Sabatine. (2015) Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?. Journal of the American College of Cardiology 65:24, 2638-2651
CrossRef269
Roberto S. Kalil, Jeffrey H. Wang, Ian H. de Boer, Roy O. Mathew, Joachim H. Ix, Arif Asif, Xuefeng Shi, William E. Boden. (2015) Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. Kidney International 87:6, 1250-1257
CrossRef270
Jean Ferrières. (2015) A paradigm shift in the treatment of atherosclerosis. Archives of Cardiovascular Diseases 108:6-7, 337-339
CrossRef271
Zhong-Min Liu, Miao Hu, Paul Chan, Brian Tomlinson. (2015) Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. Expert Opinion on Investigational Drugs 24, 611-621
CrossRef272
Bhavin B. Adhyaru, Terry A. Jacobson. (2015) New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk. Cardiology Clinics 33, 181-196
CrossRef273
Klaus G. Parhofer. (2015) Increasing HDL-cholesterol and prevention of atherosclerosis: A critical perspective. Atherosclerosis Supplements 18, 109-111
CrossRef274
Haider J. Warraich, Nathan D. Wong, Jamal S. Rana. (2015) Role for Combination Therapy in Diabetic Dyslipidemia. Current Cardiology Reports 17
CrossRef275
Todd J. Anderson, G.B. John Mancini, Jacques Genest, Jean Grégoire, Eva M. Lonn, Robert A. Hegele. (2015) The New Dyslipidemia Guidelines: What Is the Debate?. Canadian Journal of Cardiology 31, 605-612
CrossRef276
Eliot A. Brinton. (2015) Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease. Cardiology Clinics 33, 309-323
CrossRef277
Merle Myerson. (2015) Lipid Management in Human Immunodeficiency Virus. Cardiology Clinics 33, 277-298
CrossRef278
Emil M. deGoma, Ali Salavati, Russell T. Shinohara, Babak Saboury, Laura Pollan, Marisa Schoen, Drew A. Torigian, Emile R. Mohler, Richard L. Dunbar, Harold I. Litt, John Woo, Daniel J. Rader, Abass Alavi, Nehal N. Mehta. (2015) A Pilot Trial to Examine the Effect of High-Dose Niacin on Arterial Wall Inflammation Using Fluorodeoxyglucose Positron Emission Tomography. Academic Radiology 22, 600-609
CrossRef279
E. S. Stroes, P. D. Thompson, A. Corsini, G. D. Vladutiu, F. J. Raal, K. K. Ray, M. Roden, E. Stein, L. Tokgozo lu, B. G. Nordestgaard, E. Bruckert, G. De Backer, R. M. Krauss, U. Laufs, R. D. Santos, R. A. Hegele, G. K. Hovingh, L. A. Leiter, F. Mach, W. Marz, C. B. Newman, O. Wiklund, T. A. Jacobson, A. L. Catapano, M. J. Chapman, H. N. Ginsberg, , European Atherosclerosis Society Consensus, E. Stroes, P. D. Thompson, A. Corsini, G. D. Vladutiu, F. J. Raal, K. K. Ray, M. Roden, E. Stein, L. Tokgozo lu, B. G. Nordestgaard, E. Bruckert, R. M. Krauss, U. Laufs, R. D. Santos, W. Marz, C. B. Newman, M. John Chapman, H. N. Ginsberg, M. John Chapman, H. N. Ginsberg, G. de Backer, A. L. Catapano, R. A. Hegele, G. Kees Hovingh, T. A. Jacobson, L. Leiter, F. Mach, O. Wiklund. (2015) Statin-associated muscle symptoms: impact on statin therapy--European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal 36, 1012-1022
CrossRef280
J. T. M. Tan, M. K. C. Ng, C. A. Bursill. (2015) The role of high-density lipoproteins in the regulation of angiogenesis. Cardiovascular Research 106, 184-193
CrossRef281
N.V. Artemeva, M.S. Safarova, M.V. Ezhov, O.I. Afanasieva, O.A. Dmitrieva, S.N. Pokrovsky. (2015) Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype. Atherosclerosis Supplements 18, 53-58
CrossRef282
Todd J. Anderson. (2015) New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention. Canadian Journal of Cardiology 31, 585-587
CrossRef283
Sharon K. Gill. (2015) Cardiovascular Risk Factors and Disease in Women. Medical Clinics of North America 99, 535-552
CrossRef284
M. Scholz, S. Tselmin, S. Fischer, U. Julius. (2015) Hypertriglyceridemia in an outpatient department – Significance as an atherosclerotic risk factor. Atherosclerosis Supplements 18, 146-153
CrossRef285
Lisandro D. Colantonio, Vera Bittner. (2015) Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels. Cardiology Clinics 33, 299-308
CrossRef286
Elani Streja, Csaba P. Kovesdy, Dan A. Streja, Hamid Moradi, Kamyar Kalantar-Zadeh, Moti L. Kashyap. (2015) Niacin and Progression of CKD. American Journal of Kidney Diseases 65, 785-798
CrossRef287
Arshag D. Mooradian, Michael J. Haas. (2015) Targeting High-Density Lipoproteins: Increasing De Novo Production Versus Decreasing Clearance. Drugs 75, 713-722
CrossRef288
Luis Masana, Núria Plana. (2015) Actualización de las tablas de planificación terapéutica hipocolesterolemiante orientada a la obtención de los objetivos. Clínica e Investigación en Arteriosclerosis 27, 138-143
CrossRef289
Jonathan B. Finkel, Danielle Duffy. (2015) 2013 ACC/AHA cholesterol treatment guideline: Paradigm shifts in managing atherosclerotic cardiovascular disease risk. Trends in Cardiovascular Medicine 25, 340-347
CrossRef290
A. Gugliucci, R. Caccavello, H. Nassar, W. Abu Ahmad, R. Sinnreich, J.D. Kark. (2015) Low protective PON1 lactonase activity in an Arab population with high rates of coronary heart disease and diabetes. Clinica Chimica Acta 445, 41-47
CrossRef291
Miao Hu, Ya-Ling Yang, Chi-Fai Ng, Chui-Ping Lee, Vivian W.Y. Lee, Hiroyuki Hanada, Daisaku Masuda, Shizuya Yamashita, Brian Tomlinson. (2015) Effects of Phenotypic and Genotypic Factors on the Lipid Responses to Niacin in Chinese Patients With Dyslipidemia. Medicine 94, e881
CrossRef292
Neil J. Stone, C. Noel Bairey Merz, Karol E. Watson, Sidney C. Smith. (2015) Getting Guidelines Correct. Journal of the American College of Cardiology 65:18, 2051-2052
CrossRef293
John J P Kastelein, Joost Besseling, Sukrut Shah, Jean Bergeron, Gisle Langslet, G Kees Hovingh, Naab Al-Saady, Michiel Koeijvoets, John Hunter, Amy O Johnson-Levonas, Jennifer Fable, Aditi Sapre, Yale Mitchel. (2015) Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet 385:9983, 2153-2161
CrossRef294
Peter P. Toth, Avinash M. Murthy, Mandeep S. Sidhu, William E. Boden. (2015) Is HPS2-THRIVE the death knell for niacin?. Journal of Clinical Lipidology 9:3, 343-350
CrossRef295
Christie M. Ballantyne, Rene A. Braeckman, Harold E. Bays, John J. Kastelein, James D. Otvos, William G. Stirtan, Ralph T. Doyle, Paresh N. Soni, Rebecca A. Juliano. (2015) Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study). Journal of Clinical Lipidology 9:3, 377-383
CrossRef296
James McKenney, Harold Bays, Gilbert Gleim, Yale Mitchel, Olga Kuznetsova, Aditi Sapre, Waheeda Sirah, Darbie Maccubbin. (2015) Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials. Journal of Clinical Lipidology 9:3, 313-325
CrossRef297
Sabatine, Marc S., Giugliano, Robert P., Wiviott, Stephen D., Raal, Frederick J., Blom, Dirk J., Robinson, Jennifer, Ballantyne, Christie M., Somaratne, Ransi, Legg, Jason, Wasserman, Scott M., Scott, Robert, Koren, Michael J., Stein, Evan A., . (2015) Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine 372:16, 1500-1509
Free Full Text298
Mark Houston. . The Role of Nutrition and Nutritional Supplements in the Treatment of Dyslipidemia. 2015:, 75-102.
CrossRef299
Richard Delany. . Lipid Subfraction Testing. 2015:, 43-74.
CrossRef300
Jonny Bowden, Stephen Sinatra. . Myths of Cholesterol: Rethinking a Paradigm. 2015:, 1-14.
CrossRef301
Michael D. Shapiro, Sergio Fazio, Hagai Tavori. (2015) Targeting PCSK9 for Therapeutic Gains. Current Atherosclerosis Reports 17
CrossRef302
Maryam Zaid, Akira Fujiyoshi, Katsuyuki Miura, Robert D. Abbott, Tomonori Okamura, Naoyuki Takashima, Sayuki Torii, Yoshino Saito, Takashi Hisamatsu, Naoko Miyagawa, Takayoshi Ohkubo, Aya Kadota, Akira Sekikawa, Hiroshi Maegawa, Yasuyuki Nakamura, Kenichi Mitsunami, Hirotsugu Ueshima. (2015) High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in Japanese men. Atherosclerosis 239, 444-450
CrossRef303
A. Viljoen, A. S. Wierzbicki. (2015) Improving the odds: ezetimibe and cardiovascular disease. International Journal of Clinical Practice 69:10.1111/ijcp.2015.69.issue-4, 390-395
CrossRef304
Alison B. Kohan. (2015) Apolipoprotein C-III. Current Opinion in Endocrinology & Diabetes and Obesity 22, 119-125
CrossRef305
Michael N. Oda. (2015) High-density lipoprotein cholesterol. Current Opinion in Endocrinology & Diabetes and Obesity 22, 133-141
CrossRef306
G. Kees Hovingh, Daniel J. Rader, Robert A. Hegele. (2015) HDL re-examined. Current Opinion in Lipidology 26, 127-132
CrossRef307
Stefan Offermanns, Markus Schwaninger. (2015) Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation. Trends in Molecular Medicine 21, 245-255
CrossRef308
Alvin Chandra, Ian J. Neeland, Sandeep R. Das, Amit Khera, Aslan T. Turer, Colby R. Ayers, Darren K. McGuire, Anand Rohatgi. (2015) Relation of Black Race Between High Density Lipoprotein Cholesterol Content, High Density Lipoprotein Particles and Coronary Events (from the Dallas Heart Study). The American Journal of Cardiology 115, 890-894
CrossRef309
Marja-Riitta Taskinen, Jan Borén. (2015) New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 239, 483-495
CrossRef310
Christopher B. Fordyce, Matthew T. Roe, Tariq Ahmad, Peter Libby, Jeffrey S. Borer, William R. Hiatt, Michael R. Bristow, Milton Packer, Scott M. Wasserman, Ned Braunstein, Bertram Pitt, David L. DeMets, Katharine Cooper-Arnold, Paul W. Armstrong, Scott D. Berkowitz, Rob Scott, Jayne Prats, Zorina S. Galis, Norman Stockbridge, Eric D. Peterson, Robert M. Califf. (2015) Cardiovascular Drug Development. Journal of the American College of Cardiology 65, 1567-1582
CrossRef311
K.-C. Sung, S. Ryu, S. H. Wild, C. D. Byrne. (2015) An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. Heart 101, 553-558
CrossRef312
Brian A. Ference, Faisal Majeed, Raju Penumetcha, John M. Flack, Robert D. Brook. (2015) Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both. Journal of the American College of Cardiology 65, 1552-1561
CrossRef313
Liam R. Brunham, Michael R. Hayden. (2015) Human genetics of HDL: Insight into particle metabolism and function. Progress in Lipid Research 58, 14-25
CrossRef314
Ming-Lin Liu, Daniel J. Rader. . Lipoproteins. 2015:, 1-14.
CrossRef315
Gissette Reyes-Soffer, Henry N. Ginsberg. . Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals. 2015:, 262-274.
CrossRef316
Fabiana H. Rached, M. John Chapman, Anatol Kontush. (2015) HDL particle subpopulations: Focus on biological function. BioFactors 41:10.1002/biof.v41.2, 67-77
CrossRef317
Shashank R Joshi. (2015) Saroglitazar for the treatment of dyslipidemia in diabetic patients. Expert Opinion on Pharmacotherapy 16, 597-606
CrossRef318
Alev H. Gulum, Anne L. Hume. (2015) Statins: An Update on Clinical Issues and Selected Adverse Effects. The Journal for Nurse Practitioners 11, 287-294
CrossRef319
Edmond Kato Kabagambe, Sergio Fazio. (2015) Is it Time to Enhance Assessment of Alcohol Intake in Patients Slated for Statin Therapy?. Current Nutrition Reports 4, 1-5
CrossRef320
Terry A. Jacobson, Matthew K. Ito, Kevin C. Maki, Carl E. Orringer, Harold E. Bays, Peter H. Jones, James M. McKenney, Scott M. Grundy, Edward A. Gill, Robert A. Wild, Don P. Wilson, W. Virgil Brown. (2015) National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report. Journal of Clinical Lipidology 9, 129-169
CrossRef321
Yidong Wei, Huixin Guo, Erlinda The, Wenliang Che, Jianying Shen, Lei Hou, Shuiping Zhao, Ping Ye, Gang Li, Dongzhi Wang, Qiqiang Jie, Dayi Hu. (2015) Persistent lipid abnormalities in statin-treated coronary artery disease patients with and without diabetes in China. International Journal of Cardiology 182, 469-475
CrossRef322
Eric Niesor. (2015) Will Lipidation of ApoA1 through Interaction with ABCA1 at the Intestinal Level Affect the Protective Functions of HDL?. Biology 4, 17-38
CrossRef323
Wilbert S. Aronow. (2015) Newer targets and therapies for hypertension and dyslipidemia in diabetic patients. Cardiovascular Endocrinology 4:1, 11-16
CrossRef324
Hung-Yuan Chen, Wan-Chuan Tsai, Yen-Ling Chiu, Shih-Ping Hsu, Mei-Fen Pai, Ju-Yeh Yang, Yu-Sen Peng. (2015) Triglyceride to High-Density Lipoprotein Cholesterol Ratio Predicts Cardiovascular Outcomes in Prevalent Dialysis Patients. Medicine 94:10, e619
CrossRef325
Robert S. Rosenson, Michael H. Davidson, Ngoc-Anh Le, Jaime Burkle, Ray Pourfarzib. (2015) Underappreciated Opportunities for High-Density Lipoprotein Particles in Risk Stratification and Potential Targets of Therapy. Cardiovascular Drugs and Therapy 29, 41-50
CrossRef326
Antonio M Gotto, Jennifer E Moon. (2015) Twenty-five years of statins: where do we go from here?. Clinical Lipidology 10, 33-45
CrossRef327
Eric J. Niesor, Gregory G. Schwartz, Anne Perez, Andrea Stauffer, Alexandre Durrwell, Gabriela Bucklar-Suchankova, Renée Benghozi, Markus Abt, David Kallend. (2015) Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High-Density Lipoprotein. Cardiovascular Drugs and Therapy 29, 7-14
CrossRef328
L. E. Mokry, O. Ahmad, V. Forgetta, G. Thanassoulis, J. B. Richards. (2015) Mendelian randomisation applied to drug development in cardiovascular disease: a review. Journal of Medical Genetics 52, 71-79
CrossRef329
Luís Masana, Anna Cabré, Mercedes Heras, Núria Amigó, Xavier Correig, Sergio Martínez-Hervás, José T. Real, Juan F. Ascaso, Helena Quesada, Josep Julve, Xavier Palomer, Manuel Vázquez-Carrera, Josefa Girona, Núria Plana, Francisco Blanco-Vaca. (2015) Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis 238, 213-219
CrossRef330
Alana M. Munger, Dominic C. Chow, Martin P. Playford, Nisha I. Parikh, Louie Mar A. Gangcuangco, Beau K. Nakamoto, Kalpana J. Kallianpur, Lishomwa C. Ndhlovu, Cecilia M. Shikuma, Nehal N. Mehta. (2015) Characterization of Lipid Composition and High-Density Lipoprotein Function in HIV-Infected Individuals on Stable Antiretroviral Regimens. AIDS Research and Human Retroviruses 31, 221-228
CrossRef331
Mark Houston, Mimi Guarneri, Joel Kahn. (2015) The appropriate clinical use of niacin in the treatment of dyslipidemia. Clinical Lipidology 10, 17-22
CrossRef332
R. Preston Mason, Robert F. Jacob. (2015) Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochimica et Biophysica Acta (BBA) - Biomembranes 1848, 502-509
CrossRef333
J.-M. Bard, F. Paillard, J.-M. Lecerf. (2015) Effect of phytosterols/stanols on LDL concentration and other surrogate markers of cardiovascular risk. Diabetes & Metabolism 41, 69-75
CrossRef334
Dave L. Dixon, Krista L. Donohoe, Kelechi C. Ogbonna, Sarah M. Barden. (2015) Current Drug Treatment of Hyperlipidemia in Older Adults. Drugs & Aging 32, 127-138
CrossRef335
Julian Halcox, Anoop Misra. (2015) Type 2 Diabetes Mellitus, Metabolic Syndrome, and Mixed Dyslipidemia: How Similar, How Different, and How to Treat?. Metabolic Syndrome and Related Disorders 13, 1-21
CrossRef336
Xianhui Qin, Youbao Li, Hui Yuan, Di Xie, Genfu Tang, Binyan Wang, Xiaobin Wang, Xin Xu, Xiping Xu, Fanfan Hou. (2015) Relationship of MTHFR Gene 677C→T Polymorphism, Homocysteine, and Estimated Glomerular Filtration Rate Levels With the Risk of New-Onset Diabetes. Medicine 94, e563
CrossRef337
Eli M Roth. (2015) ω-3 carboxylic acids for hypertriglyceridemia. Expert Opinion on Pharmacotherapy 16, 123-133
CrossRef338
Manya Warrier, Diana M. Shih, Amy C. Burrows, Daniel Ferguson, Anthony D. Gromovsky, Amanda L. Brown, Stephanie Marshall, Allison McDaniel, Rebecca C. Schugar, Zeneng Wang, Jessica Sacks, Xin Rong, Thomas de Aguiar Vallim, Jeff Chou, Pavlina T. Ivanova, David S. Myers, H. Alex Brown, Richard G. Lee, Rosanne M. Crooke, Mark J. Graham, Xiuli Liu, Paolo Parini, Peter Tontonoz, Aldon J. Lusis, Stanley L. Hazen, Ryan E. Temel, J. Mark Brown. (2015) The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Reports 10, 326-338
CrossRef339
Laura Calabresi, Monica Gomaraschi, Sara Simonelli, Franco Bernini, Guido Franceschini. (2015) HDL and atherosclerosis: Insights from inherited HDL disorders. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1851, 13-18
CrossRef340
Younghyup Lim, Soyeon Yoo, Sang Ah Lee, Sang Ouk Chin, Dahee Heo, Jae Cheol Moon, Shinhang Moon, Kiyoung Boo, Seong Taeg Kim, Hye Mi Seo, Hyeyoung Jwa, Gwanpyo Koh. (2015) Apolipoprotein B Is Related to Metabolic Syndrome Independently of Low Density Lipoprotein Cholesterol in Patients with Type 2 Diabetes. Endocrinology and Metabolism 30, 208
CrossRef341
Aleš Žák. (2015) Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?. Medical Science Monitor 21, 2156-2162
CrossRef342
Fatima Rodriguez, Temitope Olufade, Kim Heithoff, Howard S. Friedman, Prakash Navaratnam, JoAnne M. Foody. (2015) Frequency of High-Risk Patients Not Receiving High-Potency Statin (from a Large Managed Care Database). The American Journal of Cardiology 115, 190-195
CrossRef343
M. Verdoia, A. Schaffer, H. Suryapranata, G. De Luca. (2015) Effects of HDL-modifiers on cardiovascular outcomes: A meta-analysis of randomized trials. Nutrition, Metabolism and Cardiovascular Diseases 25, 9-23
CrossRef344
(2015) 8. Cardiovascular Disease and Risk Management. Diabetes Care 38, S49-S57
CrossRef345
Amit V. Khera, Arman Qamar, Muredach P. Reilly, Richard L. Dunbar, Daniel J. Rader. (2015) Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia. The American Journal of Cardiology 115, 178-182
CrossRef346
Dawn DeWitt, David C. Dugdale, William R. Adam. (2015) Nonglycemic Targets in Diabetes. Medical Clinics of North America 99, 187-200
CrossRef347
David Preiss, Naveed Sattar. (2015) Reducing cardiovascular risk in type 2 diabetes mellitus. Medicine 43, 7-12
CrossRef348
Hai-Long Dai, Xue-Feng Guang, Zhi-Cheng Xiao. (2015) Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness. Journal of Clinical Lipidology 9, 113
CrossRef349
Bryan M. Bishop. (2015) Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol. American Journal of Therapeutics 22, 147-158
CrossRef350
Linda C. Hemphill. (2015) The Cholesterol Lowering Atherosclerosis Study (CLAS): What it tells us about niacin/colestipol therapy. Journal of Clinical Lipidology 9, 11-13
CrossRef351
Sang-Hak Lee. (2015) Combination pharmacotherapy in lipid management. Journal of the Korean Medical Association 58, 745
CrossRef352
Arshag D. Mooradian. (2015) Drug Therapy of Diabetic Dyslipidemia. American Journal of Therapeutics 22, 87-88
CrossRef353
Sang-Hak Lee. (2015) Update on the Pharmacologic Agents for Dyslipidemia. The Journal of Korean Diabetes 16, 269
CrossRef354
Stanley S. Levinson, Stephen G. Wagner. (2015) Implications of reverse cholesterol transport: Recent studies. Clinica Chimica Acta 439, 154-161
CrossRef355
Miao Hu, Ya-Ling Yang, Daisaku Masuda, Shizuya Yamashita, Brian Tomlinson. (2015) Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia. Disease Markers 2015, 1-8
CrossRef356
Deepu Daniel, Patrick Hardigan, Asif Jawaid, Rohit Bhandari, Mithun Daniel. (2015) The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease: A Retrospective Chart Review. Cholesterol 2015, 1-5
CrossRef357
Rohatgi , Anand , Khera , Amit , Berry , Jarett D. , Givens , Edward G. , Ayers , Colby R. , Wedin , Kyle E. , Neeland , Ian J. , Yuhanna , Ivan S. , Rader , Daniel R. , de Lemos , James A. , Shaul , Philip W. , . (2014) HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events. New England Journal of Medicine 371:25, 2383-2393
Free Full Text358
Anthony D Pisaniello, Daniel J Scherer, Yu Kataoka, Stephen J Nicholls. (2014) Ongoing challenges for pharmacotherapy for dyslipidemia. Expert Opinion on Pharmacotherapy, 1-10
CrossRef359
J.-C. Tardif, C. M. Ballantyne, P. Barter, J.-L. Dasseux, Z. A. Fayad, M.-C. Guertin, J. J. P. Kastelein, C. Keyserling, H. Klepp, W. Koenig, P. L. L'Allier, J. Lesperance, T. F. Luscher, J. F. Paolini, A. Tawakol, D. D. Waters, , M. Pfeffer, V. Brown, J. Rouleau, P. Watkins, L. J. Wei, G. Gosselin, C. Chayer, S. Lanthier, G. B. Pelletier, N. Racine, H. Agarwal, E. Brilakis, L. Cannon, D. Carrie, J. Corbelli, P. Coste, R. de Winter, A. Diaz, S. Eisenberg, B. Ennis, J. Fajadet, N. Fam, D. Fortuin, C. Gessler, C. Grines, D. Guerra, H. Gum, T. Haldis, T. Heestermans, J. P. Herrman, T. Huynh, E. Kedhi, M. Koren, S. Kouz, M. Krolick, G. Kumkumian, S. Lavi, R. J. Li, A. Masud, C. McAlhany, F. A. McGrew, C. O'Shaughnessy, A. J. M. Oude Ophuis, K. Parr, W. Penny, Y. Pesant, H. Post, S. Robinson, J. Rodes-Cabau, A. Roy, S. Schulman, F. Spence, G. Stouffer, T. Stys, B. Sussex, N. Tahirkheli, J.-C. Tardif, J. Gregoire, J. ten Berg, A. J. van Boven, C. von Birgelen, D. Weinstein. (2014) Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. European Heart Journal 35, 3277-3286
CrossRef360
Jennifer M. Hughes-Large, Dominic K.T. Pang, Debra L. Robson, Pak Chan, Jelena Toma, Nica M. Borradaile. (2014) Niacin receptor activation improves human microvascular endothelial cell angiogenic function during lipotoxicity. Atherosclerosis 237, 696-704
CrossRef361
J. Pedro-Botet, J.A. Flores-Le Roux, J.M. Mostaza, X. Pintó, J.J. de la Cruz, J.R. Banegas. (2014) Dislipemia aterogénica: prevalencia y control en las unidades de lípidos. Revista Clínica Española 214, 491-498
CrossRef362
Liya Wu, Klaus G. Parhofer. (2014) Diabetic dyslipidemia. Metabolism 63, 1469-1479
CrossRef363
Eberhard Windler, Gerald Klose, Klaus G. Parhofer, Elisabeth Steinhagen-Thiessen. (2014) Stärken und Grenzen randomisierter Studien zur Lipidtherapie. CardioVasc 14, 45-50
CrossRef364
David A. Hottman, Dustin Chernick, Shaowu Cheng, Zhe Wang, Ling Li. (2014) HDL and cognition in neurodegenerative disorders. Neurobiology of Disease 72, 22-36
CrossRef365
Marlys L. Koschinsky, Michael B. Boffa. (2014) Lipoprotein(a). Endocrinology and Metabolism Clinics of North America 43, 949-962
CrossRef366
Amita Singh, Michael Davidson. (2014) Combination Therapy with Statins. Endocrinology and Metabolism Clinics of North America 43, 993-1006
CrossRef367
Alexander Tenenbaum, Robert Klempfner, Enrique Z Fisman. (2014) Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovascular Diabetology 13
CrossRef368
Sophie J. Bernelot Moens, Julian C. van Capelleveen, Erik S.G. Stroes. (2014) Inhibition of ApoCIII. Current Opinion in Lipidology 25, 418-422
CrossRef369
Carlos G. Santos-Gallego, Juan J. Badimon, Robert S. Rosenson. (2014) Beginning to Understand High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America 43, 913-947
CrossRef370
Megan Harbin, Anthony Amadio, Aaron Tejani. (2014) Critical Appraisal of the SHARP Trial: The Results May Be Dull. Clinical Therapeutics 36, 2112-2117
CrossRef371
J. Pedro-Botet, J.A. Flores-Le Roux, J.M. Mostaza, X. Pintó, J.J. de la Cruz, J.R. Banegas. (2014) Atherogenic dyslipidemia: prevalence and management in lipid clinics. Revista Clínica Española (English Edition) 214, 491-498
CrossRef372
Baishali M. Ambegaonkar, Diane Tipping, Adam B. Polis, Joanne E. Tomassini, Andrew M. Tershakovec. (2014) Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis 237, 829-837
CrossRef373
Seth S. Martin, Parag H. Joshi, Michael J. Blaha. (2014) High-density lipoprotein and endothelial function in patients with myocardial infarction: Pieces in a puzzle. Atherosclerosis 237, 838-839
CrossRef374
Maria-Agata Miselli, Edoardo Dalla Nora, Angelina Passaro, Franco Tomasi, Giovanni Zuliani. (2014) Plasma triglycerides predict ten-years all-cause mortality in outpatients with type 2 diabetes mellitus: a longitudinal observational study. Cardiovascular Diabetology 13
CrossRef375
Huijun Chen, Jie Sun, William S Kerwin, Niranjan Balu, Moni B Neradilek, Daniel S Hippe, Daniel Isquith, Yunjing Xue, Kiyofumi Yamada, Suzanne Peck, Chun Yuan, Kevin D O’Brien, Xue-Qiao Zhao. (2014) Scan-rescan reproducibility of quantitative assessment of inflammatory carotid atherosclerotic plaque using dynamic contrast-enhanced 3T CMR in a multi-center study. Journal of Cardiovascular Magnetic Resonance 16
CrossRef376
Khalid Al-Rasadi, Ibrahim Al-Zakwani, Wael Al Mahmeed, Mohamed Arafah, Ali T. Al-Hinai, Abdullah Shehab, Omer Al Tamimi, Mahmoud Alawadhi. (2014) Therapeutic lipid target achievements among high and highest risk patients: results from the CEPHEUS study in the Arabian Gulf. Current Medical Research and Opinion 30, 2429-2435
CrossRef377
Matilda Florentin, Michael S Kostapanos, Anastazia Kei, Moses S Elisaf. (2014) Emerging drugs for hyperlipidaemia: an update. Expert Opinion on Emerging Drugs 19, 471-488
CrossRef378
Anthony S Wierzbicki, Adie Viljoen. (2014) Fibrates and niacin: is there a place for them in clinical practice?. Expert Opinion on Pharmacotherapy 15, 2673-2680
CrossRef379
Dinushan Nesan, Dominic S. Ng. (2014) Revising the high-density lipoprotein targeting strategies – Insights from human and preclinical studies. Critical Reviews in Clinical Laboratory Sciences 51, 321-331
CrossRef380
K. Sarat Chandra, Manish Bansal, Tiny Nair, S.S. Iyengar, Rajeev Gupta, Subhash C. Manchanda, P.P. Mohanan, V. Dayasagar Rao, C.N. Manjunath, J.P.S. Sawhney, Nakul Sinha, A.K. Pancholia, Sundeep Mishra, Ravi R. Kasliwal, Saumitra Kumar, Unni Krishnan, Sanjay Kalra, Anoop Misra, Usha Shrivastava, Seema Gulati. (2014) Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart Journal 66, S1-S51
CrossRef381
Helen M Colhoun, Jennifer G Robinson, Michel Farnier, Bertrand Cariou, Dirk Blom, Dean J Kereiakes, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari. (2014) Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. BMC Cardiovascular Disorders 14:1
CrossRef382
Zhijun Wu, Yuqing Lou, Xiaochun Qiu, Yan Liu, Lin Lu, Qiujing Chen, Wei Jin. (2014) Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach. BMC Medical Genetics 15:1
CrossRef383
Bertrand Lebouché, Mohammad-Ali Jenabian, Joel Singer, Gina M Graziani, Kim Engler, Benoit Trottier, Réjean Thomas, Marie-Josée Brouillette, Jean-Pierre Routy. (2014) The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy – CTN PT006: study protocol for a randomized controlled trial. Trials 15:1
CrossRef384
Dmitri Sviridov. (2014) High-Density Lipoprotein – A Hero, a Mirage, or a Witness?. Frontiers in Cardiovascular Medicine 1
CrossRef385
(2014) Niacin for Reduction of Cardiovascular Risk. New England Journal of Medicine 371:20, 1940-1944
Free Full Text386
Maya S. Safarova, Marat V. Ezhov. (2014) Variance in niacin response in individuals with elevated lipoprotein(a). Journal of Clinical Lipidology 8, 646-647
CrossRef387
Gregory G. Schwartz, Laurence Bessac, Lisa G. Berdan, Deepak L. Bhatt, Vera Bittner, Rafael Diaz, Shaun G. Goodman, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Kenneth W. Mahaffey, Angèle Moryusef, Robert Pordy, Matthew T. Roe, Tyrus Rorick, William J. Sasiela, Cheerag Shirodaria, Michael Szarek, Jean-François Tamby, Pierluigi Tricoci, Harvey White, Andreas Zeiher, Philippe Gabriel Steg. (2014) Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial. American Heart Journal 168, 682-689.e1
CrossRef388
Cédric Le May. (2014) Rôle de l’intestin dans le transport inverse du cholestérol. Cahiers de Nutrition et de Diététique 49, 207-212
CrossRef389
Ramesh Saeedi, Min Li, Simon Rankin, Jiri Frohlich. (2014) Reply. Journal of Clinical Lipidology 8, 647
CrossRef390
Andrea Perne, Thomas Münzel. (2014) Die konservative Therapie der stabilen koronaren Herzerkrankung. MMW - Fortschritte der Medizin 156, 52-59
CrossRef391
Thomas S. Metkus, Todd T. Brown, Wendy S. Post. (2014) Cardiovascular Disease Associated with the Human Immunodeficiency Virus: An Update. Current Treatment Options in Cardiovascular Medicine 16
CrossRef392
Claudia D. Fuchs, Thierry Claudel, Michael Trauner. (2014) Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends in Endocrinology & Metabolism 25, 576-585
CrossRef393
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2014) Dislipidemia aterogénica y riesgo residual. Estado de la cuestión en 2014. Clínica e Investigación en Arteriosclerosis 26, 287-292
CrossRef394
Heather L. Clifton, Bora Inceoglu, Linlin Ma, Jie Zheng, Saul Schaefer. (2014) TRPV1 Channels are Involved in Niacin-induced Cutaneous Vasodilation in Mice. Journal of Cardiovascular Pharmacology, 1
CrossRef395
Stephen J Nicholls. (2014) Examining controversies and new frontiers in lipid management. Clinical Lipidology 9, 587-595
CrossRef396
Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi, Andrew M. Tershakovec. (2014) Combination therapy in dyslipidemia: Where are we now?. Atherosclerosis 237, 319-335
CrossRef397
Xue-Qiao Zhao, Thomas S. Hatsukami, Daniel S. Hippe, Jie Sun, Niranjan Balu, Daniel A. Isquith, John R. Crouse, Todd Anderson, John Huston, Nayak Polissar, Kevin O'Brien, Chun Yuan. (2014) Clinical Factors Associated With High-Risk Carotid Plaque Features as Assessed by Magnetic Resonance Imaging in Patients With Established Vascular Disease (from the AIM-HIGH Study). The American Journal of Cardiology 114, 1412-1419
CrossRef398
Boris Bigalke, Alkystis Phinikaridou, Marcelo E. Andia, Margaret S. Cooper, Andreas Schuster, Thomas Wurster, David Onthank, Götz Münch, Philip Blower, Meinrad Gawaz, Eike Nagel, Rene M. Botnar. (2014) PET/CT and MR imaging biomarker of lipid-rich plaques using [64Cu]-labeled scavenger receptor (CD68-Fc). International Journal of Cardiology 177, 287-291
CrossRef399
Tanna H. Lim, Israel B. Orija, Brian L. Pearlman. (2014) The New Cholesterol Treatment Guidelines from the American College of Cardiology/American Heart Association, 2013: What Clinicians Need to Know. Postgraduate Medicine 126, 35-44
CrossRef400
Mohamed Hassan. (2014) HPS2-THRIVE, AIM-HIGH and dal-OUTCOMES: HDL-cholesterol under attack. Global Cardiology Science and Practice 2014, 37
CrossRef401
Amirhossein Sahebkar, Gerard T. Chew, Gerald F. Watts. (2014) Recent advances in pharmacotherapy for hypertriglyceridemia. Progress in Lipid Research 56, 47-66
CrossRef402
Amirhossein Sahebkar, Ali Badiee, Majid Ghayour-Mobarhan, Seyed Reza Goldouzian, Mahmoud Reza Jaafari. (2014) A simple and effective approach for the treatment of dyslipidemia using anionic nanoliposomes. Colloids and Surfaces B: Biointerfaces 122, 645-652
CrossRef403
Sony Tuteja, Daniel J. Rader. (2014) Dyslipidaemia: Cardiovascular prevention—end of the road for niacin?. Nature Reviews Endocrinology 10, 646-647
CrossRef404
Binh An P. Phan, Andrew B. Moore, Joseph Davis, Laura J. Pollan, Blazej Neradilek, B. Greg Brown, Xue-Qiao Zhao. (2014) Prolonged combination lipid therapy is associated with reduced carotid intima-media thickness: A case-control study of the 20-year Familial Atherosclerosis Treatment - Observational Study (FATS-OS). Journal of Clinical Lipidology 8, 489-493
CrossRef405
Jennifer G. Robinson. (2014) Contemporary Evidence-Based Guidelines. Mayo Clinic Proceedings 89, 1176-1182
CrossRef406
Jeffrey A. Marbach, Jessica L. McKeon, Joyce L. Ross, Danielle Duffy. (2014) Novel Treatments for Familial Hypercholesterolemia: Pharmacogenetics at Work. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34, 961-972
CrossRef407
Carlos Guijarro-Herraiz, Luis Masana-Marin, Enrique Galve, Alberto Cordero-Fort. (2014) Control del colesterol LDL en pacientes de muy alto riesgo vascular. Algoritmo simplificado para alcanzar objetivos de colesterol LDL «en dos pasos». Clínica e Investigación en Arteriosclerosis 26, 242-252
CrossRef408
Ravi Jahagirdar, Haiyan Zhang, Salman Azhar, Jennifer Tobin, Sarah Attwell, Raymond Yu, Jin Wu, Kevin G. McLure, Henrik C. Hansen, Gregory S. Wagner, Peter R. Young, Rai Ajit K. Srivastava, Norman C.W. Wong, Jan Johansson. (2014) A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis 236, 91-100
CrossRef409
James N. Kiage, Laurence O. James, Edmond K. Kabagambe. (2014) Genetic Modification of the Effects of Alcohol on Metabolic and Clinical Phenotypes: A Review. Current Nutrition Reports 3, 213-222
CrossRef410
Carlos G. Santos-Gallego, Robert S. Rosenson. (2014) Role of HDL in Those with Diabetes. Current Cardiology Reports 16
CrossRef411
J. C. Hopewell, U. Seedorf, M. Farrall, S. Parish, T. Kyriakou, A. Goel, A. Hamsten, R. Collins, H. Watkins, R. Clarke, . (2014) Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. Journal of Internal Medicine 276, 260-268
CrossRef412
Jyoti Ankam, David I. Feldman, Michael J. Blaha, Seth S. Martin. (2014) Improving lipid control following myocardial infarction. Current Opinion in Cardiology 29, 454-466
CrossRef413
Helen I Keen, Janakan Krishnarajah, Timothy R Bates, Gerald F Watts. (2014) Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?. Expert Opinion on Drug Safety 13, 1227-1239
CrossRef414
Michael H Davidson, Alyssa K Phillips, Douglas Kling, Kevin C Maki. (2014) Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. Expert Review of Cardiovascular Therapy 12, 1045-1054
CrossRef415
Michael J. Haas, Luisa M. Onstead-Haas, Emad Naem, Norman C. W. Wong, Arshag D. Mooradian. (2014) Induction of apolipoprotein A-I gene expression by black seed ( Nigella sativa ) extracts. Pharmaceutical Biology 52, 1119-1127
CrossRef416
Feng-Jun Chang, Hai-Yun Yuan, Xiao-Xia Hu, Zhi-Jun Ou, Li Fu, Ze-Bang Lin, Zhi-Ping Wang, Shen-Ming Wang, Li Zhou, Ying-Qi Xu, Cui-Ping Wang, Zhe Xu, Xi Zhang, Chun-Xiang Zhang, Jing-Song Ou. (2014) High density lipoprotein from patients with valvular heart disease uncouples endothelial nitric oxide synthase. Journal of Molecular and Cellular Cardiology 74, 209-219
CrossRef417
Stephen J. Nicholls, Alex Brown. (2014) Is Lp(a) Ready for Prime Time?∗. Journal of the American College of Cardiology 64:9, 861-862
CrossRef418
Yaniv Cozacov, Hira Ahmad, Raul Rosenthal. . Selected Nutritional Deficiencies (Zinc, Selenium, Vitamins A, D, E, and K, and Niacin). 2014:, 129-156.
CrossRef419
Robert A Hegele, Henry N Ginsberg, M John Chapman, Børge G Nordestgaard, Jan Albert Kuivenhoven, Maurizio Averna, Jan Borén, Eric Bruckert, Alberico L Catapano, Olivier S Descamps, G Kees Hovingh, Steve E Humphries, Petri T Kovanen, Luis Masana, Päivi Pajukanta, Klaus G Parhofer, Frederick J Raal, Kausik K Ray, Raul D Santos, Anton F H Stalenhoef, Erik Stroes, Marja-Riitta Taskinen, Anne Tybjærg-Hansen, Gerald F Watts, Olov Wiklund. (2014) The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. The Lancet Diabetes & Endocrinology 2, 655-666
CrossRef420
Kevin C Maki, Sylvia P Poulos, Alyssa K Phillips, Andrea L Lawless. (2014) Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia. Clinical Lipidology 9, 399-406
CrossRef421
Sidney C. Smith, Scott M. Grundy. (2014) 2013 ACC/AHA Guideline Recommends Fixed-Dose Strategies Instead of Targeted Goals to Lower Blood Cholesterol. Journal of the American College of Cardiology 64, 601-612
CrossRef422
Anastazia Kei, Constantinos Tellis, Evangelos Liberopoulos, Alexandros Tselepis, Moses Elisaf. (2014) Effect of Switch to the Highest Dose of Rosuvastatin Versus Add-on-Statin Fenofibrate Versus Add-on-Statin Nicotinic Acid/Laropiprant on Oxidative Stress Markers in Patients with Mixed Dyslipidemia. Cardiovascular Therapeutics 32:10.1111/cdr.2014.32.issue-4, 139-146
CrossRef423
Anette Varbo, Børge G. Nordestgaard. (2014) Remnant cholesterol and ischemic heart disease. Current Opinion in Lipidology 25, 266-273
CrossRef424
Michael A. Blazing, Robert P. Giugliano, Christopher P. Cannon, Thomas A. Musliner, Andrew M. Tershakovec, Jennifer A. White, Craig Reist, Amy McCagg, Eugene Braunwald, Robert M. Califf. (2014) Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population. American Heart Journal 168, 205-212.e1
CrossRef425
D. J. Rader. (2014) Spotlight on HDL biology: new insights in metabolism, function, and translation. Cardiovascular Research 103, 337-340
CrossRef426
Shobha H. Ganji, Vaijinath S. Kamanna, Moti L. Kashyap. (2014) Niacin decreases leukocyte myeloperoxidase: Mechanistic role of redox agents and Src/p38MAP kinase. Atherosclerosis 235, 554-561
CrossRef427
S. Unniachan, L. D. Bash, W. Khovidhunkit, R. Z. T. Sri, E. Vicaldo, C. Recto, B. M. Ambegaonkar. (2014) Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries. International Journal of Clinical Practice 68, 1010-1019
CrossRef428
F. Poti, M. Simoni, J.-R. Nofer. (2014) Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovascular Research 103, 395-404
CrossRef429
Barak Zafrir, Mohit Jain. (2014) Lipid-lowering Therapies, Glucose Control and Incident Diabetes: Evidence, Mechanisms and Clinical Implications. Cardiovascular Drugs and Therapy 28, 361-377
CrossRef430
Paul N. Durrington, Jonathan D. Schofield, Tarza Siahmansur, Handrean Soran. (2014) Lipoprotein (a). Current Opinion in Lipidology 25, 289-296
CrossRef431
Børge G Nordestgaard, Anette Varbo. (2014) Triglycerides and cardiovascular disease. The Lancet 384, 626-635
CrossRef432
Huifen Wang, Jeffrey B. Blumberg, C.-Y. Oliver Chen, Sang-Woon Choi, Michael P. Corcoran, Susan S. Harris, Paul F. Jacques, Aleksandra S. Kristo, Chao-Qiang Lai, Stefania Lamon-Fava, Nirupa R. Matthan, Diane L. McKay, Mohsen Meydani, Laurence D. Parnell, Max P. Prokopy, Tammy M. Scott, Alice H. Lichtenstein. (2014) Dietary modulators of statin efficacy in cardiovascular disease and cognition. Molecular Aspects of Medicine 38, 1-53
CrossRef433
A. T. Remaley, G. D. Norata, A. L. Catapano. (2014) Novel concepts in HDL pharmacology. Cardiovascular Research 103, 423-428
CrossRef434
Michael J. Haas, Luisa M. Onstead-Haas, Anna Szafran-Swietlik, Hagop Kojanian, Tim Davis, Paul Armstrong, Norman C.W. Wong, Arshag D. Mooradian. (2014) Induction of hepatic apolipoprotein A-I gene expression by the isoflavones quercetin and isoquercetrin. Life Sciences 110, 8-14
CrossRef435
Paul M Ridker. (2014) LDL cholesterol: controversies and future therapeutic directions. The Lancet 384, 607-617
CrossRef436
JoAnne M Foody, Peter P Toth, Andrew M Tershakovec, Thomas Musliner, Joanne E Tomassini, Robert S Lowe, David R Neff, Harry R Davis. (2014) Efficacy and safety of ezetimibe plus atorvastatin therapy. Clinical Lipidology 9, 441-470
CrossRef437
Arshag D. Mooradian, Michael J. Haas. (2014) The Effect of Nutritional Supplements on Serum High-Density Lipoprotein Cholesterol and Apolipoprotein A-I. American Journal of Cardiovascular Drugs 14, 253-274
CrossRef438
S Zoungas, A J Curtis, J J McNeil, A M Tonkin. (2014) Treatment of Dyslipidemia and Cardiovascular Outcomes: The Journey So Far—Is This the End for Statins?. Clinical Pharmacology & Therapeutics 96, 192-205
CrossRef439
Angela Pirillo, Gianpaolo Tibolla, Giuseppe Danilo Norata, Alberico Luigi Catapano. (2014) HDL: To Treat or Not To Treat?. Current Atherosclerosis Reports 16
CrossRef440
Daniel J Rader, G Kees Hovingh. (2014) HDL and cardiovascular disease. The Lancet 384, 618-625
CrossRef441
Thomas F. Boyden, Robert D. Brook, Elizabeth Jackson, Melvyn Rubenfire, Kim Eagle. (2014) Implementing New Guidelines in the Management of Blood Cholesterol. The American Journal of Medicine 127, 705-706
CrossRef442
Shobha Ghosh, Jinghua Bie, Jing Wang, Quan Yuan, Siddhartha S Ghosh. (2014) Cholesterol removal from plaques and elimination from the body: change in paradigm to reduce risk for heart disease. Clinical Lipidology 9, 429-440
CrossRef443
A. Kratzer, H. Giral, U. Landmesser. (2014) High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovascular Research 103, 350-361
CrossRef444
Anderson , Todd J. , , Boden , William E. , , Desvigne-Nickens , Patrice , Fleg , Jerome L. , , Kashyap , Moti L. , , McBride , Ruth , , Probstfield , Jeffrey L. , . (2014) Safety Profile of Extended-Release Niacin in the AIM-HIGH Trial. New England Journal of Medicine 371:3, 288-290
Free Full Text445
Lloyd-Jones , Donald M. , . (2014) Niacin and HDL Cholesterol — Time to Face Facts. New England Journal of Medicine 371:3, 271-273
Full Text446
The HPS2-THRIVE Collaborative Group (2014) Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine 371:3, 203-212
Free Full Text447
Jørgensen , Anders Berg , Frikke-Schmidt , Ruth , Nordestgaard , Børge G. , Tybjærg-Hansen , Anne , . (2014) Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease. New England Journal of Medicine 371:1, 32-41
Free Full Text448
Nikolaos Papageorgiou, Dimitris Tousoulis. (2014) Is HDL a prognostic biomarker for coronary atherosclerosis?. International Journal of Cardiology 174, 465-467
CrossRef449
R Tompkins, A Schwartzbard, E Gianos, E Fisher, H Weintraub. (2014) A Current Approach to Statin Intolerance. Clinical Pharmacology & Therapeutics 96, 74-80
CrossRef450
Xiao-Lin Li, Jian-Jun Li, Yuan-Lin Guo, Cheng-Gang Zhu, Rui-Xia Xu, Sha Li, Ping Qing, Na-Qiong Wu, Li-Xin Jiang, Bo Xu, Run-Lin Gao. (2014) Association of preprocedural low-density lipoprotein cholesterol levels with myocardial injury after elective percutaneous coronary intervention. Journal of Clinical Lipidology 8, 423-432
CrossRef451
S Tuteja, D J Rader. (2014) High-Density Lipoproteins in the Prevention of Cardiovascular Disease: Changing the Paradigm. Clinical Pharmacology & Therapeutics 96, 48-56
CrossRef452
David Preiss, Chris J. Packard. (2014) Emerging Therapeutic Approaches to Treat Dyslipidemia. Current Cardiology Reports 16
CrossRef453
S E Gryn, R A Hegele. (2014) Pharmacogenomics, Lipid Disorders, and Treatment Options. Clinical Pharmacology & Therapeutics 96, 36-47
CrossRef454
Marlys Koschinsky, Michael Boffa. (2014) Lipoprotein(a) as a therapeutic target in cardiovascular disease. Expert Opinion on Therapeutic Targets 18, 747-757
CrossRef455
D. J. Rader. (2014) New Therapies for Coronary Artery Disease: Genetics Provides a Blueprint. Science Translational Medicine 6, 239ps4-239ps4
CrossRef456
Marcin Barylski, Peter P. Toth, Dragana Nikolic, Maciej Banach, Manfredi Rizzo, Giuseppe Montalto. (2014) Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality. Best Practice & Research Clinical Endocrinology & Metabolism 28, 453-461
CrossRef457
Michael J. Koren, Pernille Lundqvist, Michael Bolognese, Joel M. Neutel, Maria Laura Monsalvo, Jingyuan Yang, Jae B. Kim, Rob Scott, Scott M. Wasserman, Harold Bays. (2014) Anti-PCSK9 Monotherapy for Hypercholesterolemia. Journal of the American College of Cardiology 63, 2531-2540
CrossRef458
Mark Houston. (2014) The role of nutrition and nutritional supplements in the treatment of dyslipidemia. Clinical Lipidology 9, 333-354
CrossRef459
Enrico Ammirati, Isabella Scotti, Giuseppe D. Norata. (2014) The Missing Link Between High-Density Lipoprotein Cholesterol and Inflammatory Response in Cardiovascular Disease. Journal of the American College of Cardiology 63, 2747-2748
CrossRef460
Dick C. Chan, P. Hugh R. Barrett, Gerald F. Watts. (2014) The metabolic and pharmacologic bases for treating atherogenic dyslipidaemia. Best Practice & Research Clinical Endocrinology & Metabolism 28, 369-385
CrossRef461
Davide Noto, Angelo B. Cefalù, Maurizio R. Averna. (2014) Beyond Statins: New Lipid Lowering Strategies to Reduce Cardiovascular Risk. Current Atherosclerosis Reports 16
CrossRef462
Mamta Jaiswal, Ashley Schinske, Rodica Pop-Busui. (2014) Lipids and lipid management in diabetes. Best Practice & Research Clinical Endocrinology & Metabolism 28, 325-338
CrossRef463
L. G. Hemkens, H. C. Bucher. (2014) HIV infection and cardiovascular disease. European Heart Journal 35, 1373-1381
CrossRef464
Evan A. Stein, Frederick J. Raal. (2014) Targeting LDL: Is lower better and is it safe?. Best Practice & Research Clinical Endocrinology & Metabolism 28, 309-324
CrossRef465
Dhayana Dallmeier, Wolfgang Koenig. (2014) Strategies for vascular disease prevention: The role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a)). Best Practice & Research Clinical Endocrinology & Metabolism 28, 281-294
CrossRef466
M. M. Aye, E. S. Kilpatrick, P. Afolabi, S. A. Wootton, A. S. Rigby, A. M. Coady, D. D. Sandeman, S. L. Atkin. (2014) Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome. Diabetes, Obesity and Metabolism 16, 545-552
CrossRef467
Lars Berglund, John D. Brunzell, Anne C. Goldberg, Ira J. Goldberg, Anton Stalenhoef. (2014) Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis. Best Practice & Research Clinical Endocrinology & Metabolism 28, 423-437
CrossRef468
Peter P. Toth, Marcin Barylski, Dragana Nikolic, Manfredi Rizzo, Giuseppe Montalto, Maciej Banach. (2014) Should low high-density lipoprotein cholesterol (HDL-C) be treated?. Best Practice & Research Clinical Endocrinology & Metabolism 28, 353-368
CrossRef469
Karen L. Margolis, Patrick J. O’Connor, Timothy M. Morgan, John B. Buse, Robert M. Cohen, William C. Cushman, Jeffrey A. Cutler, Gregory W. Evans, Hertzel C. Gerstein, Richard H. Grimm, Edward W. Lipkin, K.M.Venkat Narayan, Matthew C. Riddle, Ajay Sood, David C. Goff. (2014) Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. Diabetes Care 37, 1721-1728
CrossRef470
Marleen M.J. van Greevenbroek, Anton F.H. Stalenhoef, Jacqueline de Graaf, Martijn C.G.J. Brouwers. (2014) Familial combined hyperlipidemia. Current Opinion in Lipidology 25, 176-182
CrossRef471
A.M. Gotto, J.E. Moon. (2014) Merits and potential downsides of the 2013 ACC/AHA cholesterol management guidelines. Nutrition, Metabolism and Cardiovascular Diseases 24, 573-576
CrossRef472
Harun Kilic, Enver Atalar, Incilay Lay, Nuray Yazihan, Fatih Buyukcam, Ugur Saygisunar, Murat Aksoy, Huseyin Gunduz, Ramazan Akdemir. (2014) High-density lipoprotein subfractions and influence of endothelial lipase in a healthy Turkish population: A study in a land of low high-density lipoprotein cholesterol. Scandinavian Journal of Clinical and Laboratory Investigation 74, 278-284
CrossRef473
Stephen J Nicholls, Anthony D Pisaniello, Yu Kataoka, Rishi Puri. (2014) Lipid pharmacotherapy for treatment of atherosclerosis. Expert Opinion on Pharmacotherapy 15, 1119-1125
CrossRef474
Robin P.F. Dullaart, Wijtske Annema, René A. Tio, Uwe J.F. Tietge. (2014) The HDL anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of HDL cholesterol. Clinica Chimica Acta 433, 34-38
CrossRef475
Bronwyn A. Kingwell, M. John Chapman, Anatol Kontush, Norman E. Miller. (2014) HDL-targeted therapies: progress, failures and future. Nature Reviews Drug Discovery 13, 445-464
CrossRef476
Jamie Sebaaly. (2014) Management of elevated blood cholesterol in the psychiatric patient: What's new in the guidelines?. Mental Health Clinician 4, 100-106
CrossRef477
Andre B. Araujo, Gretchen R. Chiu, Jennifer B. Christian, Hae Young Kim, William J. Evans, Richard V. Clark. (2014) Longitudinal changes in high-density lipoprotein cholesterol and cardiovascular events in older adults. Clinical Endocrinology 80:10.1111/cen.2014.80.issue-5, 662-670
CrossRef478
Alberto Zambon, Xue-Qiao Zhao, B. Greg Brown, John D. Brunzell. (2014) Effects of Niacin Combination Therapy With Statin or Bile Acid Resin on Lipoproteins and Cardiovascular Disease. The American Journal of Cardiology 113, 1494-1498
CrossRef479
D. Müller-Wieland, M. Merkel. (2014) Lipidtherapie bei koronarer Herzkrankheit und Diabetes. Herz 39, 299-305
CrossRef480
Assi Milwidsky, Shaye Kivity, Eran Kopel, Robert Klempfner, Anat Berkovitch, Shlomo Segev, Yechezkel Sidi, Ilan Goldenberg, Elad Maor. (2014) Time dependent changes in high density lipoprotein cholesterol and cardiovascular risk. International Journal of Cardiology 173, 295-299
CrossRef481
A.E. Bochem, J.C. van Capelleveen, G.M. Dallinga-Thie, A.W.M. Schimmel, M.M. Motazacker, I. Tietjen, R.R. Singaraja, M.R. Hayden, J.J.P. Kastelein, E.S.G. Stroes, G.K. Hovingh. (2014) Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families. Clinical Genetics 85:10.1111/cge.2014.85.issue-5, 433-440
CrossRef482
Linda Dayer-Berenson, Mary Finckenor. (2014) Expanded Colesevelam Administration Options With Oral Suspension Formulation for Patients With Diabetes and Hypercholesterolemia. Postgraduate Medicine 126, 126-134
CrossRef483
Richard S. Castaldo. (2014) A Retrospective Case Series of the Lipid Effects of Switching From Omega-3 Fatty Acid Ethyl Esters to Icosapent Ethyl in Hyperlipidemic Patients. Postgraduate Medicine 126, 268-273
CrossRef484
Jamal Yusuf, Neeraj Yadav, Saibal Mukhopadhyay, Abhishek Goyal, Vimal Mehta, Vijay Trehan, Sanjay Tyagi. (2014) Relook at lipoprotein (A): Independent risk factor of coronary artery disease in North Indian population. Indian Heart Journal 66, 272-279
CrossRef485
Paul T. Williams, Xue-Qiao Zhao, Santica M. Marcovina, James D. Otvos, B. Greg Brown, Ronald M. Krauss. (2014) Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. Atherosclerosis 233, 713-720
CrossRef486
Soo Lim, Michael J. Quon, Kwang Kon Koh. (2014) Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 233, 721-728
CrossRef487
Karl Martin Wissing, Lissa Pipeleers. (2014) Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment. Transplantation Reviews 28, 37-46
CrossRef488
Terry A Jacobson. (2014) Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. Clinical Lipidology 9, 149-161
CrossRef489
Matthew I. Tomey, Jagat Narula, Jason C. Kovacic. (2014) Advances in the Understanding of Plaque Composition and Treatment Options. Journal of the American College of Cardiology 63, 1604-1616
CrossRef490
Jan Borén, Niina Matikainen, Martin Adiels, Marja-Riitta Taskinen. (2014) Postprandial hypertriglyceridemia as a coronary risk factor. Clinica Chimica Acta 431, 131-142
CrossRef491
Anouar Hafiane, Samantha Kellett, Jacques Genest. (2014) Treatment options for low high-density lipoproteins. Current Opinion in Endocrinology & Diabetes and Obesity 21, 134-139
CrossRef492
Marcus E. Kleber, Tanja B. Grammer, Ursula Kassner, Günther Silbernagel, Winfried März. (2014) Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis. Drugs 74, 513-520
CrossRef493
Sayed M. Tariq, Mandeep S. Sidhu, Peter P. Toth, William E. Boden. (2014) HDL Hypothesis: Where Do We Stand Now?. Current Atherosclerosis Reports 16
CrossRef494
José María Mostaza, Carlos Lahoz. (2014) Nuevas pautas en el tratamiento de las dislipidemias. Medicina Clínica 142, 306-309
CrossRef495
G. Barbarossa, A. Renzi, L. D’Erasmo, A. Gallo, E. Grieco, M. Rossetti, A. Carnovale, M. Santilli, E. Mandosi, P. Coletta, D. Pergolini, S. Morano, M. Maranghi. (2014) The relation between glycemic control and HDL-C in type 2 diabetes: a preliminary step forward?. Diabetes Research and Clinical Practice 104, e26-e28
CrossRef496
Anna Stears, Catherine Hames. (2014) Diagnosis and management of lipodystrophy: a practical update. Clinical Lipidology 9, 235-259
CrossRef497
Frederick J. Raal, Robert P. Giugliano, Marc S. Sabatine, Michael J. Koren, Gisle Langslet, Harold Bays, Dirk Blom, Mats Eriksson, Ricardo Dent, Scott M. Wasserman, Fannie Huang, Allen Xue, Moetaz Albizem, Rob Scott, Evan A. Stein. (2014) Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145). Journal of the American College of Cardiology 63, 1278-1288
CrossRef498
Kwok Leung Ong, Philip J. Barter, David D. Waters. (2014) Cardiovascular drugs that increase the risk of new-onset diabetes. American Heart Journal 167, 421-428
CrossRef499
Eleni A Karavia, Evangelia Zvintzou, Peristera-Ioanna Petropoulou, Eva Xepapadaki, Caterina Constantinou, Kyriakos E Kypreos. (2014) HDL quality and functionality: what can proteins and genes predict?. Expert Review of Cardiovascular Therapy 12, 521-532
CrossRef500
Lewis W. Johnson, Ruth S. Weinstock. . Medical complications of diabetes mellitus. 2014:, 45-68.
CrossRef501
D. John Betteridge. . Dyslipidemia and Its Management in Type 2 Diabetes. 2014:, 165-184.
CrossRef502
Gwendalyn J. Randolph, Norman E. Miller. (2014) Lymphatic transport of high-density lipoproteins and chylomicrons. Journal of Clinical Investigation 124, 929-935
CrossRef503
Eli M Roth, Philip Diller. (2014) Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future Cardiology 10, 183-199
CrossRef504
Alvin Chandra, Anand Rohatgi. (2014) The Role of Advanced Lipid Testing in the Prediction of Cardiovascular Disease. Current Atherosclerosis Reports 16
CrossRef505
Anette Varbo, Marianne Benn, Børge G. Nordestgaard. (2014) Remnant cholesterol as a cause of ischemic heart disease: Evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacology & Therapeutics 141, 358-367
CrossRef506
Stephen J. Nicholls, Yu Kataoka. (2014) Update in Therapeutic Approaches to Plaque Stabilization. Current Atherosclerosis Reports 16
CrossRef507
Joseph Rudolf, Kent B. Lewandrowski. (2014) Cholesterol, Lipoproteins, High-sensitivity C-reactive Protein, and Other Risk Factors for Atherosclerosis. Clinics in Laboratory Medicine 34, 113-127
CrossRef508
Venkatesh Mani, Mark Woodward, Daniel Samber, Jan Bucerius, Ahmed Tawakol, David Kallend, James H. F. Rudd, Markus Abt, Zahi A. Fayad. (2014) Predictors of change in carotid atherosclerotic plaque inflammation and burden as measured by 18-FDG-PET and MRI, respectively, in the dal-PLAQUE study. The International Journal of Cardiovascular Imaging 30, 571-582
CrossRef509
Jason C. Kovacic, Jose M. Castellano, Michael E. Farkouh, Valentin Fuster. (2014) The Relationships Between Cardiovascular Disease and Diabetes. Endocrinology and Metabolism Clinics of North America 43, 41-57
CrossRef510
Pablo Corral, Laura Schreier. (2014) Historia y revisión de los inhibidores de la proteína transportadora de ésteres de colesterol y su aporte a la comprensión de la fisiología y la fisiopatología de la lipoproteína de alta densidad. Clínica e Investigación en Arteriosclerosis 26, 78-84
CrossRef511
Aniket Puri, Vatsal Singh, Saurabh Pandey, Sunny R.K. Singh, Charukant Singh, Rohit Srivastav. (2014) Measurement of body fat percentage and visceral fat rating using bioelectrical impedance analysis in coronary artery disease patients and its associations with aggressive lipid lowering treatment. Journal of Indian College of Cardiology 4, 1-7
CrossRef512
Michela Triolo, Wijtske Annema, Jan Freark de Boer, Uwe J. F. Tietge, Robin P. F. Dullaart. (2014) Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. European Journal of Clinical Investigation 44:10.1111/eci.2014.44.issue-3, 240-248
CrossRef513
Lamprini Risos, Guy Berkenboom. (2014) Revascularization Versus Medical Treatments in Stable Coronary Artery Disease. Journal of Cardiovascular Pharmacology 63, 213-217
CrossRef514
Sophie Colin, Mélanie Fanchon, Loic Belloy, Andrea E. Bochem, Corinne Copin, Bruno Derudas, Erik S.G. Stroes, G. Kees Hovingh, Jan A. Kuivenhoven, Geesje M. Dallinga-Thie, Bart Staels, Giulia Chinetti-Gbaguidi. (2014) HDL does not influence the polarization of human monocytes toward an alternative phenotype. International Journal of Cardiology 172, 179-184
CrossRef515
Amirhossein Sahebkar, Gerard T Chew, Gerald F Watts. (2014) New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opinion on Pharmacotherapy 15, 493-503
CrossRef516
Jing Pang, Dick C Chan, Gerald F Watts. (2014) Critical review of non-statin treatments for dyslipoproteinemia. Expert Review of Cardiovascular Therapy 12, 359-371
CrossRef517
Ziad A. Massy. (2014) The Author Replies:. Kidney International 85:3, 712
CrossRef518
Annie Ferland, Robert Eckel. . Prevention and Management of Dyslipidemia, Hyperglycemia, and the Metabolic Syndrome in Obese Patients. 2014:, 347-362.
CrossRef519
David Preiss, Suzanne M Lloyd, Ian Ford, John J McMurray, Rury R Holman, Paul Welsh, Miles Fisher, Chris J Packard, Naveed Sattar. (2014) Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. The Lancet Diabetes & Endocrinology 2, 116-124
CrossRef520
Lars Rydén, Peter J. Grant, Stefan D. Anker, Christian Berne, Francesco Cosentino, Nicolas Danchin, Christi Deaton, Javier Escaned, Hans-Peter Hammes, Heikki Huikuri, Michel Marre, Nikolaus Marx, Linda Mellbin, Jan Ostergren, Carlo Patrono, Petar Seferovic, Miguel Sousa Uva, Marja-Riita Taskinen, Michal Tendera, Jaakko Tuomilehto, Paul Valensi, José Luis Zamorano, , Jose Luis Zamorano, Stephan Achenbach, Helmut Baumgartner, Jeroen J. Bax, Héctor Bueno, Veronica Dean, Christi Deaton, Çetin Erol, Robert Fagard, Roberto Ferrari, David Hasdai, Arno W. Hoes, Paulus Kirchhof, Juhani Knuuti, Philippe Kolh, Patrizio Lancellotti, Ales Linhart, Petros Nihoyannopoulos, Massimo F. Piepoli, Piotr Ponikowski, Per Anton Sirnes, Juan Luis Tamargo, Michal Tendera, Adam Torbicki, William Wijns, Stephan Windecker, , Guy De Backer, Per Anton Sirnes, Eduardo Alegria Ezquerra, Angelo Avogaro, Lina Badimon, Elena Baranova, Helmut Baumgartner, John Betteridge, Antonio Ceriello, Robert Fagard, Christian Funck-Brentano, Dietrich C. Gulba, David Hasdai, Arno W. Hoes, John K. Kjekshus, Juhani Knuuti, Philippe Kolh, Eli Lev, Christian Mueller, Ludwig Neyses, Peter M. Nilsson, Joep Perk, Piotr Ponikowski, Željko Reiner, Naveed Sattar, Volker Schächinger, André Scheen, Henrik Schirmer, Anna Strömberg, Svetlana Sudzhaeva, Juan Luis Tamargo, Margus Viigimaa, Charalambos Vlachopoulos, Robert G. Xuereb, . (2014) Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. Revista Española de Cardiología 67, 136.e1-136.e56
CrossRef521
John C. LaRosa. (2014) Treatment of Cholesterol in the Elderly: Statins and Beyond. Current Atherosclerosis Reports 16
CrossRef522
Olivia Gilbert, James R. Croffoot, Allen J. Taylor, Mark Nash, Katherine Schomer, Suzanne Groah. (2014) Serum lipid concentrations among persons with spinal cord injury – A systematic review and meta-analysis of the literature. Atherosclerosis 232, 305-312
CrossRef523
Michael France, Jonathan Schofield, See Kwok, Handrean Soran. (2014) Treatment of homozygous familial hypercholesterolemia. Clinical Lipidology 9, 101-118
CrossRef524
Parag Goyal, Leon I. Igel, Keith LaScalea, William B. Borden. (2014) Cardiometabolic Impact of Non-Statin Lipid Lowering Therapies. Current Atherosclerosis Reports 16
CrossRef525
F. Custodis, U. Laufs. (2014) Therapie von Fettstoffwechselstörungen. Herz 39, 119-130
CrossRef526
Michelle L. O'Donoghue, David A. Morrow, Sotirios Tsimikas, Sarah Sloan, Angela F. Ren, Elaine B. Hoffman, Nihar R. Desai, Scott D. Solomon, Michael Domanski, Kiyohito Arai, Stephanie E. Chiuve, Christopher P. Cannon, Frank M. Sacks, Marc S. Sabatine. (2014) Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of the American College of Cardiology 63, 520-527
CrossRef527
Kentaro Toyama, Toshihiko Nishioka, Ami Isshiki, Toshiyuki Ando, Yoshiro Inoue, Masato Kirimura, Tetsuo Kamiyama, Osamu Sasaki, Hiroyuki Ito, Yoshiaki Maruyama, Nobuo Yoshimoto. (2014) Eicosapentaenoic Acid Combined with Optimal Statin Therapy Improves Endothelial Dysfunction in Patients with Coronary Artery Disease. Cardiovascular Drugs and Therapy 28, 53-59
CrossRef528
Alicia H. Augustine, Lisa M. Lowenstein, William S. Harris, Gregory C. Shearer, Robert C. Block. (2014) Treatment with omega-3 fatty acid ethyl-ester alters fatty acid composition of lipoproteins in overweight or obese adults with insulin resistance. Prostaglandins, Leukotrienes and Essential Fatty Acids (PLEFA) 90, 69-75
CrossRef529
Yufeng Wang, Wu Yang, Heather J. Finlay, Lalgudi S. Harikrishnan, Ji Jiang, Muthoni G. Kamau, Katy Van Kirk, David S. Nirschl, David S. Taylor, Alice Ye A. Chen, Xiaohong Yin, Paul G. Sleph, Richard Z. Yang, Christine S. Huang, Leonard P. Adam, R. Michael Lawrence, Ruth R. Wexler, Mark E. Salvati. (2014) Diphenylpyridylethanamine (DPPE)-based aminoheterocycles as cholesteryl ester transfer protein inhibitors. Bioorganic & Medicinal Chemistry Letters 24, 860-864
CrossRef530
Joan Carles Escolà-Gil, Lídia Cedó, Francisco Blanco-Vaca. (2014) High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?. Expert Opinion on Drug Discovery 9, 119-124
CrossRef531
Joseph Yeboah, David M Herrington. (2014) Intermediate end point cardiovascular clinical trials: an excellent idea based on an obsolete paradigm. Expert Review of Cardiovascular Therapy 12, 161-165
CrossRef532
Ehimare Akhabue, Jeffrey Thiboutot, Jeh-wei Cheng, Stamatios Lerakis, Timothy J. Vittorio, Georgios Christodoulidis, Kathleen M. Grady, Constantine E. Kosmas. (2014) New and Emerging Risk Factors for Coronary Heart Disease. The American Journal of the Medical Sciences 347:2, 151-158
CrossRef533
Hiatt , William R. , Smith , Robert J. , . (2014) Assessing the Clinical Benefits of Lipid-Disorder Drugs. New England Journal of Medicine 370:5, 396-399
Free Full Text534
Ying Huang, Joseph A DiDonato, Bruce S Levison, Dave Schmitt, Lin Li, Yuping Wu, Jennifer Buffa, Timothy Kim, Gary S Gerstenecker, Xiaodong Gu, Chandra S Kadiyala, Zeneng Wang, Miranda K Culley, Jennie E Hazen, Anthony J DiDonato, Xiaoming Fu, Stela Z Berisha, Daoquan Peng, Truc T Nguyen, Shaohong Liang, Chia-Chi Chuang, Leslie Cho, Edward F Plow, Paul L Fox, Valentin Gogonea, W H Wilson Tang, John S Parks, Edward A Fisher, Jonathan D Smith, Stanley L Hazen. (2014) An abundant dysfunctional apolipoprotein A1 in human atheroma. Nature Medicine 20, 193-203
CrossRef535
Nathan B. Mantlo, Ana Escribano. (2014) Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk. Journal of Medicinal Chemistry 57, 1-17
CrossRef536
Stefan Offermanns. (2014) Free Fatty Acid (FFA) and Hydroxy Carboxylic Acid (HCA) Receptors. Annual Review of Pharmacology and Toxicology 54:1, 407-434
CrossRef537
Mari Tabuchi, Tsugikazu Komoda. . Introduction of HDL Molecules, Past and Brief Future. 2014:, 1-8.
CrossRef538
Jonathan E. Feig. (2014) Regression of Atherosclerosis: Insights from Animal and Clinical Studies. Annals of Global Health 80, 13-23
CrossRef539
Loek P. Smits, Ruud S. Kootte, Erik S. Stroes. (2014) Reversal of atherosclerosis with apolipoprotein A1: Back to basics. Atherosclerosis 232, 217-219
CrossRef540
Arun Kumar. (2014) Correlation of serum paraoxonase activities in known cases of 130 elderly hypertensive South Asian aged 56–64 years – a hospital based study. Asian Pacific Journal of Tropical Disease 4, S330-S335
CrossRef541
Lacey B. Robinson, William H. Frishman. (2014) Anacetrapib. Cardiology in Review 22, 253-261
CrossRef542
Ruth-Maria Korth. (2014) Women with overweight, mixed hyperlipidemia, intolerance to glucose and diastolic hypertension. Health 06, 454-467
CrossRef543
Arshag D. Mooradian. (2014) Is High-Density Lipoprotein Cardioprotective or Simply a Marker of Cardiovascular Disease?. American Journal of Therapeutics 21, 438-439
CrossRef544
Kohei Takata, Satoshi Imaizumi, Emi Kawachi, Yasunori Suematsu, Tomohiko Shimizu, Satomi Abe, Yoshino Matsuo, Hitomi Tsukahara, Keita Noda, Eiji Yahiro, Bo Zhang, Yoshinari Uehara, Shin-ichiro Miura, Keijiro Saku. (2014) Impact of Cigarette Smoking Cessation on High-Density Lipoprotein Functionality. Circulation Journal 78, 2955-2962
CrossRef545
Ross Walker, Elzbieta Janda, Vincenzo Mollace. . The Use of Bergamot-Derived Polyphenol Fraction in Cardiometabolic Risk Prevention and its Possible Mechanisms of Action. 2014:, 1087-1105.
CrossRef546
Wakana Ohashi, Yuichi Hattori. . Drugs that affect lipid metabolism. 2014:, 807-819.
CrossRef547
Olov Wiklund, Carlo Pirazzi, Stefano Romeo. (2014) Pharmacological lipid lowering for prevention of cardiovascular disease in older adults. Clinical Practice 11, 49-58
CrossRef548
Brian S. Katz, Kelly D. Flemming. (2014) Antithrombotic selection and risk factor management in ischemic stroke and transient ischemic attack. Neurosurgical Focus 36, E10
CrossRef549
(2014) An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report. Journal of Clinical Lipidology 8, 29-60
CrossRef550
Robert Fried. . Selected Micronutrients and the Metabolic Basis for Their Support of Endothelial Health and Erectile Function. 2014:, 293-328.
CrossRef551
Robert Fried. . Introduction. 2014:, 1-25.
CrossRef552
Anouar Hafiane, Bashar Jabor, Isabelle Ruel, Jennifer Ling, Jacques Genest. (2014) High-Density Lipoprotein Mediated Cellular Cholesterol Efflux in Acute Coronary Syndromes. The American Journal of Cardiology 113, 249-255
CrossRef553
Bela F. Asztalos, Mariko Tani, Brian Ishida. . The Complexity of High-Density Lipoproteins. 2014:, 37-64.
CrossRef554
Srinivasa T. Reddy, Mohamad Navab, G.M. Anantharamaiah, Alan M. Fogelman. (2014) Searching for a successful HDL-based treatment strategy. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1841, 162-167
CrossRef555
Harumi Uto-Kondo, Makoto Ayaori, Kazuhiro Nakaya, Shunichi Takiguchi, Emi Yakushiji, Masatsune Ogura, Yoshio Terao, Hideki Ozasa, Makoto Sasaki, Tomohiro Komatsu, Grace Megumi Sotherden, Tamaki Hosoai, Masami Sakurada, Katsunori Ikewaki. (2014) Citrulline increases cholesterol efflux from macrophages in vitro and ex vivo via ATP-binding cassette transporters. Journal of Clinical Biochemistry and Nutrition 55, 32-39
CrossRef556
László Bajnok. (2014) HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia. Orvosi Hetilap 155, 62-68
CrossRef557
Konstantinos N. Aronis, Christos S. Mantzoros. (2014) Novel concepts in lipoprotein particle metabolism and regulation. Metabolism 63, 1-4
CrossRef558
Kieran F. Docherty, Sandosh Padmanabhan. . Genomics and Pharmacogenomics of Lipid-Lowering Therapies. 2014:, 715-746.
CrossRef559
Sally M. Sultan, Nicole Schupf, Michael M. Dowling, Gabrielle A. DeVeber, Adam Kirton, Mitchell S. V. Elkind. (2014) Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke. International Journal of Stroke 9, 79-87
CrossRef560
Benoit J. Arsenault, S. Matthijs Boekholdt. (2014) Clinical and Biological Relevance of Statin-Mediated Changes in HDL Metabolism. Current Atherosclerosis Reports 16
CrossRef561
Manabu Ogita, Katsumi Miyauchi, Tadashi Miyazaki, Ryo Naito, Hirokazu Konishi, Shuta Tsuboi, Tomotaka Dohi, Takatoshi Kasai, Takayuki Yokoyama, Shinya Okazaki, Takeshi Kurata, Hiroyuki Daida. (2014) Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart and Vessels 29, 35-41
CrossRef562
Seung-Ho Hur. (2014) Recent Guidelines on the Management of Blood Cholesterol: 2013 ACC/AHA Guidelines and 2014 NICE Draft Guidelines. Korean Journal of Medicine 87, 142
CrossRef563
(2014) Standards of Medical Care in Diabetes--2014. Diabetes Care 37, S14-S80
CrossRef564
Maki Komiyama, Hiromichi Wada, Koji Hasegawa. (2014) Matters of Controversy Regarding Lipid Therapy for Japanese Patients with Coronary Artery Disease. Internal Medicine 53, 817-818
CrossRef565
Ruihua Cao, Yongyi Bai, Lan Sun, Jin Zheng, Mian Zu, Guanhua Du, Ping Ye. (2014) Xuezhikang Therapy Increases miR-33 Expression in Patients with Low HDL-C Levels. Disease Markers 2014, 1-5
CrossRef566
Christopher T Johansen, Austin MacDonald, Robert A Hegele. . Recent Insights into the Genetics of Plasma Triglycerides and Possible Causal Mechanisms in Cardiovascular Disease. 2013.
CrossRef567
Dominic De Nardo, Larisa I Labzin, Hajime Kono, Reiko Seki, Susanne V Schmidt, Marc Beyer, Dakang Xu, Sebastian Zimmer, Catharina Lahrmann, Frank A Schildberg, Johanna Vogelhuber, Michael Kraut, Thomas Ulas, Anja Kerksiek, Wolfgang Krebs, Niklas Bode, Alena Grebe, Michael L Fitzgerald, Nicholas J Hernandez, Bryan R G Williams, Percy Knolle, Manfred Kneilling, Martin Röcken, Dieter Lütjohann, Samuel D Wright, Joachim L Schultze, Eicke Latz. (2013) High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nature Immunology 15, 152-160
CrossRef568
P. K. Shah. (2013) Jekyll and Hyde of HDL: a lipoprotein with a split personality. European Heart Journal 34, 3531-3534
CrossRef569
E. Angeloni, F. Paneni, U. Landmesser, U. Benedetto, G. Melina, T. F. Luscher, M. Volpe, R. Sinatra, F. Cosentino. (2013) Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. European Heart Journal 34, 3557-3562
CrossRef570
Shahed Islam, Adam Timmis. (2013) Almanac 2013: stable coronary artery disease. Wiener klinische Wochenschrift 125, 776-783
CrossRef571
Eric J. Niesor, Kekulawalage Gauthamadasa, R. A. Gangani D. Silva, Gabriela Suchankova, David Kallend, Helena Gylling, Bela Asztalos, Elisabetta Damonte, Simona Rossomanno, Markus Abt, W. Sean Davidson, Renee Benghozi. (2013) Xanthophylls, Phytosterols and Pre-β1-HDL are Differentially Affected by Fenofibrate and Niacin HDL-Raising in a Cross-Over Study. Lipids 48, 1185-1196
CrossRef572
Gerd Brunner, Eric Y. Yang, Anirudh Kumar, Wensheng Sun, Salim S. Virani, Smita I. Negi, Tyler Murray, Peter H. Lin, Ron C. Hoogeveen, Changyi Chen, Jing-Fei Dong, Panagiotis Kougias, Addison Taylor, Alan B. Lumsden, Vijay Nambi, Christie M. Ballantyne, Joel D. Morrisett. (2013) The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT). Atherosclerosis 231, 371-377
CrossRef573
Anthony S Wierzbicki. . Novel therapies for dyslipidemia. 2013:, 58-69.
CrossRef574
Beth A. Connolly, Daniel P. O’Connell, Stefania Lamon-Fava, Daniel F. LeBlanc, Yu-Lin Kuang, Ernst J. Schaefer, Andrew L. Coppage, Claude R. Benedict, Christopher P. Kiritsy, William W. Bachovchin. (2013) The high-fat high-fructose hamster as an animal model for niacin’s biological activities in humans. Metabolism 62, 1840-1849
CrossRef575
F. R. Hobbs. (2013) Commentary: Last and Icebergs - spotting the iceberg doesn't predict its scale, even after 50 years. International Journal of Epidemiology 42, 1615-1617
CrossRef576
Henry N. Ginsberg, Gissette Reyes-Soffer. (2013) Niacin. Current Opinion in Lipidology 24, 475-479
CrossRef577
Jing Pang, Alistair W Vickery, Gerald F Watts. . Familial hypercholesterolemia: bridging and minding the gap in healthcare. 2013:, 18-41.
CrossRef578
Aaron Rockoff, Vaijinath S Kamanna, Moti L Kashyap. . Dyslipidemia: current management and the challenge of residual cardiovascular risk reduction. 2013:, 110-122.
CrossRef579
Geetha Mukerji, Rawand M Abdin, Dominic S Ng. . PCSK9 inhibition: drug development for low-density lipoprotein lowering. 2013:, 42-57.
CrossRef580
Y.-L. Yang, M. Hu, M. Chang, B. Tomlinson. (2013) A high incidence of exanthematous eruption associated with niacin/laropiprant combination in Hong Kong Chinese patients. Journal of Clinical Pharmacy and Therapeutics 38:10.1111/jcpt.2013.38.issue-6, 528-532
CrossRef581
David M. Tehrani, Julius M. Gardin, David Yanez, Calvin H. Hirsch, Donald M. Lloyd-Jones, Phyllis K. Stein, Nathan D. Wong. (2013) Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: Cardiovascular Health Study. Atherosclerosis 231, 246-251
CrossRef582
David Preiss, Naveed Sattar. (2013) Choice of medical therapy to lower triglycerides in those at risk of pancreatitis. Current Opinion in Lipidology 24, 532-533
CrossRef583
K. Jameson, V. Amber, K. D'Oca, D. Mills, A. Giles, B. Ambegaonkar. (2013) Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study. International Journal of Clinical Practice 67, 1228-1237
CrossRef584
K.-C. Sung, S.H. Wild, C.D. Byrne. (2013) Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort. Nutrition, Metabolism and Cardiovascular Diseases 23, 1239-1246
CrossRef585
Konstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis. . Management of dyslipidemia in patients with nonalcoholic fatty liver disease. 2013:, 98-109.
CrossRef586
P.C. Manoria, H.K. Chopra, S.K. Parashar, A.L. Dutta, Brian Pinto, Ajit Mullasari, Samir Prajapati. (2013) The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies. Indian Heart Journal 65, 683-690
CrossRef587
Katie Jerzewski, Marc Ruel, Pierre Voisine, Michel R Le May, Alexander Kulik. (2013) Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial. Journal of Cardiothoracic Surgery 8:1
CrossRef588
M. J. Blaha, E. D. Michos. (2013) Niacin--a case study for the role of event-driven versus surrogate endpoint trials. Heart 99, 1631-1632
CrossRef589
S. Islam, A. Timmis. (2013) Almanac 2013: stable coronary artery disease. Heart 99, 1652-1657
CrossRef590
C. T. Sibley, A. L. Vavere, I. Gottlieb, C. Cox, M. Matheson, A. Spooner, G. Godoy, V. Fernandes, B. A. Wasserman, D. A. Bluemke, J. A. C. Lima. (2013) MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. Heart 99, 1675-1680
CrossRef591
Alexander Kamb, Sean Harper, Kari Stefansson. (2013) Human genetics as a foundation for innovative drug development. Nature Biotechnology 31, 975-978
CrossRef592
K. M. Kostner, W. Marz, G. M. Kostner. (2013) When should we measure lipoprotein (a)?. European Heart Journal 34, 3268-3276
CrossRef593
Jacques Genest. (2013) High-Density Lipoprotein and Residual Cardiovascular Risk. Journal of the American College of Cardiology 62, 1842-1844
CrossRef594
Salim S. Virani, Vei-Vei Lee, Ariel Brautbar, Megan L. Grove, Vijay Nambi, Mahboob Alam, MacArthur Elayda, James M. Wilson, James T. Willerson, Eric Boerwinkle, Christie M. Ballantyne. (2013) Single Nucleotide Polymorphisms in Cholesteryl Ester Transfer Protein Gene and Recurrent Coronary Heart Disease or Mortality in Patients With Established Atherosclerosis. The American Journal of Cardiology 112, 1287-1292
CrossRef595
Carrie Palmer. (2013) Dyslipidemia in Adults: How Recent Research and Recommendations Affect Nurse Practitioner Practice. The Journal for Nurse Practitioners 9, 669-678
CrossRef596
A. Bhargava, S. Gleason, A. G. Vaughan, J. F. Johnson, K. V. S. N. Yarlagadda. (2013) The effect of pioglitazone and extended-release niacin on HDL-cholesterol in diabetes patients in a real-world setting. International Journal of Clinical Practice 67, 1151-1158
CrossRef597
T. F. Luscher. (2013) The bumpy road to evidence: why many research findings are lost in translation. European Heart Journal 34, 3329-3335
CrossRef598
Mario Bonomini, Lorenzo Di Liberato, Goffredo Del Rosso, Antonio Stingone, Giancarlo Marinangeli, Agostino Consoli, Silvio Bertoli, Amedeo De Vecchi, Emanuele Bosi, Roberto Russo, Roberto Corciulo, Loreto Gesualdo, Francesco Giorgino, Paolo Cerasoli, Augusto Di Castelnuovo, Maria Pia Monaco, Ty Shockley, Claudia Rossi, Arduino Arduini. (2013) Effect of an l-Carnitine–Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial. American Journal of Kidney Diseases 62, 929-938
CrossRef599
Gerardo Moreno, Carol M. Mangione. (2013) Management of Cardiovascular Disease Risk Factors in Older Adults with Type 2 Diabetes Mellitus: 2002-2012 Literature Review. Journal of the American Geriatrics Society 61:10.1111/jgs.2013.61.issue-11, 2027-2037
CrossRef600
Seth S. Martin, Michael J. Blaha, Peter P. Toth, Parag H. Joshi, John W. McEvoy, Haitham M. Ahmed, Mohamed B. Elshazly, Kristopher J. Swiger, Erin D. Michos, Peter O. Kwiterovich, Krishnaji R. Kulkarni, Joseph Chimera, Christopher P. Cannon, Roger S. Blumenthal, Steven R. Jones. (2013) Very Large Database of Lipids: Rationale and Design. Clinical Cardiology 36, 641-648
CrossRef601
Mohammed Al-Hijji, Seth S. Martin, Parag H. Joshi, Steven R. Jones. (2013) Effect of Equivalent On-Treatment Apolipoprotein Levels on Outcomes (from the AIM-HIGH and HPS2-THRIVE). The American Journal of Cardiology 112, 1697-1700
CrossRef602
Amit V. Khera, Parin J. Patel, Muredach P. Reilly, Daniel J. Rader. (2013) The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels But Not Metrics of Functionality. Journal of the American College of Cardiology 62, 1909-1910
CrossRef603
Anton P. van de Woestijne, Yolanda van der Graaf, An-Ho Liem, Maarten J.M. Cramer, Jan Westerink, Frank L.J. Visseren. (2013) Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. Journal of the American College of Cardiology 62, 1834-1841
CrossRef604
Terry A. Jacobson. (2013) Lipoprotein(a), Cardiovascular Disease, and Contemporary Management. Mayo Clinic Proceedings 88, 1294-1311
CrossRef605
Subroto Acharjee, William E. Boden, Pamela M. Hartigan, Koon K. Teo, David J. Maron, Steven P. Sedlis, William Kostuk, John A. Spertus, Marcin Dada, Bernard R. Chaitman, G.B. John Mancini, William S. Weintraub. (2013) Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients. Journal of the American College of Cardiology 62, 1826-1833
CrossRef606
Michael B. Boffa, Marlys L. Koschinsky. (2013) Screening for and Management of Elevated Lp(a). Current Cardiology Reports 15
CrossRef607
Paul Lee, Robert A Hegele. (2013) Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia. Expert Opinion on Investigational Drugs 22, 1411-1423
CrossRef608
Shirya Rashid, John JP Kastelein. (2013) PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia. Expert Review of Cardiovascular Therapy 11, 1567-1577
CrossRef609
Anastazia Kei, Evangelos Liberopoulos, Costantinos Tellis, Moses Elisaf, Alexandros Tselepis. (2013) Lipid-Modulating Treatments for Mixed Dyslipidemia Increase HDL-Associated Phospholipase A2 Activity with Differential Effects on HDL Subfractions. Lipids 48, 957-965
CrossRef610
Howard Weintraub. (2013) Update on marine omega-3 fatty acids: Management of dyslipidemia and current omega-3 treatment options. Atherosclerosis 230, 381-389
CrossRef611
Vincent E. Friedewald, Christie M. Ballantyne, Harold E. Bays, Peter H. Jones. (2013) The Editor's Roundtable: Hypertriglyceridemia. The American Journal of Cardiology 112, 1133-1141
CrossRef612
T. Speer, S. Zewinger, D. Fliser. (2013) Uraemic dyslipidaemia revisited: role of high-density lipoprotein. Nephrology Dialysis Transplantation 28, 2456-2463
CrossRef613
Jane A O’Halloran, Claudette S Satchell, Patrick WG Mallon. (2013) Dyslipidemia, atherosclerosis and cardiovascular disease: an increasingly important triad in an aging population living with HIV. Future Virology 8, 1021-1034
CrossRef614
Baishali M. Ambegaonkar, Lori D. Bash, Diana R. Chirovsky, Kevin Jameson, Susan Grant, Gonzalo Nocea, Billie Pettersson, Vasilisa Sazonov. (2013) Attainment of normal lipid levels among high cardiovascular risk patients: Pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada. European Journal of Internal Medicine 24, 656-663
CrossRef615
Michael R. Jones, Oliseyenum M. Nwose. (2013) Role of Colesevelam in Combination Lipid-Lowering Therapy. American Journal of Cardiovascular Drugs 13, 315-323
CrossRef616
John R. Guyton, April E. Slee, Todd Anderson, Jerome L. Fleg, Ronald B. Goldberg, Moti L. Kashyap, Santica M. Marcovina, Stephen D. Nash, Kevin D. O'Brien, William S. Weintraub, Ping Xu, Xue-Qiao Zhao, William E. Boden. (2013) Relationship of Lipoproteins to Cardiovascular Events. Journal of the American College of Cardiology 62, 1580-1584
CrossRef617
Michael B. Boffa, Marlys L. Koschinsky. (2013) Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator. Current Atherosclerosis Reports 15
CrossRef618
John J. Albers, April Slee, Kevin D. O'Brien, Jennifer G. Robinson, Moti L. Kashyap, Peter O. Kwiterovich, Ping Xu, Santica M. Marcovina. (2013) Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes. Journal of the American College of Cardiology 62, 1575-1579
CrossRef619
Matthew Vorsanger, James A. Underberg. (2013) New Treatment Approaches for Dyslipidemia and its Management. Current Cardiovascular Risk Reports 7, 395-400
CrossRef620
G. Klose, R. Hambrecht. (2013) HDL – „Game over“?. Der Kardiologe 7, 346-351
CrossRef621
Francesco Paneni, Sarah Costantino, Massimo Volpe, Thomas Felix Lüscher, Francesco Cosentino. (2013) Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective. Atherosclerosis 230, 191-197
CrossRef622
Ibragim Gaidarov, Xiaohua Chen, Todd Anthony, Dominique Maciejewski-Lenoir, Chen Liaw, David J. Unett. (2013) Differential tissue and ligand-dependent signaling of GPR109A receptor: Implications for anti-atherosclerotic therapeutic potential. Cellular Signalling 25, 2003-2016
CrossRef623
Gerald F. Watts, Esther M. M. Ooi, Dick C. Chan. (2013) Demystifying the management of hypertriglyceridaemia. Nature Reviews Cardiology 10, 648-661
CrossRef624
Robin P.F. Dullaart, Arjan J. Kwakernaak, Geesje M. Dallinga-Thie. (2013) The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome. Atherosclerosis 230, 6-11
CrossRef625
Guido Franceschini, Elda Favari, Laura Calabresi, Sara Simonelli, Alighiero Bondioli, Maria Pia Adorni, Francesca Zimetti, Monica Gomaraschi, Karine Coutant, Simona Rossomanno, Eric J. Niesor, Franco Bernini, Renee Benghozi. (2013) Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. Journal of Clinical Lipidology 7, 414-422
CrossRef626
Francine K. Welty. (2013) How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?. Current Cardiology Reports 15
CrossRef627
Kelley Newlin Lew, Daniel J. Kent, Angelica A. Muñoz, Gail D'Eramo Melkus. (2013) Therapeutic options for lowering LDL-C in type 2 diabetes: A nurse practitioner's perspective. Journal of the American Association of Nurse Practitioners 25:10.1002/jaan.2013.25.issue-9, 488-494
CrossRef628
Alisa Blazek, Jessica Rutsky, Kwame Osei, Andrei Maiseyeu, Sanjay Rajagopalan. (2013) Exercise-mediated changes in high-density lipoprotein: Impact on form and function. American Heart Journal 166, 392-400
CrossRef629
K.G. Parhofer. (2013) Update Fettstoffwechselstörungen. Der Internist 54, 1089-1103
CrossRef630
Ž. Reiner. (2013) Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. Nutrition, Metabolism and Cardiovascular Diseases 23, 799-807
CrossRef631
Xiao-Hua Yu, Yu-Chang Fu, Da-Wei Zhang, Kai Yin, Chao-Ke Tang. (2013) Foam cells in atherosclerosis. Clinica Chimica Acta 424, 245-252
CrossRef632
Peter P. Toth, Philip J. Barter, Robert S. Rosenson, William E. Boden, M. John Chapman, Marina Cuchel, Ralph B. D'Agostino, Michael H. Davidson, W. Sean Davidson, Jay W. Heinecke, Richard H. Karas, Anatol Kontush, Ronald M. Krauss, Michael Miller, Daniel J. Rader. (2013) High-density lipoproteins: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology 7, 484-525
CrossRef633
Catherine Martel, Gwendalyn J. Randolph. (2013) Atherosclerosis and Transit of HDL Through the Lymphatic Vasculature. Current Atherosclerosis Reports 15
CrossRef634
Daniel Seung Kim, Judit Marsillach, Clement E Furlong, Gail P Jarvik. (2013) Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease. Pharmacogenomics 14, 1495-1515
CrossRef635
Jessica S. Lilley, MacRae F. Linton, Sergio Fazio. (2013) Oral retinoids and plasma lipids. Dermatologic Therapy 26:10.1111/dth.2013.26.issue-5, 404-410
CrossRef636
Olov Wiklund, Carlo Pirazzi, Stefano Romeo. (2013) Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. Current Cardiology Reports 15
CrossRef637
Scott J. Cameron, Robert C. Block, John Franklin Richeson. (2013) Severe coronary disease in an adult considered at low cardiovascular disease risk with a healthy lifestyle. Journal of Clinical Lipidology 7, 526-530
CrossRef638
Mary G. Sorci-Thomas, Michael J. Thomas. (2013) Why Targeting HDL Should Work as a Therapeutic Tool, but Has Not. Journal of Cardiovascular Pharmacology 62, 239-246
CrossRef639
George Stojan, Michelle Petri. (2013) Atherosclerosis in Systemic Lupus Erythematosus. Journal of Cardiovascular Pharmacology 62, 255-262
CrossRef640
Alberto Dávalos, Carlos Fernández-Hernando. (2013) From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport. Pharmacological Research 75, 60-72
CrossRef641
Walter M. van den Bergh. (2013) Disturbing the Programmed Cell Death*. Critical Care Medicine 41, 2250-2251
CrossRef642
Antonio M. Gotto, Jennifer E. Moon. (2013) Pharmacotherapies for lipid modification: beyond the statins. Nature Reviews Cardiology 10, 560-570
CrossRef643
Alexios Antonopoulos, Regent Lee, Dimitris Tousoulis, Charalambos Antoniades. . The Role of Genetic Traits in Cardiovascular Disease. 2013:, 399-422.
CrossRef644
Y.-H. Chang, D.-M. Chang, K.-C. Lin, C.-H. Hsieh, Y.-J. Lee. (2013) High-density lipoprotein cholesterol and the risk of nephropathy in type 2 diabetic patients. Nutrition, Metabolism and Cardiovascular Diseases 23, 751-757
CrossRef645
J. A. Beckman, F. Paneni, F. Cosentino, M. A. Creager. (2013) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. European Heart Journal 34, 2444-2452
CrossRef646
Emmanuel E. Egom, Mamas A. Mamas, Handrean Soran. (2013) HDL quality or cholesterol cargo. Current Opinion in Lipidology 24, 351-356
CrossRef647
James Barnett, Adie Viljoen, Anthony S. Wierzbicki. (2013) The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. Current Cardiology Reports 15
CrossRef648
G.C. Schuler, W. Koenig, V. Adams, H. Gohlke. (2013) Kommentar zu den neuen Leitlinien (2012) der Europäischen Gesellschaft für Kardiologie zur kardiovaskulären Prävention. Der Kardiologe 7, 251-260
CrossRef649
Arnold von Eckardstein, Jerzy-Roch Nofer. (2013) Frail HDLs and Stiff Arteries in Type 2 Diabetes in Juveniles. Diabetes 62:8, 2662-2664
CrossRef650
Ryan D. Madder, James A. Goldstein, Sean P. Madden, Rishi Puri, Kathy Wolski, Michael Hendricks, Stephen T. Sum, Annapoorna Kini, Samin Sharma, David Rizik, Emmanouil S. Brilakis, Kendrick A. Shunk, John Petersen, Giora Weisz, Renu Virmani, Stephen J. Nicholls, Akiko Maehara, Gary S. Mintz, Gregg W. Stone, James E. Muller. (2013) Detection by Near-Infrared Spectroscopy of Large Lipid Core Plaques at Culprit Sites in Patients With Acute ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions 6:8, 838-846
CrossRef651
A. S. Wierzbicki. (2013) All at sea: new lipid-lowering drug trials continue to disappoint. International Journal of Clinical Practice 67, 595-598
CrossRef652
Harold E. Bays, Peter P. Toth, Penny M. Kris-Etherton, Nicola Abate, Louis J. Aronne, W. Virgil Brown, J. Michael Gonzalez-Campoy, Steven R. Jones, Rekha Kumar, Ralph La Forge, Varman T. Samuel. (2013) Obesity, adiposity, and dyslipidemia: A consensus statement from the National Lipid Association. Journal of Clinical Lipidology 7, 304-383
CrossRef653
A. Sämann, G. Wolf. (2013) Diabetische Nephropathie. Der Nephrologe 8, 355-366
CrossRef654
Kelly W. Jones. (2013) Do patients on statins also need niacin?. Journal of the American Academy of Physician Assistants 26, 9-10
CrossRef655
David J. Becker, Benjamin French, Patti B. Morris, Erin Silvent, Ram Y. Gordon. (2013) Phytosterols, red yeast rice, and lifestyle changes instead of statins: A randomized, double-blinded, placebo-controlled trial. American Heart Journal 166, 187-196.e2
CrossRef656
Robert N. Schuck, Philip M. Mendys, Ross J. Simpson. (2013) Beyond Statins: Lipid Management to Reduce Cardiovascular Risk. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:10.1002/phar.2013.33.issue-7, 754-764
CrossRef657
Anastazia Kei, Evangelos Liberopoulos, Kostantinos Tellis, Manfredi Rizzo, Moses Elisaf, Alexandros Tselepis. (2013) Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. European Journal of Clinical Investigation 43:10.1111/eci.2013.43.issue-7, 698-707
CrossRef658
Venkata M. Alla, Vrinda Agrawal, Andrew DeNazareth, Syed Mohiuddin, Sudha Ravilla, Marc Rendell. (2013) A Reappraisal of the Risks and Benefits of Treating to Target with Cholesterol Lowering Drugs. Drugs 73, 1025-1054
CrossRef659
Steven Hsu, Van-Khue Ton, M. Dominique Ashen, Seth S. Martin, Ty J. Gluckman, Payal Kohli, Stephen D. Sisson, Roger S. Blumenthal, Michael J. Blaha. (2013) A Clinician's Guide to the ABCs of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative. Clinical Cardiology 36, 383-393
CrossRef660
Fernando Civeira. (2013) La prevención de las enfermedades cardiovasculares requiere la prevención del desarrollo de arteriosclerosis y sus factores de riesgo. Clínica e Investigación en Arteriosclerosis 25, 110-111
CrossRef661
Richard M. Cubbon, Ben N. Mercer, Anshuman Sengupta, Mark T. Kearney. (2013) Importance of insulin resistance to vascular repair and regeneration. Free Radical Biology and Medicine 60, 246-263
CrossRef662
Christie M Ballantyne, Rene A Braeckman, Paresh N Soni. (2013) Icosapent ethyl for the treatment of hypertriglyceridemia. Expert Opinion on Pharmacotherapy 14, 1409-1416
CrossRef663
G. D. Norata, C. M. Ballantyne, A. L. Catapano. (2013) New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. European Heart Journal 34, 1783-1789
CrossRef664
Soo Lim, Yae Min Park, Ichiro Sakuma, Kwang Kon Koh. (2013) How to control residual cardiovascular risk despite statin treatment: Focusing on HDL–cholesterol. International Journal of Cardiology 166, 8-14
CrossRef665
Vaijinath S. Kamanna, Shobha H. Ganji, Moti L. Kashyap. (2013) Recent advances in niacin and lipid metabolism. Current Opinion in Lipidology 24, 239-245
CrossRef666
Nishtha Sodhi, Richard A. Krasuski. (2013) Therapy and clinical trials. Current Opinion in Lipidology 24, 281-282
CrossRef667
Dana Sheely, Ishwarlal Jialal. (2013) Strategies to Lower Low-Density Lipoprotein Cholesterol in Metabolic Syndrome: Averting the Diabetes Risk. Metabolic Syndrome and Related Disorders 11, 149-151
CrossRef668
Julian C. van Capelleveen, Andrea E. Bochem, M. Mahdi Motazacker, G. Kees Hovingh, John J. P. Kastelein. (2013) Genetics of HDL-C: A Causal Link to Atherosclerosis?. Current Atherosclerosis Reports 15
CrossRef669
Julian P Halcox. (2013) Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega-3 polyunsaturated fatty acid ethyl esters. Clinical Lipidology 8, 329-344
CrossRef670
Michela Triolo, Wijtske Annema, Robin PF Dullaart, Uwe JF Tietge. (2013) Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomarkers in Medicine 7, 457-472
CrossRef671
H. Takagi, T. Umemoto. (2013) Through the looking-glass of conventional meta-regression: An alternative approach based on fractional polynomials to a meta-analysis of niacin. Nutrition, Metabolism and Cardiovascular Diseases 23, e23-e25
CrossRef672
Miao Hu, Brian Tomlinson. (2013) Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics 14, 981-995
CrossRef673
Jane Stock. (2013) Triglyceride-rich lipoproteins and HDL: What do recent trials tell us?. Atherosclerosis 228, 329-331
CrossRef674
Daniel E Hilleman. (2013) Optimal use of lipid-altering therapy: guidelines versus evidence. Clinical Lipidology 8, 269-272
CrossRef675
Libby , Peter , . (2013) Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy. New England Journal of Medicine 368:21, 2004-2013
Full Text676
C. M. Schooling, G. Freeman, B. J. Cowling. (2013) Mendelian Randomization and Estimation of Treatment Efficacy for Chronic Diseases. American Journal of Epidemiology 177, 1128-1133
CrossRef677
U. Landmesser. (2013) The difficult search for a 'partner' of statins in lipid-targeted prevention of vascular events: the re-emergence and fall of niacin. European Heart Journal 34, 1254-1257
CrossRef678
Russell M. Medford, T. Forcht Dagi, Robert S. Rosenson, Margaret K. Offermann. (2013) Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield. Current Atherosclerosis Reports 15
CrossRef679
Anthony S. Wierzbicki. (2013) Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. International Journal of Clinical Practice 67, 391-393
CrossRef680
A. Kei, E. N. Liberopoulos, D. P. Mikhailidis, M. Elisaf. (2013) Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia. International Journal of Clinical Practice 67, 412-419
CrossRef681
Timothy Raymond, Russell Raymond, A Michael Lincoff. (2013) Management of the patient with diabetes and coronary artery disease: a contemporary review. Future Cardiology 9, 387-403
CrossRef682
L. Maria Belalcazar, Steven M. Haffner, Wei Lang, Ron C. Hoogeveen, Julia Rushing, Dawn C. Schwenke, Russell P. Tracy, F. Xavier Pi-Sunyer, Andrea M. Kriska, Christie M. Ballantyne and the Look AHEAD Actio. (2013) Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: From the look AHEAD study. Obesity 21:10.1002/oby.v21.5, 944-950
CrossRef683
C.S. Siegel, L.D. McCullough. (2013) NAD+ and Nicotinamide: Sex Differences in Cerebral Ischemia. Neuroscience 237, 223-231
CrossRef684
, R. Haynes, L. Jiang, J. C. Hopewell, J. Li, F. Chen, S. Parish, M. J. Landray, R. Collins, J. Armitage, R. Collins, J. Armitage, C. Baigent, Z. Chen, M. Landray, Y. Chen, L. Jiang, T. Pedersen, M. Landray, L. Bowman, F. Chen, M. Hill, R. Haynes, C. Knott, K. Rahimi, J. Tobert, P. Sleight, D. Simpson, S. Parish, A. Baxter, M. Lay, C. Bray, E. Wincott, G. Leijenhorst, A. Skattebol, G. Moen, Y. Mitchel, O. Kuznetsova, S. MacMahon, J. Kjekshus, C. Hill, T. H. Lam, P. Sandercock, R. Peto, J. C. Hopewell. (2013) HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. European Heart Journal 34, 1279-1291
CrossRef685
Valentina Kon, T. Alp Ikizler, Sergio Fazio. (2013) Importance of high-density lipoprotein quality. Current Opinion in Nephrology and Hypertension 22, 259-265
CrossRef686
Alan Garber, Martin Abrahamson, Joshua Barzilay, Lawrence Blonde, Zachary Bloomgarden, Michael Bush, Samuel Dagogo-Jack, Michael Davidson, Daniel Einhorn, W. Garvey, George Grunberger, Yehuda Handelsman, Irl Hirsch, Paul Jellinger, Janet McGill, Jeffrey Mechanick, Paul Rosenblit, Guillermo Umpierrez, Michael Davidson. (2013) American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement. Endocrine Practice 19, 1-48
CrossRef687
Marina G. Damiano, R. Kannan Mutharasan, Sushant Tripathy, Kaylin M. McMahon, C. Shad Thaxton. (2013) Templated high density lipoprotein nanoparticles as potential therapies and for molecular delivery. Advanced Drug Delivery Reviews 65, 649-662
CrossRef688
Joshua T. Chai, Janet E. Digby, Robin P. Choudhury. (2013) GPR109A and Vascular Inflammation. Current Atherosclerosis Reports 15
CrossRef689
Van-Khue Ton, Seth S. Martin, Roger S. Blumenthal, Michael J. Blaha. (2013) Comparing the New European Cardiovascular Disease Prevention Guideline With Prior American Heart Association Guidelines: An Editorial Review. Clinical Cardiology 36:10.1002/clc.2013.36.issue-5, E1-E6
CrossRef690
Carl J. Lavie, James J. DiNicolantonio, Richard V. Milani, James H. O'Keefe. (2013) Niacin Therapy Lives for Another Day—Maybe?. Journal of the American College of Cardiology 61:21, 2197-2198
CrossRef691
Andrew J Murphy, Nora Bijl, Laurent Yvan-Charvet, Carrie B Welch, Neha Bhagwat, Adili Reheman, Yiming Wang, James A Shaw, Ross L Levine, Heyu Ni, Alan R Tall, Nan Wang. (2013) Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nature Medicine 19, 586-594
CrossRef692
Anthony S. Wierzbicki. (2013) Dyslipidaemia: Failure to THRIVE: the end for niacin?. Nature Reviews Cardiology 10, 246-247
CrossRef693
Carlos Guijarro, Juan de Dios García-Díaz. (2013) Estrategias terapéuticas. Evolución y estado actual de las Guías Europeas de Prevención Cardiovascular. Clínica e Investigación en Arteriosclerosis 25, 92-97
CrossRef694
Carlos Fernández-Hernando. (2013) Lymphatic vessels clean up your arteries. Journal of Clinical Investigation 123, 1417-1419
CrossRef695
Folkert W. Asselbergs, Ruth C. Lovering, Fotios Drenos. (2013) Progress in genetic association studies of plasma lipids. Current Opinion in Lipidology 24, 123-128
CrossRef696
Brian A Ference, Nitin Mahajan. (2013) The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease. Current Atherosclerosis Reports 15
CrossRef697
Boudewijn Klop, Jan Elte, Manuel Cabezas. (2013) Dyslipidemia in Obesity: Mechanisms and Potential Targets. Nutrients 5, 1218-1240
CrossRef698
P. Pellicori, P. Costanzo, A. C. Joseph, A. Hoye, S. L. Atkin, J. G. F. Cleland. (2013) Medical Management of Stable Coronary Atherosclerosis. Current Atherosclerosis Reports 15
CrossRef699
A. S. Wierzbicki. (2013) Sugar, sugar. International Journal of Clinical Practice 67, 294-296
CrossRef700
Melvyn Rubenfire, Robert D. Brook. (2013) HDL Cholesterol and Cardiovascular Outcomes: What Is the Evidence?. Current Cardiology Reports 15
CrossRef701
C. Guijarro. (2013) Los fibratos en el control del síndrome metabólico. Hipertensión y Riesgo Vascular 30, 39-44
CrossRef702
Thimoteus Speer, Lucia Rohrer, Przemyslaw Blyszczuk, Rukshana Shroff, Kira Kuschnerus, Nicolle Kränkel, Gabriela Kania, Stephen Zewinger, Alexander Akhmedov, Yi Shi, Tina Martin, Damir Perisa, Stephan Winnik, Maja F. Müller, Urban Sester, Gabriel Wernicke, Andreas Jung, Ursula Gutteck, Urs Eriksson, Jürgen Geisel, John Deanfield, Arnold von Eckardstein, Thomas F. Lüscher, Danilo Fliser, Ferdinand H. Bahlmann, Ulf Landmesser. (2013) Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2. Immunity 38, 754-768
CrossRef703
Jane Hoover-Plow, Menggui Huang. (2013) Lipoprotein(a) metabolism: Potential sites for therapeutic targets. Metabolism 62, 479-491
CrossRef704
H. Gohlke, C. Albus, G. Bönner, H. Darius, S. Eckert, C. Gohlke-Bärwolf, D. Gysan, H. Hahmann, M. Halle, R. Hambrecht, P. Mathes, H.-G. Predel, G. Sauer †, C. von Schacky, G. Schuler, J. Siegrist, J. Thiery, D. Tschöpe, H. Völler, A. Wirth. (2013) Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. Der Kardiologe 7, 141-156
CrossRef705
Julie R. Dominguez, Bryan Kestenbaum, Michel Chonchol, Geoffrey Block, Gail A. Laughlin, Cora E. Lewis, Ronit Katz, Elizabeth Barrett-Connor, Steve Cummings, Eric S. Orwoll, Joachim H. Ix. (2013) Relationships Between Serum and Urine Phosphorus With All-Cause and Cardiovascular Mortality: The Osteoporotic Fractures in Men (MrOS) Study. American Journal of Kidney Diseases 61, 555-563
CrossRef706
Robert A. Hegele. (2013) Editorial comment. Current Opinion in Lipidology 24, 109-110
CrossRef707
Tun-Ying Hsu, Diana Chirovsky, Foong Ming Moy, Baishali M. Ambegaonkar. (2013) Attainment of Goal and Normalized Lipid Levels With Lipid-Modifying Therapy in Malaysia. Clinical Therapeutics 35, 450-460
CrossRef708
S. Leonardi, P. W. Armstrong, P. J. Schulte, E. M. Ohman, L. K. Newby. (2013) Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review. European Heart Journal 34, 894-902
CrossRef709
Oliver Soehnlein, Filip K. Swirski. (2013) Hypercholesterolemia links hematopoiesis with atherosclerosis. Trends in Endocrinology & Metabolism 24, 129-136
CrossRef710
Rose Q. Do, Robert A. Vogel, Gregory G. Schwartz. (2013) PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics. Current Cardiology Reports 15
CrossRef711
Joost Besseling, Julian van Capelleveen, John J. P. Kastelein, G. Kees Hovingh. (2013) LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?. Drugs 73, 293-301
CrossRef712
Wanda C. Lakey, Nicole Greyshock, John R. Guyton. (2013) Adverse reactions of Achilles tendon xanthomas in three hypercholesterolemic patients after treatment intensification with niacin and bile acid sequestrants. Journal of Clinical Lipidology 7, 178-181
CrossRef713
Yu Kataoka, Kiyoko Uno, Rishi Puri, Stephen J Nicholls. (2013) Epanova ® and hypertriglyceridemia: pharmacological mechanisms and clinical efficacy. Future Cardiology 9, 177-186
CrossRef714
Amanda Brahm, Robert Hegele. (2013) Hypertriglyceridemia. Nutrients 5, 981-1001
CrossRef715
Robert H. Nelson. (2013) Hyperlipidemia as a Risk Factor for Cardiovascular Disease. Primary Care: Clinics in Office Practice 40, 195-211
CrossRef716
Patrick M. Moriarty, James Backes, Julie-Ann Dutton, Jianghua He, Janelle F. Ruisinger, Kristin Schmelzle. (2013) Apple pectin for the reduction of niacin-induced flushing. Journal of Clinical Lipidology 7, 140-146
CrossRef717
Joe M. Chehade, Margaret Gladysz, Arshag D. Mooradian. (2013) Dyslipidemia in Type 2 Diabetes: Prevalence, Pathophysiology, and Management. Drugs 73, 327-339
CrossRef718
Stella Aslibekyan, Robert J Straka, Marguerite R Irvin, Steven A Claas, Donna K Arnett. (2013) Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies. Expert Review of Cardiovascular Therapy 11, 355-364
CrossRef719
Joseph Yeboah. (2013) Targeting specific traditional risk factors to improve cardiovascular outcomes: Sound or flawed?. Atherosclerosis 226, 335-336
CrossRef720
Andrew C. Philpott, Jaroslav Hubacek, Yichun C. Sun, Darlene Hillard, Todd J. Anderson. (2013) Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. Atherosclerosis 226, 453-458
CrossRef721
Alberico Catapano, Peter P Toth, Joanne E Tomassini, Andrew M Tershakovec. (2013) The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clinical Lipidology 8, 13-41
CrossRef722
David A. Cook, Colin P. West. (2013) Perspective. Academic Medicine 88, 162-167
CrossRef723
Todd J. Anderson, Jean Grégoire, Robert A. Hegele, Patrick Couture, G.B. John Mancini, Ruth McPherson, Gordon A. Francis, Paul Poirier, David C. Lau, Steven Grover, Jacques Genest, André C. Carpentier, Robert Dufour, Milan Gupta, Richard Ward, Lawrence A. Leiter, Eva Lonn, Dominic S. Ng, Glen J. Pearson, Gillian M. Yates, James A. Stone, Ehud Ur. (2013) 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology 29, 151-167
CrossRef724
Robert Rountree. (2013) Roundoc Rx: Using Nutraceuticals to Complement Drug Treatments. Alternative and Complementary Therapies 19, 3-8
CrossRef725
Pam R. Taub, Erin Higginbotham, Robert R. Henry. (2013) Beneficial and Detrimental Effects of Glycemic Control on Cardiovascular Disease in Type 2 Diabetes. Current Cardiology Reports 15
CrossRef726
Amita Singh, Arthur Schwartzbard, Eugenia Gianos, Jeffrey S. Berger, Howard Weintraub. (2013) What should we do about Hypertriglyceridemia in Coronary Artery Disease Patients?. Current Treatment Options in Cardiovascular Medicine 15, 104-117
CrossRef727
Ken Kishida, Tohru Funahashi, Iichiro Shimomura. (2013) Effects of pitavastatin on HDL metabolism. Clinical Lipidology 8, 55-68
CrossRef728
Robert A. Comley, David Kallend. (2013) Imaging in the cardiovascular and metabolic disease area. Drug Discovery Today 18, 185-192
CrossRef729
Binh An P. Phan, Luis Muñoz, Pey Shadzi, Daniel Isquith, Michael Triller, B. Greg Brown, Xue-Qiao Zhao. (2013) Effects of Niacin on Glucose Levels, Coronary Stenosis Progression, and Clinical Events in Subjects With Normal Baseline Glucose Levels (<100 mg/dl): A Combined Analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Atherosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI During Lipid-Lowering (CPC) Study. The American Journal of Cardiology 111, 352-355
CrossRef730
Luís Masana, Daiana Ibarretxe, Mercedes Heras, Anna Cabré, Raimon Ferré, Jordi Merino, Núria Plana, Josefa Girona. (2013) Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy. Atherosclerosis 226, 471-475
CrossRef731
Nidhi Mehta, Emil M. deGoma. (2013) Pharmacologic Interactions of Multidrug Therapy for Dyslipidemia. Current Atherosclerosis Reports 15
CrossRef732
The Four Secrets the Drug Companies Don't Want You to Know. 2013:, 4-24.
CrossRef733
A. Sämann, G. Wolf. (2013) Diabetische Nephropathie. Humanmedizin kompakt
CrossRef734
Dominic S. Ng, Norman C. W. Wong, Robert A. Hegele. (2013) HDL—is it too big to fail?. Nature Reviews Endocrinology 9, 308-312
CrossRef735
A. E. Bochem, D. F. van Wijk, A. G. Holleboom, R. Duivenvoorden, M. M. Motazacker, G. M. Dallinga-Thie, E. de Groot, J. J. P. Kastelein, A. J. Nederveen, G. K. Hovingh, E. S. G. Stroes. (2013) ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. European Heart Journal 34, 286-291
CrossRef736
Willibald Hochholzer, Robert P. Giugliano. (2013) Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. Current Atherosclerosis Reports 15
CrossRef737
F. Kronenberg, G. Utermann. (2013) Lipoprotein(a): resurrected by genetics. Journal of Internal Medicine 273, 6-30
CrossRef738
Joseph M. Keenan. (2013) Wax-matrix extended-release niacin vs inositol hexanicotinate: A comparison of wax-matrix, extended-release niacin to inositol hexanicotinate “no-flush” niacin in persons with mild to moderate dyslipidemia. Journal of Clinical Lipidology 7, 14-23
CrossRef739
Piotr Sobieszczyk. . Cerebrovascular Disease. 2013:, 553-570.
CrossRef740
K. Taseva, S. Fischer, J. Passauer, N. Weiss, S.R. Bornstein, U. Julius. (2013) Factors inducing cardiovascular events in patients treated by lipoprotein apheresis. Atherosclerosis Supplements 14, 45-50
CrossRef741
Philip J. Barter. (2013) High Density Lipoprotein: A Therapeutic Target in Type 2 Diabetes. Endocrinology and Metabolism 28, 169
CrossRef742
William F Keane, Joanne E Tomassini, David R Neff. (2013) Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis. Journal of Atherosclerosis and Thrombosis 20, 123-133
CrossRef743
Chee Jeong Kim. (2013) Management of Hypertriglyceridemia for Prevention of Cardiovascular Diseases. Journal of Lipid and Atherosclerosis 2, 53
CrossRef744
Neil J. Stone. . Drugs for Elevated Low-Density Lipoprotein Cholesterol. 2013:, 421-433.
CrossRef745
Michael T. Murray. . Atherosclerosis. 2013:, 1225-1245.
CrossRef746
U. Julius, S. Fischer. (2013) Nicotinic acid as a lipid-modifying drug – A review. Atherosclerosis Supplements 14, 7-13
CrossRef747
Bo Kyung Koo, Min Kyong Moon. (2013) Impact of Isolated Low HDL Cholesterolemia on the Risk of Coronary Artery Disease: A 4-Year Community-Based Prospective Study. Korean Journal of Medicine 84, 229
CrossRef748
Tsuyoshi Nozue, Kazuki Fukui, Shingo Yamamoto, Tomoyuki Kunishima, Shigeo Umezawa, Yuko Onishi, Shinichi Tohyama, Youichi Takeyama, Yoshihiro Morino, Takao Yamauchi, Kiyoshi Hibi, Takashi Sozu, Mitsuyasu Terashima, Ichiro Michishita. (2013) C-Reactive Protein and Future Cardiovascular Events in Statin-Treated Patients with Angina Pectoris: The Extended TRUTH Study. Journal of Atherosclerosis and Thrombosis 20, 717-725
CrossRef749
S. Martinez-Hervas, J. T. Real, M. A. Priego, A. Carratalá, A. D. Sniderman, R. Carmena, J. F. Ascaso. (2013) Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population. International Journal of Clinical Practice 67, 81-88
CrossRef750
Mae Sheikh-Ali, Prafull Raheja, Nancy Borja-Hart. (2013) Medical Management and Strategies to Prevent Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus. Postgraduate Medicine 125, 17-33
CrossRef751
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, Anders B. Jørgensen, Ruth Frikke-Schmidt, Børge G. Nordestgaard. (2013) Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease. Journal of the American College of Cardiology 61:4, 427-436
CrossRef752
Paul M. Lavigne, Richard H. Karas. (2013) The Current State of Niacin in Cardiovascular Disease Prevention. Journal of the American College of Cardiology 61:4, 440-446
CrossRef753
Anouar Hafiane, Jacques Genest. (2013) HDL, Atherosclerosis, and Emerging Therapies. Cholesterol 2013, 1-18
CrossRef754
Beth Parker, Kamlesh Kothawade, Namee Kim, Maura Paul-Labrador, Noel Bairey Merz, Donna Polk. (2013) Lipid Lowering Therapy with Combination of Niacin and Statin in Women: Age-Related Endothelial Effects. ISRN Vascular Medicine 2013, 1-7
CrossRef755
Jennifer B. Christian, Eric J. Olson, Jeffery K. Allen, Kimberly A. Lowe. (2013) HDL-C Response Variability to Niacin ER in US Adults. Cholesterol 2013, 1-8
CrossRef756
F. M. van der Valk, D. F. van Wijk, E. S. G. Stroes. (2012) Serendipity of post-hoc surrogate marker research. European Heart Journal 33, 2897-2898
CrossRef757
Brian Kolski, Sotirios Tsimikas. (2012) Emerging therapeutic agents to lower lipoprotein (a) levels. Current Opinion in Lipidology 23, 560-568
CrossRef758
Daniel B. Larach, Emil M. deGoma, Daniel J. Rader. (2012) Targeting High Density Lipoproteins in the Prevention of Cardiovascular Disease?. Current Cardiology Reports 14, 684-691
CrossRef759
Matthew J Sorrentino. (2012) An update on statin alternatives and adjuncts. Clinical Lipidology 7, 721-730
CrossRef760
Wilbert S Aronow. (2012) Treatment of hypercholesterolemia and hypertension in diabetics with coronary artery disease. Clinical Lipidology 7, 689-695
CrossRef761
Niina Matikainen, Marja-Riitta Taskinen. (2012) Management of Dyslipidemias in the Presence of the Metabolic Syndrome or Type 2 Diabetes. Current Cardiology Reports 14, 721-731
CrossRef762
Scott M. Grundy. (2012) Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?. Current Cardiology Reports 14, 692-700
CrossRef763
Ian Graham, Marie-Therese Cooney, David Bradley, Alexandra Dudina, Zeljko Reiner. (2012) Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality. Current Cardiology Reports 14, 709-720
CrossRef764
Matthew C Pahl, Kimberly Derr, Gabor Gäbel, Irene Hinterseher, James R Elmore, Charles M Schworer, Thomas C Peeler, David P Franklin, John L Gray, David J Carey, Gerard Tromp, Helena Kuivaniemi. (2012) MicroRNA expression signature in human abdominal aortic aneurysms. BMC Medical Genomics 5:1
CrossRef765
Chunyu Zheng, Masanori Aikawa. (2012) High-Density Lipoproteins. Journal of the American College of Cardiology 60:23, 2380-2383
CrossRef766
Jennifer G. Robinson. (2012) What Is the Role of Advanced Lipoprotein Analysis in Practice?. Journal of the American College of Cardiology 60:25, 2607-2615
CrossRef767
Schwartz , Gregory G. , Olsson , Anders G. , Abt , Markus , Ballantyne , Christie M. , Barter , Philip J. , Brumm , Jochen , Chaitman , Bernard R. , Holme , Ingar M. , Kallend , David , Leiter , Lawrence A. , Leitersdorf , Eran , McMurray , John J.V. , Mundl , Hardi , Nicholls , Stephen J. , Shah , Prediman K. , Tardif , Jean-Claude , Wright , R. Scott , . (2012) Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine 367:22, 2089-2099
Free Full Text768
Adie Viljoen, Anthony S. Wierzbicki. . Lipid Management. 2012:, 68-89.
CrossRef769
K Mahdy Ali, A Wonnerth, K Huber, J Wojta. (2012) Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities. British Journal of Pharmacology 167, 1177-1194
CrossRef770
T. Stulnig. (2012) Kardiovaskuläres Risiko und medikamentöse Lipidtherapie. Der Diabetologe 8, 568-572
CrossRef771
David D. Waters. (2012) Utility of Biomarkers and Imaging in the Development of Drugs for the Treatment of Coronary Atherosclerosis. Canadian Journal of Cardiology 28, 687-692
CrossRef772
Pamela M. Katz, Lawrence A. Leiter. (2012) Drugs Targeting High-Density Lipoprotein Cholesterol for Coronary Artery Disease Management. Canadian Journal of Cardiology 28, 667-677
CrossRef773
Kyeong Ho Yun, Seoung-Nam Shin, Jum Suk Ko, Sang Jae Rhee, Nam-Ho Kim, Seok Kyu Oh, Jin-Won Jeong. (2012) Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Journal of Cardiology 60, 383-388
CrossRef774
F. L. Santos, S. S. Esteves, A. da Costa Pereira, W. S. Yancy Jr, J. P. L. Nunes. (2012) Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obesity Reviews 13:10.1111/obr.2012.13.issue-11, 1048-1066
CrossRef775
Koh Ono. (2012) Current concept of reverse cholesterol transport and novel strategy for atheroprotection. Journal of Cardiology 60, 339-343
CrossRef776
Kevin Jon Williams. (2012) What does HDL do? A new mechanism to slow atherogenesis – But a new problem in type 2 diabetes mellitus. Atherosclerosis 225, 36-38
CrossRef777
H. Robert Superko, Lakshmana Pendyala, Paul T. Williams, Katherine M. Momary, Spencer B. King, Brenda C. Garrett. (2012) High-density lipoprotein subclasses and their relationship to cardiovascular disease. Journal of Clinical Lipidology 6, 496-523
CrossRef778
Christian Ukena, Michael Böhm, Stephan H. Schirmer. (2012) Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTIDUDE, FAME II and more. Clinical Research in Cardiology 101, 861-874
CrossRef779
Zachary Bloomgarden, Lawrence Blonde, Alan Garber, Carol Wysham. (2012) Current Issues in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes. Endocrine Practice 18, 6-26
CrossRef780
Hua Ling, Tammy L. Burns, Daniel E. Hilleman. (2012) Novel Strategies for Managing Dyslipidemia: Treatment beyond Statins. Postgraduate Medicine 124, 43-54
CrossRef781
Trine Holm Johannsen, Ruth Frikke-Schmidt, Jesper Schou, Børge G. Nordestgaard, Anne Tybjærg-Hansen. (2012) Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects. Journal of the American College of Cardiology 60:20, 2041-2048
CrossRef782
Sabu Thomas, William E. Boden. . Management of Chronic Coronary Artery Disease. 2012:, 60-85.
CrossRef783
M. Haris U. Usman, Arman Qamar, Ramprasad Gadi, Scott Lilly, Harsh Goel, Jaison Hampson, Megan L. Mucksavage, Grace A. Nathanson, Daniel J. Rader, Richard L. Dunbar. (2012) Extended-release Niacin Acutely Suppresses Postprandial Triglyceridemia. The American Journal of Medicine 125, 1026-1035
CrossRef784
Christie M. Ballantyne, Harold E. Bays, John J. Kastelein, Evan Stein, Jonathan L. Isaacsohn, Rene A. Braeckman, Paresh N. Soni. (2012) Efficacy and Safety of Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients With Persistent High Triglycerides (from the ANCHOR Study). The American Journal of Cardiology 110, 984-992
CrossRef785
J.-C. Kaski. (2012) HDL- Cholesterol: A Nut Too Hard to Crack?. Cardiovascular Drugs and Therapy 26, 433-434
CrossRef786
Aneta Otocka-Kmiecik, Dimitri P. Mikhailidis, Stephen J. Nicholls, Michael Davidson, Jacek Rysz, Maciej Banach. (2012) Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?. Progress in Lipid Research 51, 314-324
CrossRef787
Julien Hanson, Andreas Gille, Stefan Offermanns. (2012) Role of HCA2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacology & Therapeutics 136, 1-7
CrossRef788
A. Sämann, G. Wolf. (2012) Diabetische Nephropathie. Der Internist 53, 1195-1206
CrossRef789
Daniel J Rader, Alan R Tall. (2012) The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?. Nature Medicine 18, 1344-1346
CrossRef790
Marika Massaro, Egeria Scoditti, Maria Annunziata Carluccio, Raffaele De Caterina. (2012) Alcohol and atherosclerosis: A double edged sword. Vascular Pharmacology 57, 65-68
CrossRef791
Kevin C. Maki, Harold E. Bays, Mary R. Dicklin. (2012) Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. Journal of Clinical Lipidology 6, 413-426
CrossRef792
Amanda J Hooper, John R Burnett. (2012) Dalcetrapib, a cholesteryl ester transfer protein modulator. Expert Opinion on Investigational Drugs 21, 1427-1432
CrossRef793
Rigotti R. Attilio. (2012) Actualización en el manejo del colesterol hdl bajo. Revista Médica Clínica Las Condes 23:6, 689-692
CrossRef794
Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2012) The Year in Atherothrombosis. Journal of the American College of Cardiology 60:10, 932-942
CrossRef795
S. Offermanns. (2012) It Ain't Over 'Til the Fat Lady Sings. Science Translational Medicine 4, 148fs30-148fs30
CrossRef796
Kevin C Maki, Mary R Dicklin, Harold E Bays. (2012) Clinical lipid management of patients with mild-to-moderate hypertriglyceridemia. Clinical Lipidology 7, 367-370
CrossRef797
Benoit J. Arsenault, Ekaterini A. Kritikou, Jean-Claude Tardif. (2012) Regression of Atherosclerosis. Current Cardiology Reports 14, 443-449
CrossRef798
Tyan Thomas. (2012) Attainment of combined optimal lipid values with the use of niacin: has AIM-HIGH closed the book on this debate?. Clinical Lipidology 7, 389-396
CrossRef799
Harold Bays, Hilde Giezek, James M. McKenney, Edward A. O'Neill, Andrew M. Tershakovec. (2012) Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus. Metabolic Syndrome and Related Disorders 10, 260-266
CrossRef800
L. V. Riella, S. Gabardi, A. Chandraker. (2012) Dyslipidemia and Its Therapeutic Challenges in Renal Transplantation. American Journal of Transplantation 12, 1975-1982
CrossRef801
Jing Pang, Dick C. Chan, P. Hugh R. Barrett, Gerald F. Watts. (2012) Postprandial dyslipidaemia and diabetes. Current Opinion in Lipidology 23, 303-309
CrossRef802
Antonio M Gotto, Jennifer E Moon. (2012) Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study. Expert Review of Cardiovascular Therapy 10, 955-963
CrossRef803
Benjamin F Voight, Gina M Peloso, Marju Orho-Melander, Ruth Frikke-Schmidt, Maja Barbalic, Majken K Jensen, George Hindy, Hilma Hólm, Eric L Ding, Toby Johnson, Heribert Schunkert, Nilesh J Samani, Robert Clarke, Jemma C Hopewell, John F Thompson, Mingyao Li, Gudmar Thorleifsson, Christopher Newton-Cheh, Kiran Musunuru, James P Pirruccello, Danish Saleheen, Li Chen, Alexandre FR Stewart, Arne Schillert, Unnur Thorsteinsdottir, Gudmundur Thorgeirsson, Sonia Anand, James C Engert, Thomas Morgan, John Spertus, Monika Stoll, Klaus Berger, Nicola Martinelli, Domenico Girelli, Pascal P McKeown, Christopher C Patterson, Stephen E Epstein, Joseph Devaney, Mary-Susan Burnett, Vincent Mooser, Samuli Ripatti, Ida Surakka, Markku S Nieminen, Juha Sinisalo, Marja-Liisa Lokki, Markus Perola, Aki Havulinna, Ulf de Faire, Bruna Gigante, Erik Ingelsson, Tanja Zeller, Philipp Wild, Paul I W de Bakker, Olaf H Klungel, Anke-Hilse Maitland-van der Zee, Bas J M Peters, Anthonius de Boer, Diederick E Grobbee, Pieter W Kamphuisen, Vera H M Deneer, Clara C Elbers, N Charlotte Onland-Moret, Marten H Hofker, Cisca Wijmenga, WM Monique Verschuren, Jolanda MA Boer, Yvonne T van der Schouw, Asif Rasheed, Philippe Frossard, Serkalem Demissie, Cristen Willer, Ron Do, Jose M Ordovas, Gonçalo R Abecasis, Michael Boehnke, Karen L Mohlke, Mark J Daly, Candace Guiducci, Noël P Burtt, Aarti Surti, Elena Gonzalez, Shaun Purcell, Stacey Gabriel, Jaume Marrugat, John Peden, Jeanette Erdmann, Patrick Diemert, Christina Willenborg, Inke R König, Marcus Fischer, Christian Hengstenberg, Andreas Ziegler, Ian Buysschaert, Diether Lambrechts, Frans Van de Werf, Keith A Fox, Nour Eddine El Mokhtari, Diana Rubin, Jürgen Schrezenmeir, Stefan Schreiber, Arne Schäfer, John Danesh, Stefan Blankenberg, Robert Roberts, Ruth McPherson, Hugh Watkins, Alistair S Hall, Kim Overvad, Eric Rimm, Eric Boerwinkle, Anne Tybjaerg-Hansen, L Adrienne Cupples, Muredach P Reilly, Olle Melander, Pier M Mannucci, Diego Ardissino, David Siscovick, Roberto Elosua, Kari Stefansson, Christopher J O'Donnell, Veikko Salomaa, Daniel J Rader, Leena Peltonen, Stephen M Schwartz, David Altshuler, Sekar Kathiresan. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet 380:9841, 572-580
CrossRef804
Philip Green, Mathew S. Maurer, Joanne M. Foody, Daniel E. Forman, Nanette K. Wenger. (2012) Representation of Older Adults in the Late-Breaking Clinical Trials American Heart Association 2011 Scientific Sessions. Journal of the American College of Cardiology 60:9, 869-871
CrossRef805
Emil M. deGoma, Daniel J. Rader. (2012) High-Density Lipoprotein Particle Number. Journal of the American College of Cardiology 60:6, 517-520
CrossRef806
Clara C. Blad, Cong Tang, Stefan Offermanns. (2012) G protein-coupled receptors for energy metabolites as new therapeutic targets. Nature Reviews Drug Discovery 11, 603-619
CrossRef807
Nicole A Terpolilli, Michael A Moskowitz, Nikolaus Plesnila. (2012) Nitric oxide: considerations for the treatment of ischemic stroke. Journal of Cerebral Blood Flow & Metabolism 32, 1332-1346
CrossRef808
Eliot A. Brinton. (2012) Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: Still problematic after the primary publication. Journal of Clinical Lipidology 6, 312-317
CrossRef809
William E. Boden, William Clifford Roberts. (2012) WILLIAM EDWARD BODEN, MD: A Conversation With the Editor. The American Journal of Cardiology 110, 145-159
CrossRef810
O.P. Ganda, C.G. Jumes, M.J. Abrahamson, M. Molla. (2012) Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia. Diabetes Research and Clinical Practice 97, 51-56
CrossRef811
Antonio M. Gotto, Jennifer E. Moon. (2012) Recent Clinical Studies of the Effects of Lipid-Modifying Therapies. The American Journal of Cardiology 110, 15A-26A
CrossRef812
Tisha R. Joy. (2012) Novel HDL-based therapeutic agents. Pharmacology & Therapeutics 135, 18-30
CrossRef813
Michael A. Kadoch. (2012) The power of nutrition as medicine. Preventive Medicine 55, 80
CrossRef814
Anthony S. Wierzbicki, Rosemary E. Clarke, Adie Viljoen, Dimitri P. Mikhailidis. (2012) Triglycerides. Current Opinion in Cardiology 27, 398-404
CrossRef815
Anastazia Kei, Moses S Elisaf. (2012) Nicotinic acid: clinical considerations. Expert Opinion on Drug Safety 11, 551-564
CrossRef816
Francesco Paneni, Francesco Cosentino, Federica Marrara, Francesca Palano, Giuliana Capretti, Mario Gregori, Giuliano Tocci, Marco Testa, Massimo Volpe. (2012) The clinical relevance of dysfunctional HDL in patients with coronary artery disease: A 3-year follow-up study. International Journal of Cardiology 158, 158-160
CrossRef817
Ishwarlal Jialal, Gerred Smith. (2012) Managing the Dyslipidemia of Metabolic Syndrome: Beyond Statin Therapy. Metabolic Syndrome and Related Disorders 10, 159-160
CrossRef818
Jennifer G. Robinson. (2012) Identification and Treatment of Women with Familial Hypercholesterolemia. Current Cardiovascular Risk Reports 6, 196-204
CrossRef819
W. Koenig, N. Marx, J. Thiery, G. Klose. (2012) Kommentar zu den neuen Leitlinien (2011) der Europäischen Gesellschaft für Kardiologie zum Management von Dyslipidämien. Der Kardiologe 6, 210-216
CrossRef820
Robert S. Rosenson. (2012) Clinical Trials of HDL Cholesterol–Raising Therapy: What Have We Learned About the HDL Hypothesis from AIM-HIGH?. Current Atherosclerosis Reports 14, 190-192
CrossRef821
Rahul Yadav, Michael France, Naveed Younis, Salam Hama, Basil J Ammori, See Kwok, Handrean Soran. (2012) Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety. Expert Opinion on Pharmacotherapy 13, 1345-1362
CrossRef822
Avishay Elis. (2012) Should HDL cholesterol levels be the primary target of cardiovascular disease risk assessment and therapy?. Expert Review of Cardiovascular Therapy 10, 675-677
CrossRef823
Terry A Jacobson. (2012) A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Expert Review of Cardiovascular Therapy 10, 687-695
CrossRef824
Robert A. Vogel. (2012) PCSK9 Inhibition. Journal of the American College of Cardiology 59:25, 2354-2355
CrossRef825
Erin D. Michos, Christopher T. Sibley, Jefferson T. Baer, Michael J. Blaha, Roger S. Blumenthal. (2012) Niacin and Statin Combination Therapy for Atherosclerosis Regression and Prevention of Cardiovascular Disease Events. Journal of the American College of Cardiology 59:23, 2058-2064
CrossRef826
Stephen J. Nicholls. (2012) The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) Trial. Journal of the American College of Cardiology 59:23, 2065-2067
CrossRef827
Tsung O. Cheng. (2012) The use of coercive trial acronyms should be discouraged. International Journal of Cardiology 157, 157-159
CrossRef828
Baishali Ambegaonkar, Diana Chirovsky, Hung Fat Tse, Yuk Kong Lau, Brian Tomlinson, Shu Kin Li, Chiu Sun Yue, Tai Hung Wong, Man Chun Choi, Prabowo Tunggal, Vasilisa Sazonov. (2012) Attainment of Normal Lipid Levels Among Patients on Lipid-Modifying Therapy in Hong Kong. Advances in Therapy 29, 427-441
CrossRef829
Fernando Civeira, Elena Burillo. (2012) Colesterol HDL bajo o hipofunción HDL. Medicina Clínica 138, 565-566
CrossRef830
Wilbert S. Aronow. (2012) Evidence-Based Medicine Should Be Practiced for Primary Prevention and Secondary Prevention of Cardiovascular Disease. Clinical Cardiology 35:10.1002/clc.v35.5, 257-258
CrossRef831
Anthony S Wierzbicki, Timothy C Hardman, Adie Viljoen. (2012) Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. Expert Opinion on Investigational Drugs 21, 667-676
CrossRef832
Christian Besler, Thomas F. Lüscher, Ulf Landmesser. (2012) Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Molecular Medicine 4, 251-268
CrossRef833
Jane Stock. (2012) Controversies in dyslipidaemia management. Atherosclerosis 221, 321-324
CrossRef834
Menno Hoekstra, Miranda Van Eck, Suzanne J.A. Korporaal. (2012) Genetic studies in mice and humans reveal new physiological roles for the high-density lipoprotein receptor scavenger receptor class B type I. Current Opinion in Lipidology 23, 127-132
CrossRef835
Mark T. Ledwidge, Fiona Ryan, David M. Kerins, Damian O’Connell, Gene Cefali, Shona Harmon, Michael Jones, John F. Gilmer. (2012) In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: Is this a new immediate-release therapeutic option for niacin?. Atherosclerosis 221, 478-483
CrossRef836
Joseph B. Dubé, Michael B. Boffa, Robert A. Hegele, Marlys L. Koschinsky. (2012) Lipoprotein(a). Current Opinion in Lipidology 23, 133-140
CrossRef837
Danielle Duffy, DaJuanicia N. Holmes, Matthew T. Roe, Eric D. Peterson. (2012) The impact of high-density lipoprotein cholesterol levels on long-term outcomes after non–ST-elevation myocardial infarction. American Heart Journal 163, 705-713
CrossRef838
Nima Alipour, Nathan D Wong, Shaista Malik. (2012) The metabolic syndrome and dyslipidemia in primary and secondary prevention: examining the implications of recent trials. Clinical Lipidology 7, 223-239
CrossRef839
Alok Saurav, Manu Kaushik, Syed M Mohiuddin. (2012) Fenofibric acid for hyperlipidemia. Expert Opinion on Pharmacotherapy 13, 717-722
CrossRef840
Vasilios G. Athyros, Niki Katsiki, Asterios Karagiannis, Dimitri P. Mikhailidis. (2012) Should raising high-density lipoprotein cholesterol be a matter of debate?. Journal of Cardiovascular Medicine 13:4, 254-259
CrossRef841
(2012) Niacin in Cardiovascular Patients Receiving Statins. New England Journal of Medicine 366:13, 1255-1256
Free Full Text842
Adie Viljoen, Anthony S. Wierzbicki. . Lipid Management. 2012:, 449-460.
CrossRef843
Sang-Hak Lee, Kyoung-Im Cho, Jang-Young Kim, Young Keun Ahn, Seung-Woon Rha, Yong-Jin Kim, Yun-Seok Choi, Si Wan Choi, Dong Woon Jeon, Pil-Ki Min, Dong-Ju Choi, Sang Hong Baek, Kwon Sam Kim, Young Sup Byun, Yangsoo Jang. (2012) Non-lipid effects of rosuvastatin–fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia. Atherosclerosis 221, 169-175
CrossRef844
Veena Rajanna, Kristen B. Campbell, Jeffrey Leimberger, Bibhu D. Mohanty, John R. Guyton. (2012) Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins. Journal of Clinical Lipidology 6, 168-173
CrossRef845
Zachary Bloomgarden, Yehuda Handelsman. (2012) Did AIM-HIGH aim too low?. Journal of Diabetes 4:10.1111/jdb.2012.4.issue-1, 1-2
CrossRef846
Julia C. Creider, Robert A. Hegele, Tisha R. Joy. (2012) Niacin: another look at an underutilized lipid-lowering medication. Nature Reviews Endocrinology 8, 517-528
CrossRef847
Madhumita Venkataramanan. (2012) More trials are cut short, but not the debate over their trajectory. Nature Medicine 18, 4-4
CrossRef848
Ragavendra R. Baliga. (2012) HDL–Cholesterol: Perfection is the Enemy of Good?. Medical Clinics of North America 96, 27-37
CrossRef849
P.P. Toth. (2012) On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy: JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Yearbook of Endocrinology 2012, 62-65
CrossRef850
P.P. Toth. (2012) LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals. Yearbook of Endocrinology 2012, 47-49
CrossRef851
Seth S. Martin, Roger S. Blumenthal, Michael Miller. (2012) LDL Cholesterol: The Lower the Better. Medical Clinics of North America 96, 13-26
CrossRef852
P.P. Toth. (2012) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. Yearbook of Medicine 2012, 426-430
CrossRef853
Reynaria Nieva, Seyed A. Safavynia, Kathy Lee Bishop, Sperling Laurence. (2012) Herbal, Vitamin, and Mineral Supplement Use in Patients Enrolled in a Cardiac Rehabilitation Program. Journal of Cardiopulmonary Rehabilitation and Prevention 32, 270-277
CrossRef854
Alberto Cordero, David Sirera, Vicente Bertomeu-Martínez. (2012) Parámetros lipídicos y objetivos terapéuticos. Revista Española de Cardiología Suplementos 12, 12-18
CrossRef855
P.P. Toth. (2012) Association of High-Density Lipoprotein Cholesterol With Incident Cardiovascular Events in Women, by Low-Density Lipoprotein Cholesterol and Apolipoprotein B100 Levels: A Cohort Study. Yearbook of Endocrinology 2012, 35-41
CrossRef856
P.P. Toth. (2012) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. Yearbook of Endocrinology 2012, 79-84
CrossRef857
Yehuda Handelsman, Vivian Fonseca, Julio Rosenstock. (2012) Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?. Expert Review of Clinical Pharmacology 5, 43-54
CrossRef858
James M. McKenney. (2012) Combination Treatment with Atorvastatin plus Niacin Provides Effective Control of Complex Dyslipidemias: A Literature Review. Postgraduate Medicine 124, 7-20
CrossRef859
Charles U. Osuji, Emeka G. Omejua, Emmanuel I. Onwubuya, Gladys I. Ahaneku. (2012) Serum Lipid Profile of Newly Diagnosed Hypertensive Patients in Nnewi, South-East Nigeria. International Journal of Hypertension 2012, 1-7
CrossRef860
Dean G. Karalis, Brett Victor, Lilian Ahedor, Longjian Liu. (2012) Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol 2012, 1-7
CrossRef861
Giuseppe Danilo Norata. (2012) Established and Emerging Approaches for the Management of Dyslipidaemia. Scientifica 2012, 1-14
CrossRef862
Maningat , Patricia , Breslow , Jan L. , . (2011) Needed: Pragmatic Clinical Trials for Statin-Intolerant Patients. New England Journal of Medicine 365:24, 2250-2251
Full Text863
Giugliano , Robert P. , . (2011) Niacin at 56 Years of Age — Time for an Early Retirement?. New England Journal of Medicine 365:24, 2318-2320
Full Text
- Comments (5)
- Letters
- Metrics
Social Media statistics are not yet available.